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Abstract 
To date, a gluten-free diet is the only accepted form of therapy for coeliac disease 
(CD). Because of the important role of transglutaminase2 enzyme in the initiation of 
coeliac disease (CD).This study was aimed at the identification of TG2 inhibitors from 
natural sources, as a potential intervention in CD therapy. The natural products chosen 
for this study were dietary flavonoids. Kaempferol, morin, and quercetin displayed 
inhibition on hr TG2 (human recombinant transglutaminase 2) and in fewer extent 
gplTG2 (Guinea pig transglutaminase2) amine incorporation activity. However, the 
majority of flavonoids showed a trend of inhibitions (>50% of inhibition at 1.25, 12.5 
and125µM) on the cross-linking activity of hrTG2.The flavonoids used did not show 
a significant inhibitory effect on the amount of ammonia released in the deamidating 
activity of hrTG2. A novel method for purification of flavonoids from food extracts 
was developed, using Immobilized Metal Ion Affinity Chromatography (IMAC). In 
addition, a BCA assay was optimised in a novel quantification method using quercetin 
as a standard flavonoid. In addition, to the pure flavonoids, flavonoids were extracted 
from different food samples. In the TG2 amine incorporation activity, all of food 
extracts display a significant inhibition effect towards the hrTG2 and gplTG2 (20-50% 
of inhibition). While in the TG2 cross-linking activity, the majority of food extracts 
did display an inhibition effect on the gpl TG2 cross-linking activity (50-70% of 
inhibition), but only the Strawberry and kale extract had an effect on hrTG2 activity 
(40-50% of inhibition). In the deamidation assay, no food extracts showed inhibition. 
A cell-based fluorescence assay confirmed the TG2 inhibitory characteristic of 
kaempferol on HT29 cell lines. This was among the first studies to examine the effects 
of flavonoids on the activity of TG2. The inhibition of transglutaminase 2 (TG2) 
deamidating activity can be considered as a potential therapeutic target in the treatment 
of coeliac disease (CD). All current TG2 assays measure amine incorporation, none 
can specifically measure TG2 deamidating activity because there would be little or no 
deamidation in the presence of an amine. A novel deamidating assay has been 
developed using o-pthaldehyde (OPA) to measure the ammonia released in 
deamidation. This assay demonstrated that the TG2 deamidation of Vicia faba storage 
proteins and gliadin peptides was enhanced by presence calcium and inhibited by 
EDTA. 
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Chapter 1 : General Introduction 
1.1 Introduction 
Transglutaminases (EC: 2.3.2.13; TGs), also known as protein-glutamine γ-glutamyl 
transferases, are calcium-dependent enzymes which catalyse posttranslational 
modifications to many proteins. This happens through inter- or intramolecular covalent 
cross-linking by an acyl-transfer between the γ-carboxyamide groups of glutamine 
residues and ε-amino groups of lysine residues or other primary amines leading to the 
formation of covalent isodipeptide cross-links. (Martins, et al. 2014). Transglutaminases 
are a 9- member family of multifunctional proteins. Eight  TGs  (TG1-7  and factor  XIIIa  
(FXIIIa)  possess transamidation/deamidation activity, while band 4.2 does not have a 
catalytic role but mainly acts as a structural protein of erythrocyte membranes (Kárpáti, 
et al., 2018). 
1.2 History of the discovery of transglutaminases 
 In 1957, Sarkar and co-workers clarified homogenates of brain, kidney, and liver of 
guinea pig showing the transamidation activities catalysed by TGs for the first time 
(Sarkar, Clarke and Waelsch 1957). Clarke et al., (1959), also observed the 
transamidation activity of TG in the guinea-pig liver. Pisano et al., (1969) found that 
Factor XIIIa had the ability to cross-link and stabilise fibrin monomers as the final step 
in the blood coagulation cascade, a finding that has established the idea that these 
enzymes can modify proteins and act as biological glues(Griffin, Casadio and Bergamini 
2002). 
1.3 Biological activities of transglutaminases 
Transglutaminase enzymes cross-link many different proteins containing glutamine and 
lysine residues through a transamidation reaction (see Figure 1-1). The isodipeptide bonds 
formed between cross-linked proteins are peptidase resistant (Kanchan, Fuxreiter and 
Fésüs 2015). Cross-linking of proteins helps in some cellular functions such as stabilising 
the extracellular matrix (ECM), blood clotting, wound healing, bone growth, apoptosis, 
cell adhesion, cell survival and cell signaling (Kanchan, et al. 2015). In addition, to 
protein: protein cross-linking, TGs mediate the incorporation of primary amines into 
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proteins and, in the absence of amine nucleophiles, the deamidation of protein/peptide 
glutamine residues to glutamate (see Figure 1-1; (Kárpáti, et al. 2018). Transglutaminases 
are considered as “housekeeping” enzymes; the biological functions attributed to TG2 
include but are not limited to, tissue repair, inflammation, the development of some 
cancer, fibrosis and coeliac disease (Kobayashi, et al. 1998) and (Bergamini, et al. 1999).  
 
 
 
Figure 1-1: Schematic diagram for TGs activity 
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1.4 Isoforms of mammalian transglutaminases 
The different isoforms of transglutaminases are distinguishable from each other due to 
their different physical properties and their distribution throughout the body (Lentini, et 
al. 2013). Although the catalytic activities of most TGs overlap, not all are homologous 
and sequence variations in substrate preference have been observed among TG enzymes 
(Makarova, Aravind and Koonin 1999). All of the mammalian isotypes of TGs are 
calcium-dependent except the erythrocyte band 4.2 protein, which is not catalytically 
active (Satchwell, et al. 2009). In addition, TG1, TG3, and Factor XIIIa are synthesised 
as zymogens, which are proteolytically cleaved to present the activated form of the 
enzyme (Pedersen, et al., 1994; Eckert, et al., 2005). The TG2 enzyme targets proteins 
which act as cellular scaffolds, controlling cell adhesion and regulating signal 
transduction (see Table 1-1) (Satchwell, et al. 2009). 
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Table 1-1: Human Transglutaminases               
 
(Modified from Eckert et al., 2014)  
1.4.1 Transglutaminase 1 (TGM1) 
Transglutaminase 1 also known as keratinocyte TG resides in the stratified squamous 
epithelia of the skin, the lower female reproductive system, and the upper alimentary tract. 
As a result of proteolytic cleavage, a cellular Ca2+ level increase leads to the activation of 
TG1’s catalytic activity (Sturniolo and Eckert 2005;  Eckert, et al., 2014). 
Transglutaminase 1 protein was linked with the plasma membrane by a fatty acid acyl 
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linkage in an N-terminal cysteine residue. The enzyme was released from the membrane 
by proteolysis as 10-, 33-, and 66-kDa fragments (Kim, Chung and Steinert 1995). 
Impairment in the function of TG1 is responsible for the skin condition lamellar 
ichthyosis, occurring due to the inability of TG1 to form ester bonds (Nemes, et al., 1999); 
(Iismaa, et al., 2009). Transglutaminase1 is central for the cross-linking of substrate 
proteins essential for the complete development of the cornified envelope of the skin, a 
cross-linked scaffold located in the outermost layer of the epidermis (Yamane, et al., 
2016).  
1.4.2 Transglutaminase 2 (TGM2) 
Tissue TG (TG2) is widely distributed in tissues and cell types; it is mainly a cytosolic 
protein but has been shown to be also present in the nucleus and on the plasma membrane 
of cells (Lorand and Graham 2003). It is encoded by the TGM2 gene on the human 
chromosome 20q11-12. Transglutaminase 2 shows GTPase, protein disulphide isomerase 
(PDI), ATPase and protein kinase activity, in addition to transamidation and deamidation 
reactions (Tatsukawa, et al. 2016). Both Ca2+ and GTP can regulate the enzyme’s activity.  
The function of the TG2 isoform has been linked to coeliac disease, neurodegenerative 
disorders and cataract formation (Griffin, et al., 2002); (Tong, et al., 2013). This enzyme 
will be discussed in more detail in section 1.5. 
1.4.3 Transglutaminase 3 (TGM3) 
Transglutaminase 3 (TG3) is also known as epidermal TG exists in the follicles of hair, 
skin epidermis, and brain tissue. The TG3 gene (TGM3) promoter includes Sp1- and Ets-
motifs (Lee, et al., 1996). Calcium enhances the expression of the pro-transglutaminase 
3 mRNA and the final TG3 protein appears as two polypeptide chains formed from a 
single precursor protein after proteolysis. Transglutaminase 3, like TG2, binds to and 
hydrolyses GTP (Ahvazi, et al., 2003). Transglutaminase 3 is responsible for the 
hardening of the internal root sheath of the hair follicles via activation of the cross-linking 
of keratin and trichohyalin intermediate filaments, which is crucial for the morphology of 
the hair fibre (Hitomi, et al., 2001); (Hitomi, et al., 2003) and (John, et al., 2012). It also 
contributes to the formation of the keratinocyte cell envelope through the later stages of 
differentiation (John, et al., 2012). Dysfunction of TG3 causes impaired development of 
hair and reduction in skin barrier function (John, et al., 2012) and (Bognar, et al., 2014). 
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Moreover, it is supposed that TG3 is the dominant autoantigen in dermatitis herpetiformis 
in coeliac patients (Sárdy, et al., 2002). 
1.4.4 Transglutaminase 4 (TGM4) 
Transglutaminase 4 (TG4), also known as prostate TG, exists in the prostatic fluids of the 
prostate gland and seminal plasma of humans (Dubbink, et al., 1999); (Grenard, Bates 
and Aeschlimann 2001) and (W. Jiang and Ablin 2011). Transglutaminase 4 mRNA 
levels in human prostate cancer cells increase following androgen treatment (Cho, et al., 
2010). The TG4 isoform is encoded by TGM4 gene on human chromosome 3p21-22. The 
role of TG4 in humans is at present unknown. Some studies suggest that there is a link 
between the promotion of an aggressive prostate cancer phenotype and increased 
expression of TG4 (Jiang and Ablin 2011). Overexpression of TG4 has a probable role in 
stimulation and adherence of endothelial cells in prostate cancer, as these effects were 
decreased when TG4 expression was knocked down ( Jiang, et al., 2009). Other studies 
suggest that TG4 improves fertility in males ( Iismaa 2016).  
1.4.5  Transglutaminase 5 (TGM5) 
Transglutaminase 5 (TG5) is mostly present in foreskin keratinocytes, skeletal muscle 
and the epithelial barrier (Cassidy, et al., 2005). Transglutaminase 5, like TG2, is a 
calcium-dependent enzyme, which is regulated via GTP and ATP levels. 
Transglutaminase 5 is encoded by the TGM5 gene, which is located on human 
chromosome 15q15.2 and has a molecular weight of ~ 81 kDa. The enzyme is responsible 
for cross-linking loricrin, involucrin, and SPR3 in the skin epidermis (Melino, et al. 2001) 
and has a role in hyperkeratosis in patients with ichthyosis and psoriasis. Overexpression 
of TG5 was detected in, and indirectly related with, numerous pathologies of human 
epidermis, including ichthyosis Vulgaris, psoriasis and Darier's disease (Candi, et al., 
2002). Transglutaminase 5 mutations can lead to skin peeling syndrome (Cassidy, et al., 
2005).  
1.4.6 Transglutaminase 6 (TGM6) 
Transglutaminase 6 (TG6) is expressed in human lungs and testes, brain and in human 
neuronal carcinoma cells (Thomas, et al., 2013). It includes two polypeptide chains that 
are cleaved from a single precursor.  The proteolytic cleavage of the proenzyme leads to 
the activation of the catalytic function of TG6 (Stamnaes, et al., 2010; Thomas, et al., 
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2013) revealed the participation of TG6 in coeliac disease autoantibody-mediated gluten 
ataxia (Mulder, Rouvroye and van Dam 2018). 
1.4.7 Transglutaminase 7 (TGM7) 
The TG7 protein is encoded by the TGM7 gene located on human chromosome 15q15.2 
(Griffin et al., 2002). This enzyme is expressed in the skin epidermis (Kuramoto et al., 
2013).  
1.4.8 Factor XIIIa (F13A1) 
Plasma TG (FXIIIa) is found in plasma, platelets, macrophages, astrocytes, placenta, 
heart, eyes, dermal dendritic cells, chondrocytes, and synovial fluid in cells of the 
osteoblast lineage.  Factor XIIIa is an important component of the blood coagulation 
cascade involved in the terminal stage of blood coagulation processes (Lorand and 
Graham 2003b). The A subunit is the catalytic site of FXIII, whereas, the B subunit acts 
as a carrier protein. Factor XIIIa catalyses cross-linking of fibrin molecules to stabilize 
fibrin clots, which are resistant to proteolysis and fibrinolysis (Tone et al., 2016). This 
activity occurs in the presence of Ca2+ ions and ultimately contributes to hemostasis and 
wound healing (Włodarczyk et al., 2014). Deficiency in Factor XIIIa is characterized by 
prolonged bleeding time and impaired wound healing. (Koseki-Kuno et al., 2003; Dardik 
et al., 2006; Nahrendorf et al., 2006; Tsujimoto et al., 2011). 
1.4.9 Erythrocyte membrane protein band 4.2 (EPB42) 
Band 4.2, which is encoded by the EPB42 gene, is a unique member of the mammalian 
TG family, which lacks catalytic activity. The lack of enzymatic activity is the result of 
the substitution of the active site cysteine residue for an alanine residue. Band 4.2 protein 
is located predominantly in foetal liver, bone marrow, spleen and erythrocytes and plays 
an important role in the organisation of cell stability and maintenance the integrity of the 
cell membrane (Peters et al., 1999). Band 4.2 protein prefers to bind with ATP instead of 
GTP, in contrast to the other TG family members (Azim et al., 1996). 
1.5  Transglutaminase 2 
Transglutaminase 2 (EC: 2.3.2.13) exhibits a number of functions with different 
molecules acting as substrates for this enzyme, such as proteins, amines, and water. For 
these reasons and its ubiquitous distribution, it is considered the most interesting member 
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of the TG family (Lerner et al., 2015).  The TG2 gene is localized to chromosome 20q11-
12, the protein has 687 amino acids, and it is the most studied and abundant of the nine 
members of the TG enzyme family (Odii and Coussons 2014). 
1.5.1  Structure and conformational changes of TG2 
The X-ray α-crystal structure of TG2 has reported the nature of the enzyme’s complex 
structure (Liu et al., 2002). Human TG2 is composed of four globular domains: an N-
terminal β-sandwich domain, which contains the binding site for fibronectin. A catalytic 
domain that consists of the catalytic triad (cysteine-histidine-aspartic acid) plus two 
tryptophan residues (Yee et al., 1994; Liu et al., 2002). Two C-terminal β-barrel domains, 
which are implicated in the ability of TG2 to bind and hydrolyse GDP/GTP (Achyuthan 
and Greenberg, 1987; Liu et al., 2002a) (See Figure 1-2). Three crystal structures of TG2 
have been elucidated, one complexed with ATP, one with GDP and another complexed 
to an irreversible inhibitor (Liu et al., 2002b, Pinkas et al., 2007). Upon the binding of 
irreversible inhibitor at the active site, TG2 structure undergoes a large conformational 
change. Inactivation of TG2 via GTP and low calcium levels promotes a compact 
conformation, whereas activation of TG2 by calcium ions leads to an open conformation 
(See Figure 1-2). It has been proposed that, because of GTP binding, intracellular TG2 
will be sustained in a closed conformation. However, in different circumstances such as 
cell lysis and necrosis in which calcium levels are increased, there will be a rapid 
activation of TG2 into an open conformation (Jang et al., 2014). The conformations of 
TG2 could be essential for its role in cell survival/death pathways (Gundemir, et al., 2013).  
 
   
Figure 1-2: Schematic diagram for conformations of TG2. 
Overall Structures of GDP-Bound and Inhibitor-Bound TG2. The enzyme consists of 4 domains; an N 
terminal β sandwich domain (blue), a catalytic core (green) and two C terminal domains, β-barrel 1 (yellow) 
and β barrel 2 (red). (A) GDP-bound TG2. (B) TG2 inhibited with the active-site inhibitor Ac-P(DON)LPF-
NH 2                                                                             
  (Modified from Situ Boman., 2008) 
A B 
GDP  inhibitor  
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1.5.2 Catalytic functions of TG2 
Tranglutaminase2 catalytic functions are divided into two main reaction pathways with a 
2-step “ping pong” mechanism (Palmer and Bonner, 2007). In the first step, the sulphur 
of the active site cysteine (cys277) in TG2 (acyl acceptor) interacts with the γ-carbon of 
the protein/peptide bound glutamine (acyl donor). This leads to the formation of a 
thioester bond with the release of ammonia as a by-product (see Figure 1-3). In the second 
step, the thioester bond is attacked by a primary amine either in transamidation or, in the 
absence of suitable amine, with water in deamidation. The transamidation reaction of TG2 
leads to protein cross-linking which has a critical role in wound healing, blood clot 
formation, apoptosis and semen coagulation (Lorand and Graham 2003a), thus offering 
more protection for the organs or tissues. This alteration also comes under the category 
of a posttranslational modification. (Ju-Hong, et al., 2003).  Alternatively, in the 
transamidation pathway, the nucleophile can be a polyamine (e.g. putrecine, spermidine 
or spermine). The addition of a polyamine results in an additional positive charge to the 
surface of the target protein, altering the protein’s isoelectric point (pI).  In the 
deamidation reaction, the thioester-glutamine at the active site is displaced by water 
acting as the nucleophile, which converts protein/peptide bound glutamine to glutamate 
(Fleckenstein et al., 2002; Sollid & Jabri, 2011). The additional negative charge on the 
protein/peptide will alter some of the protein’s properties such as isoelectric point (pI), 
surface charge and interactions with other neighbouring amino acids on the target protein 
and its interactions with other proteins. 
 
Figure 1-3: Catalytic activity of TG2 
Digram shows that TG2 can catalyse the transamidation of glutamine to a suitable amine or the deamidation 
of glutamine to glutamic acid. 
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It is crucial to emphasise that water is an inferior nucleophile to amines so there would 
little or no deamidation in the presence of an amine (Folk, 1983; Fleckenstein et al., 2002). 
The deamidation activity of TG2 is central to the initiation of coeliac disease, by 
converting glutamine in a gliadin peptide to glutamate causing an immune response in 
CD patients, resulting in the typical symptoms of the disease (Sollid & Jabri, 2011). In 
the literature, the deamidation reaction is described to have a slower rate than the 
transamidation reaction (Fleckenstein et al., 2002).  
Transglutaminase 2 has been reported to have a number of additional activities, one of 
which is related to its role as a cellular G protein (Gh). Hydrolysis of GTP to GDP can be 
achieved by TG2, which as a G protein in a combination with the plasma membrane-
associated α1 adrenergic receptor via the transfer of signaling to the activation of 
phospholipase C (Nakaoka et al., 1994). Transglutaminase2 also exhibits phosphorylation 
and kinase activity, which are modulated through stimulation of A1 adenosine receptor 
by protein kinase and extracellular Ca2+-dependent pathways (Vyas et al., 2016). 
Transglutaminase 2 as a protein kinase has been shown to phosphorylate different 
proteins including histones in breast cancer cells retinoblastoma protein in fibroblasts and 
p53 (Mishra et al., 2007). One more activity of TG2 is its ability to act as protein 
disulphide isomerase (PDI) in the cytosol (Hasegawa, et al., 2003). Protein disulphide 
isomerase is a member of the thioredoxin family normally existing in the lumen of the 
endoplasmic reticulum (ER). Transglutaminase 2 may have a cytoplasmic or extracellular 
PDI role in the correction of disulphide bridges inside polypeptides, which may also 
correct the conformation of different proteins (Ferrari and Söling 1999). The PDI activity 
of TG2 is independent of Ca2+ ions and nucleotides, it active in cytosol where there are a 
high nucleotide concentration and low Ca2+ concentration (Hasegawa, et al., 
2003).However, the majority of cytoplasmic proteins do not have disulphide bonds 
(Cumming et al., 2004). 
1.5.3 Cellular role of Transglutaminase 2 
Unlike other members of the transglutaminase family, TG2 can be found in both the 
intracellular and the extracellular spaces of different types of tissues (Giera et al., 2018). 
Transglutaminase 2 has been found to be involved in both enzymatic and non-enzymatic 
cellular and extracellular interactions. Enzymatic interactions are formed between TG2 
and substrate proteins or polyamines in the presence of calcium ions (Kanchan et al., 
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2015) (See Figure 1-4). During normal cellular activities, when calcium levels are low 
(<0.1mM) and GTP levels are high (>1mM), TG2 has been proposed to be inactive 
(Zemskov et al., 2006). Cell lysis and necrosis can damage calcium homeostasis, resulting 
in increased translocation of Ca2+ into the intracellular environment ultimately increasing 
the activity of TG2 (Griffin et al., 2002). The concentration of Ca2+ needed for activation 
of TG2 differs in vitro and in vivo. For instance, the Ca2+concentration required for 
activating TG2in vitro  (500µM) is far higher than net resting intracellular Ca2+ion 
concentrations (about 100 nM) (Ahvaziet al., 2003). 
 
Figure 1-4: Biochemical activities of TG2. 
TG2 catalyses Ca2+-dependent acyl-transfer reaction between γ-carboxamide group of a specific protein-
bound glutamine and either (A) the ε-amino group of a distinct protein-bound lysine residue (covalent 
protein cross-linking activity) or (B)primary amines such as polyamines(amine incorporation in 
proteins).(C)Water can replace amine donor substrates, leading to deamidation of the recognized 
glutamines.  
                                                                 Adapted from Primary and Piacentini (2002) 
These TG2 activities facilitate it is a role in various cellular processes, such as interactions 
of cells with each other and with the extracellular matrix, apoptosis, gene transcription 
regulations and mitochondrial function (Yakubov et al., 2013). 
1.5.4 TG2 Tissue Localization 
Transglutaminase 2 is mainly cytosolic; nevertheless, the presence of TG2 has been 
demonstrated in the nucleus (Gundemir, et al., 2013). In addition, it has been shown to be 
present in other intracellular compartments and organelles such as endoplasmic reticulum, 
mitochondria, and cytoskeleton, as well as the extracellular environment and on the cell 
surface (Piacentini, et al., 2014). Transglutaminase2 is also expressed in many different 
cell types including; osteoblasts, fibroblasts, endothelial cells, smooth muscle cells, 
monocytes, neurons, chondrocyte, neutrophils, oligodendrocyte, epithelium, dendritic 
cells, stem cells and macrophages (Wang and Griffin,2012). The route by which TG2 is 
exported from the cell to undertake extracellular remodeling is not completely understood 
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(Scarpellini, et al., 2009; Iismaa, et al., 2016). A  study by (Aeschlimann and Knäuper 
2017) showed that TG2 externalization is mediated by the P2X7 receptors which are a 
member of the P2X family of nucleotide regulated ion channels that are activated by high 
concentrations of extracellular ATP (Hattori and Gouaux, 2012). Because of injury or 
inflammation, P2X7receptors will be activated, leading to the release of ATP from 
immune cells, serving as a danger indication amplification system. Transglutaminase 2 
expression is highly up-regulated by acute phase injury cytokines. Consequently, P2X7 
receptor-driven TG2 secretion will occur in such a situation (Aeschlimann and Knäuper 
2017). It is also known that TG2 is exported from the intestinal epithelial cells into the 
intestinal lamina propria to operate in an extracellular form (Elli et al., 2009).   
1.5.5  Transglutaminase 2 substrate properties 
The identification of proteins and target amino acids, which act as substrates for TG2 
activity, is important for discovering TG2's biological functions in diverse cell types and 
tissues. A considerable number of cytoplasmic TG2 protein substrates have been 
identified, such as enzymes, hormones, extracellular and intracellular structural proteins, 
and small heat shock proteins. Transglutaminase 2 appears to be more selective for 
glutamine residues on protein/peptides which is the first step in its “ping pong” kinetic 
pathway (Lorand and Graham, 2003a ; Esposito and Caputo, 2005).  
1.5.6 Transglutaminase 2 in disease states 
Transglutaminase 2 disruption has been implicated in many different diseases processes. 
For example, neurodegenerative disorders such as Huntington’s and Parkinson’s diseases 
(Hoffner and Djian, 2005), different cancers such as breast, ovarian and pancreatic 
cancers (Mangala and Mehta, 2005). In addition, during the diagnosis of type 1 diabetes, 
there is around 4% to 17% positive tests for TG2 antibodies (anti‐tTG) (Bernassola et al., 
2002; Parkkola et al., 2018). Coeliac disease is the one disease state that TG2 activity 
plays a crucial role, by mediating the deamidation of glutamine in a 33mer gliadin peptide 
initiating a chain of events leading to the destruction of the small intestinal villi (Molberg 
et al., 2000), 
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a) Transglutaminase 2 and neurodegenerative diseases 
Transglutaminase 2 is involved in a number of neurodegenerative disorders including 
Huntington's, Alzheimer's, and Parkinson's diseases (Jeitner et al., 2009b; Min and Chung, 
2018) due to several reasons. First, it is found in most regions of the brain, particularly in 
neurons (Appelt et al., 1996; Kim et al., 1999; Lesort et al., 1999). Second, the 
pathophysiology of all these diseases is characterised by the formation of insoluble 
protein aggregates (Mastroberardino and Piacentini, 2010). These aggregates are a result 
of the covalent cross-linking of pathogenic proteins by TG2, which is effectively 
irreversible. Thirdly, in neurodegenerative diseases where there are energy depletion and 
loss of calcium homeostasis, in these circumstances low GTP and high calcium levels 
may result in TG2 activation its intracellular cross-linking activity (see Section  1.3 ) 
(Lesort et al., 2000; Siegel & Khosla, 2007; Jeitner et al., 2009b; Grosso et al., 2012). 
i. Transglutaminase 2 and Huntington’s disease 
Huntington’s disease (HD) is a neurodegenerative disease that occurs because of the 
expansion of CAG trinucleotide repeats in the gene encoding huntingtin (htt). This 
expansion leads to a large number of contiguous glutamine residues in the htt protein. 
Aggregation of ubiquitinylated htt in the nucleus and the loss of neuronal cells is observed. 
One of the proposed mechanisms of htt aggregation is based on the action of TG2 because 
expanded polyglutamine repeats are excellent glutamine donor substrates for TG2-
catalyzed cross-linking (Fesus and Piacentini 2002). In addition, TG2 mediates the cross-
linking of mutation htt or its N-terminal fragment, generating an intra-nuclear inclusion 
with ε-(γ-glutamyl) lysine bonds in the frontal cortex of HD patient brains. There have 
been studies reporting that cystamine (a nonspecific TG2 inhibitor) treatment of HD 
patients extends survival, promoting the motor performance and minimising the number 
of cellular aggregates (Min and Chung, 2018). 
ii. Transglutaminase 2 in Parkinson's disease and dementia with Lewy 
bodies 
Parkinson’s disease is a neurodegenerative disorder, which is characterised by the loss of 
dopaminergic neurones in the substantia nigra pars compacta, formation of aggregates 
α-synuclein and cytoplasmic proteins to form Lewy bodies (Junn et al., 2003). 
Transglutaminase2 has a pathogenic role in Parkinson’s disease and dementia with Lewy 
bodies. These diseases are associated with the protein α synuclein, which is an excellent 
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substrate for TG2 (Junn et al., 2003).  Transglutaminase 2 catalyses the formation of 
insoluble high molecular weight aggregates of α-synuclein in a calcium-dependent 
manner (Junn et al., 2003). These insoluble aggregates contain isodipeptide bonds, a 
process that is dependent on the concentration of TG2. The involvement of TG2 cross-
linking activity in inducing the formation of these polymeric forms of α-synuclein is 
indicated by cystamine blocking α-synuclein aggregation (Junn et al., 2003; Grosso and 
Mouradian, 2012). 
iii. Transglutaminase 2 and Alzheimer’s disease 
Alzheimer’s disease is characterised by the formation of neurofibrillary tangles, 
extracellular senile plaques and neuronal loss of brain function (McKhann et al., 1984). 
Transglutaminase 2 has been found to be involved in the pathogenesis of Alzheimer’s 
disease having been found to catalyse amyloid beta-protein oligomerisation and 
aggregation at a physiological level. Indeed, TG2 activity induces protofibril-like amyloid 
beta-protein assemblies that are peptidase-resistant and inhibit long-term potentiation 
(Buée et al., 2000; Lee et al., 2001). Therefore, TG2 activity could also contribute to 
Alzheimer's disease (AD) symptoms and progression. Work by Basso et al., (2012) 
demonstrates that, in addition to TG2, TG1 gene expression level is significantly 
increased following a stroke or due to oxidative stress in vitro. It has been further 
established that the protein cross-links formed by transglutaminases co-localise with 
pathological lesions in the Alzheimer’s disease brain, thereby suggesting TG2 inhibitors 
may be appropriate for the treatment of Alzheimer’s disease (Wilhelmus et al., 2009). 
b) Transglutaminase 2 and Renal Fibrosis 
Several studies have demonstrated the role of TG2 in the development of fibrotic 
conditions in humans (Shweke et al., 2008). The cross-linking actions of TG2 in ECM 
proteins leads to accumulation of proteolytic enzyme resistant cross-linked protein 
polymers in the kidney, thereby causing fibrotic lesions and renal failure (Johnson et al., 
2003; Shweke et al., 2008). The TG2 mediated cross-linking of ECM proteins such as 
fibrinogen/fibrin, vitronectin, fibronectin, collagens I, III, IV, and V makes them resistant 
to degradation by matrix metalloproteinases (MMPs) (Aeschlimann & Thomazy, 2000; 
Fisher et al., 2009). Treatment with site-directed, irreversible inhibitors of TG activity led 
to a considerable improvement in both kidney function and prevention of renal 
remodeling, which highlights the importance of TG2 in both disease initiation and as a 
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potential therapeutic target for treatments (Johnson et al., 2007). Recently, a study by 
Furini et al., (2018) suggested that the therapeutic block of TG2 might potentially impede 
the ECM accumulation role of TG2 and the transfer of TG2 from cell to cell during 
fibrosis progression, and consequently diminish renal fibrosis (Furini et al., 2018). 
c) Transglutaminase 2 and cardiovascular diseases 
Cardiovascular diseases are one of the major sources of death worldwide (Yusuf et al., 
2015). Cardiovascular diseases include various disorders involving the blood vessels –
e.g. coronary heart disease, cerebrovascular and peripheral arterial diseases– and the heart 
organ, such as rheumatic and congenital heart disease. Studies have reported the 
important function of TG2 in the biology and pathophysiology of heart disease. For 
example, TG2has been implicated in promoting vasoconstriction of vascular smooth 
muscle cells, leading to raised blood pressure (hypertension) (Janiak et al., 2006). 
Through its cross-linking activity, TG2 caused a reduction in the lumen diameter of 
vessels of arteries. In addition, transglutaminase 2 has an effect on cardiac hypertrophy 
(heart enlargement) which is considered as a potential risk factor connected with heart 
failure and ischaemic heart disease (Shiojima et al., 2005). In atherosclerosis, TG2 is 
widely expressed in smooth muscle cells, macrophages, and endothelial cells and it was 
reported to accumulate in plaques to interact with atherosclerotic processes (Haroon et al., 
2001; Szondy et al., 2017). Nitric oxide is known to inhibit TG2 protein cross-linking 
function through S-nitrosation (Lai et al., 2001). In addition, nitric oxide opposes TG2-
dependent small-artery remodeling in response to vasoconstrictive stimuli (Bakker et al., 
2008; Pistea et al. 2008). Reduced nitric oxide bioavailability in aging vasculature leads 
to diminished TG2 S-nitrosation, then increased cross-linking activity in the extracellular 
matrix (ECM). Therefore, nitric oxide can directly inhibit TG2 cross-linking function via 
S-nitrosation (Lai, et al. 2001) and regulate TG2 by constraining it to the cytosol. 
d) Transglutaminase 2 and cancer 
Transglutaminase 2 has a vital and physiological role in inflammation mainly via its 
modulation the structure and stability of ECM with its influence on gene expression. It 
also regulates tumour progression, via various intracellular and extracellular ways, 
depending on its pro-cross-link and signalling transduction mediation propensities, which 
attenuates cell adhesion and promotes ECM proteolysis (Huang and Liu, 2015). 
Transglutaminase 2 is overexpressed in breast, ovarian, brain, and pancreatic tumours; 
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however, several studies described TG2 as a pro-tumourigenic protein that enhances 
metastasis, cellular invasion, and chemoresistance. These actions have been attributed to 
stimulation of oncogenic signalling, controlled in part by the transcription factors nuclear 
factor-kappa B (NF-κB), cyclic adenosine monophosphate response element–binding 
protein (CREB) and by protein kinase B (Akt) (Yakubov, 2013). Generally, TG2 
performs vital functions in inflammation mainly via its modification of the extracellular 
matrix (ECM) stability and structure (Huang, et al., 2015). 
e)  Transglutaminases and age-related cataract formation 
Transglutaminase 2 has been implicated in the development of age-related cataract 
formation (Boros et al., 2008). The β-crystallin component is a major part of the lens 
proteins that are needed for the refractivity of the light onto the retina (Soderberg, 1990; 
Jeong and Kim, 2015). These proteins contain numerous glutamine residues, which can 
become sites of deamidation mediated by TG2 prior to the proteins being cross-linked 
(Takemoto and Boyle 1998; Lapko et al., 2002; Wilmarth et al., 2006; Boros et al., 2008). 
Boros and co-workers proposed that TG2 was able to mediate age-related cataract 
formation through disruption of β-crystallin structure (Boros et al., 2008). 
f) Apoptotic and anti-apoptotic role of TG2 
Apoptosis is a process of programmed cell death whereby the deletion of cells from a 
tissue occurs because of stimulation of specific death-signaling pathways (Tiwari et al., 
2015). This stimulation of pathways is affected by different environmental factors such 
as redox potential and ultraviolet light. Apoptosis results in DNA fragmentation, cell 
volume reduction and phagocytosis of the apoptotic cell via nearby phagocytes. Dys-
regulation or inhibition of apoptosis may lead to human disease (Fadok et al.,. 1998, 
Matute-Bello and Martin, 2003). Therefore, the management of apoptosis is central for 
cell survival, whereas upregulation of apoptosis can lead to a human disease condition. 
Transglutaminase 2 has been linked with pro-apoptotic and anti-apoptotic roles, 
depending on cell type, mode of death stimulation and the localization of the enzyme 
(Milakovic et al., 2004; Cao et al., 2008; Gundemir et al., 2013; Garabuczi et al., 2013). 
One probable anti-apoptotic role of TG2 is due to its ability to prevent the degradation of 
retinoblastoma protein, which is an important suppressor for apoptosis, consequently 
sustaining the anti-apoptotic role of retinoblastoma protein (Boehm et al., 2002; 
Milakovic et al., 2004). On the other hand, TG2 has been reported to encourage the release 
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of apoptosis regulators such as cytochromes C and B through conformational 
modifications by its BH3-like (Bcl-2 homology) domain (Rodolfo et al., 2004). 
g) Transglutaminase 2 and coeliac disease 
The TG2 posttranslational modifications of gliadin peptides that produced by the catalytic 
activity of dietary peptidases on gluten have been proven to cause the generation of 
autoantibodies in the gluten sensitivity disease or coeliac disease (CD) (Lionetti and 
Catassi, 2011). The deamidating action of TG2 is primarily responsible for the initiation 
of the coeliac disease (see section 1-8). Transglutaminase 2 deamidates an undigested 
gliadin (33mer) peptide found in the intestinal lamina propria (Dahlbom, et al., 2005; 
Lionetti and Catassi, 2011). Thereafter, the deamidated glutamine residue on the gliadin 
peptide becomes a significantly better binder to the HLA DQ2/DQ8 receptors. This leads 
to the activation of T cells, the production of cytokines and the production of 
autoantibodies against TG2 (Nadalutti et al., 2013). This autoimmune response causes 
damage to the small intestine occurs, which involves disruption of the villi, thus leading 
to the development of typical CD symptoms (Lionetti and Catassi, 2011). It is important 
to mention that CD occurs only in humans and does not have a good animal or cell culture 
model (Discussed in detail later in section 1.8). 
1.6 Transglutaminase inhibitors  
The implication of TG2 in the range of pathologies discussed above demonstrated the 
necessity for potent and specific inhibitors. Studies have shown that the pathogenic 
function of TG2 is mainly linked to its role in protein cross-linking and deamidation, with 
little evidence to suggest the involvement of its GTPase activity. (Keillor et al., 2015) 
1.6.1  Types of Transglutaminase inhibitors 
Transglutaminase 2 inhibitors are generally classified into reversible and irreversible 
inhibitors based on the transamidation activity of TG2. The effect of reversible inhibitors 
can be reversed after incubation of the enzyme with inhibitor followed by dialysis. On 
the other hand, the activity of irreversible inhibitors is not reversed after incubation of the 
enzyme with inhibitor followed by dialysis. 
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1.6.2 Reversible inhibitors 
Reversible TG inhibitors act by blocking the binding of the substrate amine to the active 
site of the enzyme; however, they do not modify the enzyme covalently. This type of 
inhibitor acts by inhibiting the function of the enzyme by competing as a substrate in the 
cross-linking reaction (Keillor et al., 2015).  The reversible TG inhibitors can be classified 
into (a) competitive and (b) non-competitive amine inhibitors (Siegel & Khosla, 2007; 
Badarau et al., 2013). 
a) Competitive amine inhibitors 
Competitive amine inhibitors are relatively non-toxic in living cells and chemically 
stable; these inhibitors, which include putrescine, cadaverine, and methylamine, are the 
most widely used TG inhibitors and are commercially available (Siegel & Khosla, 2007). 
Reversible TG2 inhibitors block the access of the substrate to the enzyme active site 
without covalently modifying the latter. These competitive amine inhibitors moderate 
TG2 activity in the transamidation reaction by competing with natural amine-containing 
substrates, such as protein-bound lysine residues. One such agent that is commonly used 
to inhibit TG2 activity is monodansylcadaverine (MDC). The similarity in structure of 
MDC with the lysine side chain permits MDC to be used as a competitive substrate to 
inhibit amine incorporation and cross-linking of natural protein substrates (See  
Figure 1-5). In addition, it can be utilised as an amine donor substrate for the fluorescence 
incorporation assay of TG2 transamidating activity (Yuan et al., 2005, Budillon et al., 
2013). 
 
 
Figure 1-5: Structure of DMC and cystamine 
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Cystamine is a non-specific TG inhibitor that exerts its inhibition of TG2, through the 
formation of Nβ-(γ-L-glutamyl)-cystamine bonds at the active site of TG2 and possibly 
interacting with the sulphydryl residues on the surface of TG2. The formation of these 
bonds would compete with the generation of other TG-catalysed reactions such as 
polyamination, protein cross-linking, and the deamination of proteins (Jeitner et al., 2005; 
Okauchi, et al., 2009). The reduced form of cystamine, which is cysteamine or 2-
mercaptoethylamine (MEA) has been shown to be a competitive amine inhibitor of TG2 
in a time-dependent manner through an irreversible inhibition mechanism (Lorand & 
Conrad, 1984; Siegel & Khosla, 2007). 
b) Non-competitive amine inhibitors 
These inhibitors inhibit TG allosterically by competing for the co-factors of the enzyme, 
such as GTP and GDP (Badura et al., 2013). These inhibitors are able to bind to TG 
independent of GTP, but they may potentially compete with GTP for the same site of 
binding to TG2 (Duval et al., 2005; Case & Stein., 2007).  
1.6.3 Irreversible Inhibitors 
Irreversible inhibitors act by blocking the binding of the substrate to TG2 via covalently 
binding to the active site cysteine of the enzyme (Badarau et al., 2013). An example of an 
irreversible inhibitor of TG2 is iodoacetamide, which forms a thioester bond with the 
active site cysteine of TG2, leading to inhibiting of TG2 activity (Siegel & Khosla, 
2007)(See Figure 1-6). 
 
Figure 1-6: Mechanism of TG2 inhibition by iodoacetamide.  
Another example of an irreversible inhibitor of TG is 3-halo-4, 5-dihydroisoxazole, which 
acts in a similar way to iodoacetamide by reacting with a thiol group on TG2 and forming 
a thioester bond at the active site, which cannot be broken (Keillor et al., 2015). Michael 
acceptors which are α and β-unsaturated carbonyl derivatives that have been used to 
inhibit many cysteine peptidases have been modified to become irreversible inhibitors of 
TG2 (Pardin et al., 2006). Pliura and coworkers (1992) prepared a group of inhibitors that 
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have a dimethyl sulfonium component and reported their ability to inhibit epidermal 
transglutaminase (TG3) and TG2 (Pliura et al., 1992). A reagent company Zedira (DE) 
established products that are used in scientific literature: These include Z-DON, which is 
a very potent and specific inhibitor of TG2 (IC50 about 0.02 μM) and is membrane 
permeable, in addition to TAMRA-DON which is a fluorescent blocker of TG2 with an 
IC50 of about 0.1 μM (https://zedira.com/Mechanism-of-TG-inhibitors/DON-
compounds). Two irreversible TG inhibitors NTU R283 and carboxybenzoyl-glutamyl 
lysine (referred to as NTU-R281) have been synthesised. The inhibitor R283 was found 
to reduce the toxicity induced by gliadin in ex vivo and in vitro studies (Rauhavirta et al., 
2013). While R283 does not enter the cell, R281 is cell-permeable.  
1.6.4 Natural inhibitors 
Inhibitors of transglutaminases have been discovered in extracts from different natural 
sources. A study was done by Jong et al., (2001) has reported that bovine milk contains 
an inhibitor of TG2 in several types of activity assay. This inhibitor was detected in a 
milk fraction without casein and whey proteins (De Jong et al., 2003). Another natural 
TG2 inhibitor was extracted from garlic, as mentioned in a study by Lee et al., (2007); 
this inhibitor was thermostable, had low molecular weight and it also reversibly inhibited 
microbial transglutaminase (Lee et al., 2007). Recently, a study by Madagi et al., (2018) 
reported that phytochemicals such as nobiletin and curcumin displayed a potential 
inhibition of TG2 and could be implicated for treatment of lung cancer. The isolation and 
development of new reliable natural TG inhibitors could be advantageous to help cure 
various pathological impacts of TGs. The major reasons for using these natural inhibitors 
include that they are easily available and, because they are ingested on a regular basis, 
they have potentially no adverse side effects. Natural inhibitors have thus played a critical 
role in drug discovery and have led to a revolution in pharmacology and medicine (Dash, 
2018). Therefore, one of the main aims of this study was to screen some natural products 
for the presence of TG2 inhibitors, which could be used in the management of coeliac 
disease. 
1.7 Assays for measuring TG2 activity 
In order to screen modulators of TG2 activity, it is necessary to use enzyme assays to 
recognise inhibitors/activators of the enzyme (Pietsch et al., 2013). The classical assay 
methods, such as standard end-point, fluorimetric and colorimetric assays are still used, 
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although there is always the need to develop more sensitive assays (Song et al., 2016). 
Some methods that are used for measuring TG2 activity are explained below as 
representative examples. 
1.7.1 Transamidation assay using radioisotopes.  
Radioactivity assays are very sensitive methods. Lorand et al., (1972) developed a filter 
paper assay for measuring the activity of transamidating enzymes by the incorporation of 
radioactive amine substrates into proteins. The main advantages of this technique are the 
use of minimal amounts of reagents, as well as the simplicity of handling a large number 
of test samples simultaneously (Lorand et al., 1972). This technique was used to assess 
the TG2 activity of the brain, prefrontal cortex, and cerebellum samples of Alzheimer’s 
disease subjects. In this assay, TG2 activity is measured directly by incorporation of the 
tritiated amine nucleophile putrescine into a glutamine-containing protein substrate N, N 
dimethyl casein (NMC) (Song et al., 2016). 
1.7.2 Fluorescence Anisotropy Assay.  
Detection of fluorescence anisotropy caused by the cross-linking of a fluorescein-labelled 
glutamine donor peptide to a larger protein acceptor (BSA) by transamidation activity of 
TG2 was achieved with the assay developed by Kenniston et al., (2013). Transamidation 
reactions between donor peptide and acceptor BSA resulting in a cross-linking product 
leads to bigger changes in the fluorescence anisotropy. 
1.7.3 Fluorescence Transamidation Assay.  
In this assay, the activity was determined by a fluorescent Lys substrate (KXD) as the 
amine nucleophile-labelled N, N-dimethylated casein (NMC) which is Gln-containing 
protein substrate, at the end of the transamidation reaction. The TG-catalysed covalent 
coupling of KXD and NMC causes a shift in strength and wavelength of fluorescence of 
the dansyl group (Case et al., 2005). The fluorescence transamidation assay could be 
applied for selectivity profiling across other transamidating enzymes (TG1, TG3, TG6 
and factor XIIIa) and is widely used for screening to discover TG2 inhibitors (Schaertl et 
al., 2010). 
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1.7.4 Enzyme-Coupled Assay.  
The enzyme-coupled assay was firstly developed by Day and Keillor (1999), based on 
the indirect measurement of TG2 activity through detecting the quantity of NADH by 
measuring absorbance at 340nm (Day and Keillor, 1999). The assay involves two steps; 
in first step ammonia is released as a result of TG2 action on its substrate (protein/peptide 
bound glutamine), while in the second step, reductive amination of α-ketoglutarate (α-
KG) with consumption of NADH occurs to yield glutamate, this latter reaction being 
catalysed by glutamate dehydrogenase (GDH)( Oteng-Pabi et al.,  2013; Michael et al., 
2015) . In addition, this assay could be used to evaluate the activity and kinetic parameters 
of TG2 substrates (Song et al., 2016). 
1.7.5 Absorbance Based Assay 
A nonradioactive transglutaminase assay was developed by Slaughter and co-workers 
using 5-(biotinamido) - pentylamine and NMC (N, N-dimethylated casein) (Slaughter et 
al., 1992). In this assay, a microtiter plate is coated by NMC followed by incubation with 
5-(biotinamido) pentylamine and TG. Then, by using streptavidin-alkaline phosphatase, 
the transamidation of 5-(biotinamido)-pentylamine and NMC was detected and measured 
by absorbance at 405 nm. Another absorbance based assay for transglutaminase activities 
has been developed by Seiving et al., (1980) and then optimised by Choi et al., (1992). 
This assay was established to monitor cross-linking activities between casein bound to 
microtiter plates and free biotinylated casein by the sample. Then quantitation of 
immobilized biotin-labeled casein, which formed as the result of the enzymatic reaction, 
was conducted by avidin or streptavidin conjugated enzymes. Trigwell and co-workers 
(2004) developed an assay by replacing the free biotinylated casein substrate with 
biotinylated hexapeptide (biotin-TVQQEL),which leads to reduction in the background 
signal and increases the assay sensitivity(Trigwell et al., 2004). 
1.8 Coeliac disease 
Coeliac disease (CD) is an autoimmune small bowel disease that can be triggered in 
genetically susceptible individuals by ingestion of gluten and similar proteins contained 
in wheat, rye, and barley (Wingren et al., 2012). Partially digested gluten can prompt an 
autoimmune response, which causes damage to intestinal villi, thereby reducing the 
absorptive surface of the small intestine (Assa, 2017). Patients with the early developing 
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coeliac disease still have a normal small-intestinal mucosal villus structure, but they may 
already have TG2-autoantibody in their circulation, leading to increasing in a number of 
inflammatory cells in their small-bowel mucosa. Moreover, these patients may suffer 
from various gastrointestinal symptoms, such as abdominal pain and diarrhoea, before 
development of villous atrophy (Kalliokoski et al., 2016). 
1.8.1 Pathogenicity of coeliac disease 
The major environmental factor responsible for the development of the coeliac disease is 
gluten, which is a collective term for the prolamin storage proteins of the cereal grains 
wheat, rye, and barley. Its partial digestion by gastric, pancreatic, and brush border 
peptidases leaves long peptides up to 33 amino acids in length containing glutamines and 
prolines (Shan et al., 2002).  These peptides pass to the lamina propria of the small 
intestine through transcellular or paracellular routes (Matysiak et al., 2008; Visser et al., 
2009; Schumann et al., 2017). Because of the accumulation of gliadin peptides, the 
permeability of the intestines will increase, which allows macromolecules to enter and 
exit through the gaps in the intestine. Intestinal permeability can be evaluated by 
numerous methods (Kim and Ko 2018), such as measuring the excretion of orally ingested 
sugars like sucrose, mannitol, cellulose and lactulose that are absorbed from different 
regions of the gastrointestinal tract in trace quantities and are excreted unchanged in the 
urine (Farhadi et al., 2003). The lactulose to mannitol (L/M) ratio is considered to be a 
sensitive and accurate marker of small bowel permeability and the urinary excretion of 
sucralose can be used to estimate whole gut (small bowel and colon) permeability 
(Bjarnason et al., 1994; Meddings and Gibbons, 1998). Urinary lactulose and mannitol 
have been quantitated by several methods including thin layer and paper chromatography, 
enzymatic assays, gas chromatography and HPLC (Farhadi et al., 2003). Furthermore, 
plasma haptoglobin-2 (zonulin) concentrations are used to assess intestinal permeability 
(Wang et al., 2000). However, this may be inaccurate as the haptoglobulin 2 protein has 
a completely different role to its precursor protein. Haptoglobin-2-precursor (pre-HP2) 
was identified as the precursor of haptoglobin-2 HP (Tripathi et al., 2009). The 
Haptoglobin protein (HP2) is a protein that circulates in the plasma and mops up free iron 
ion to avoid oxidative stress. Human haptoglobin (HP) occurs as two common alleles, 
HP1and HP2. The HPHP2 allele only exists in humans. The pro-protein of HPHP2 (pre-
HP2) is active as zonulin (Sturgeon et al., 2017). Therefore, only patients who have an 
HP2 gene can produce pre HP2 (zonulin).   This protein controls the permeability of the 
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intestine epithelial cells by controlling the binding between the epithelial cells of the 
intestinal mucosa (Kim and Ko, 2018). The pre-hp2 expression is upregulated in patients 
with celiac disease and type 1 diabetes (Wang et al., 2000; Drago et al., 2006). In affected 
individuals, an adaptive immune reaction occurs, which is dependent on the deamidation 
of a 33mer gliadin peptide (LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF) by 
intestinal TG2 (Dieterich et al., 1997).  Deamidation changes one glutamine to glutamate 
in the 33mer gliadin peptide (changes are underlined) and enhances the immunogenicity 
of the peptide, greatly enhancing its binding to HLA-DQ2 or HLA-DQ8 molecules and 
subsequently to antigen-presenting cells (APCs). The structure of DQ2 was found in 
complexes with an immunogenic epitope from gluten, namely QLQPFPQPELPY (Kim 
et al., 2004). During this process, autoantibodies against TG2, gliadin, and actin are 
formed. These antibodies are thought to contribute to extra-intestinal complications of 
coeliac disease, such as gluten ataxia and dermatitis herpetiformis (Lebwohl et al., 2018) 
(See Figure 1-7)  
Coeliac disease has a genetic element in that patients have specific variants of the HLA 
class II genes HLA-DQA1 and HLA-DQB1 (Lundin and Wijmenga, 2015). More than 
90% of CD patients are HLA-DQ2 positive and most of the others are HLA-DQ8 positive. 
A study by Liu, et al., (2017) in the United States reported that, by the age of 15 years, an 
estimated 3.1% of the population develops CD, with a risk of 14·2% among those 
homozygous for DQ2 and 1·5% through those who had one copy of DQ8. Nearly all CD 
patients possess HLA-DQ2, HLA-DQ8, or half HLA-DQ2, whereas, up to 40% of people 
in the Americas, Europe, and Southeast Asia also have these alleles. This means that these 
genes are necessary but not sufficient for CD to display, contributing to only about 40% 
of the genetic risk for the disease (Lebwohl et al., 2018). Moreover, an important role of 
other environmental factors in the pathogenesis of CD was suggested, including exposure 
to heavy metals, gastrointestinal infections, drugs and the intestinal microbiome (Elli et 
al., 2018). 
1.8.2 Epidemiology 
Coeliac disease is considered an infrequent or rare disorder; the diagnosis of CD was 
based on the detection of typical symptoms of the gastrointestinal tract and confirmed by 
the small intestinal biopsy. In recent times, an international study investigated wide-
ranging population samples in four different European countries; on average, the total 
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prevalence of CD was 1%, with big variations between countries (2.0% in Finland, 1.2% 
in Italy, 0.9% in Northern Ireland, and 0.3% in Germany). This study has reported that 
many CD cases would remain undetected without serological screening (Catassi et al., 
2014). Recently, a study to estimate the prevalence of CD in Australia showed that 1.2% 
of adult men and 1.9% of adult women proved positive (Walker et al., 2017). Recent 
studies for the epidemiology of CD performed in developing countries, show spread rates 
overlapping European Figures. For example, epidemiological studies performed in areas 
of the developing world show 0.79% in Libya, 0.6% in Tunisia, 0.53% in Egypt and 3% 
in Saudi Arabia (Costa et al., 2014). Coeliac disease is more frequent in women compared 
to men, with a female: male ratio of up to 2.8:1 (Gujral et al., 2012). For a long time, CD 
was believed to be a pediatric disease; however, a study in the UK reported that the 
highest rates of prevalence of CD were in people and aged less than 5 years and between 
50 and 69 years. Moreover, this study reported a fourfold increase in the prevalence rate 
of CD in the United Kingdom over a period of 22 years (West et al., 2014). This may, in 
part, reflect the ease of correct diagnosis using the serological test over that time. 
1.8.3  Symptoms of coeliac disease 
Coeliac disease is commonly asymptomatic; indeed, the UK study commented that the 
mean duration of symptoms before an initial diagnosis of CD was 13 years. This because 
of, wide-ranging symptoms, with similarity to those in other conditions, and/or lack of 
attention and recognition of CD in the individuals and healthcare professionals (Gray et 
al., 2010). The classical symptoms in early childhood are diarrhea and failure to thrive 
after weaning (Lebwohl et al., 2015). Obviously, typical symptoms of CD comprise 
symptomatic malabsorption, abdominal pain and cramping, wind, nausea, diarrhoea with 
or without weight loss, iron deficiency and anaemia, increased levels of liver enzymes, 
irritable bowel syndrome, premature osteoporosis, discoloration of teeth, thyroid disease 
(Fasano and Catassi, 2001; Lionetti and Catass, 2011) . 
1.8.4 Transglutaminase 2 role in coeliac disease 
Transglutaminase 2 plays a vital role in coeliac disease by converting specific glutamine 
residues in gluten peptides into glutamic acid in deamidation reaction. This procedure 
raises the peptide binding (sequence) affinity of gluten peptides to the coeliac disease-
associated HLA-molecules (du Pré and Sollid, 2015). The HLA-DQ2.5, HLA-DQ8, and 
HLA-DQ2.2 protein molecules all show a greater affinity for negatively charged anchor 
 Chapter 1 
 
40 
 
residues, which are introduced into gluten peptides through deamidation by TG2 (du Pré 
and Sollid, 2015).  
The HLA-DQ2/DQ8 bound glutamate-rich peptides present on the antigen-presenting 
cells to activate the CD4+ T cells, which in turn activate the B cells in the lamina propria 
of the small intestine. The B cell clonal expansion results in the production of circulating 
anti-gliadin and anti-TG2 antibodies against self-TG2. The gluten-specific T cells have 
been proposed to cause the activation of TG2 specific B cells to produce anti-TG2 
antibodies (see 1.8.1). All of these consecutive actions result in inflammation and 
intestinal epithelial layer destruction (See Figure 1-7) (Lionetti and Catass, 2011). The 
villi of the small intestine provide the absorptive surface for the nutrients into the blood. 
The destruction of the intestinal villi causes mal-absorption of nutrients into the blood, 
thereby causing typical symptoms of CD such as weight loss and anaemia (Lionetti & 
Catass, 2011). 
 (Adapted from Alaedini & Green (2005) 
 
Figure 1-7: Schematic representation to show the development of CD after exposure to the gluten 
peptides 
A; Because of increasing the intestinal permeability the gluten peptides cross the lamina propria. B; 
Deamidation of the glutamine residues in the gliadin peptides by intestinal TG2 leads to the formation of 
glutamate, creating epitopes with increased immunostimulatory potential. C; Deamidated gluten peptides 
have higher binding affinity for class I MHC HLA/DQ2/DQ8. These glutamate rich peptides on the HLA-
DQ2/DQ8 activate the CD4+T cells which in turn activates the B cells. D; The clonal expansion of B cells 
results in the production of antibodies against gluten and TG2. E; In addition, the T cell activation produces 
pro-inflammatory cytokines that activate matrix metalloproteinases resulting inflammation and intestinal 
epithelial layer destruction. 
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1.8.5 Diagnosis of CD 
The diagnosis of CD depends on a series of clinical signs, positive CD serological tests 
and histological findings of duodenal biopsies (Rubio et al., 2013). Serology and 
duodenal histology were undertaken after gluten-containing diet, to confirm mucosal 
healing in CD patients. Anti- TG2 IgA antibody (TG2-Ab) is the recommended 
serological test for CD screening in individuals < 2 years of age; this test has high 
sensitivity and specificity (> 95%) (Van Der Wind et al., 2010). Anti-endomysium 
antibody titre is another test with higher specificity (around 99%), but it is not used 
initially; is used as a confirmatory test because of technical difficulties and cost (Leffler, 
and Schuppan, 2010). Negative serological results do not mean the exclusion of the CD 
with 100% accuracy. Histological investigation of duodenal biopsy is still a crucial factor 
for the diagnosis of CD. The histological markers of mucosal damage of CD include 
villous atrophy (see Figure 1-8), increased intraepithelial lymphocytes (IELs), in 
combination with crypt hyperplasia (Marsh, 1992). The identification of HLA DQ2 
and/or DQ8 through genetic testing can be used to rule out CD. This test could be used in 
certain clinical settings, in order to exclude the possibility of a likely future onset of CD 
in high-risk patients (Elli et al., 2018). 
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Figure 1-8: Changes in intestinal villi caused by CD. 
Adopted from https://www.shutterstock.com/image-vector/celiac-disease-small-intestinal-normal-villi-794121334  
1.8.6 CD complications 
• Intestinal mucosal inflammation and calcium malabsorption can occur in CD 
patients, which leads to suffering from bone loss (Malamut and Cellier, 2015). 
• There is an increased risk of diseases such as diabetes type I, autoimmune 
thyroiditis, autoimmune hepatitis, rheumatoid arthritis Addison’s disease, 
antiphospholipid syndrome, myasthenia gravis and dermatitis herpetiformis 
(Cosnes et al., 2008; Iqbal et al., 20013). 
• There is a higher risk of the development of obstetric complications in women 
with coeliac disease. This is because treatment with a gluten-free diet leads to a 
significant decrease in preterm birth (Saccone et al., 2016). 
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1.8.7 Therapeutic intervention for the treatment of CD 
To date, the only accepted form of therapy for CD is the avoidance of gluten through 
dietary control (Pluges and Khosla, 2015). In recent years, the high quality of gluten-free 
products has improved; however, the adherence to these products depends on different 
individual and environmental factors (Hall et al., 2013). One study reported that in the 
UK, diet adherence in adult CD patients ranged from 36% to 96% (Ford et al., 2012). It 
has been established that the CD patients who keep to a gluten-free diet shown 
improvements in vitamin deficiencies and abnormalities linked with the disease (Cosnes 
et al., 2008). However, the majority of CD patients fail to adhere to a gluten-free diet. In 
some parts of the world, especially in developing or third world countries, gluten-free 
products are not readily available (Hauser et al., 2007). In addition, a gluten-free diet is 
usually more expensive. Therefore, it is challenging to adhere to a gluten-free diet for life 
and alternative therapeutic strategies are warranted for sufferers of CD (Hauser et al., 
2007). Previous and current clinical trials for CD comprise treatment with glucocorticoids, 
zonulin (pre-HP2) antagonists, gluten-sequestering polymers, oral peptidases, gluten 
vaccines, probiotics and TG2 inhibitors (Pluges and Khosla, 2015).  
a) Treatments with Glucocorticoids 
Glucocorticoids are normally used to decrease the morbidity of immune-mediated 
diseases such as Crohn's disease and asthma. However, their significant side effects limit 
their uses in the treatment of lifelong diseases, such as CD. Budesonide, which is a 
glucocorticoid with poor oral bioavailability, is used in the treatment of Crohn's disease. 
Pilot studies reported that budesonide might provide clinical benefit to CD patients 
(Daum et al., 2006; Ciacci et al., 2009). Another pilot study has mentioned that using 
prednisolone, which is a glucocorticoid that has a higher oral bioavailability, induced a 
rapid reduction in epithelial apoptosis in celiac patients; however, it was accompanied 
with suppression of villous regeneration, suggesting that short courses of oral 
prednisolone could benefit specific patient groups (Das et al., 2012). 
b)  Oral peptidase treatments 
The ability of several fungi, bacteria, and plants to degrade gluten has been used to 
develop oral peptidase therapies for CD. The high content of glutamine and proline in 
gliadin is the reason for gliadin resistance to breakdown by the intestinal brush border 
membrane peptidases, pepsin and pancreatic peptidases (Shan et al., 2002). Utilisation of 
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prolyl endopeptidases has been considered for detoxifying gluten peptides to give them 
the ability to cleave peptides at proline residues (Hausch et al., 2002). Prolyl 
endopeptidases are broadly expressed in both mammals and microbes; however, their 
levels in humans are insufficient for detoxifying gluten peptides. In contrast, recombinant 
prolyl endopeptidases from a diversity of bacteria and fungi have ability to proteolysis 
the gliadin peptides both in vitro and in vivo (Shan et al., 2004; Mitea et al., 2008). 
c) Haptoglobin-2 (pre-HP2) antagonists 
Haptoglobin-2 precursor protein (pre-HP2; previously known as zonulin) is an epithelial 
protein which has been shown to be involved in modulating barrier permeability. The 
intestinal barrier is normally impermeable to macromolecules but due to gluten exposure 
in coeliac patients, the permeability of this barrier will increase, leading to movement of 
gliadin peptides into the lamina propria (Fasano et al., 2001; Tripathi et al., 2009). Gluten 
peptides stimulate the overexpression of pre-HP2) in CD patients’ intestinal tissue, 
consequently increasing intestinal permeability. As a result, the blocking of pre-HP2 has 
been proposed as a possible therapeutic strategy for the treatment of CD. Larazotide 
acetate inhibits the opening of tight junctions in epithelial cells in the small intestine (Di 
Pierro et al.,. 2001). This compound probably inhibits the pre-HP2 interaction and is thus 
thought to prevent gliadin-induced permeability both ex vivo and in vivo (Clemente et al., 
2003; Drago, et al., 2006). 
d) Treatments with probiotics 
The ability of microorganisms to regulate the function of the intestinal barrier has 
motivated research towards using intestinal bacteria as probiotics for the treatment CD. 
The in vitro studies by De Angelis et al., (2006) demonstrated that several bifidobacteria 
species have the ability to hydrolyse gliadin peptides into less immunogenic peptides. 
e) Treatments with therapeutic vaccines 
The production of peptide-based immunotherapy that can specifically stop the adverse 
inflammatory cascade activated by gluten proteins is currently one of the most promising 
therapies for CD (Di Sabatino et al., 2018). This type of immunotherapy is targeted to the 
complete recovery of immune tolerance toward ingested gluten by targeting intestinal 
CD4+ T-cells, which have a crucial pathogenic role in CD, without affecting the systemic 
immune responses. Recently, the characterisation of the collection of gluten epitopes that 
is responsible for mucosal inflammation in CD has permitted the design of the Nexvax2 
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drug. Further studies are still needed to demonstrate the efficacy of this drug to protect 
CD patients from the damaging effects of gluten ingestion (Goel et al., 2017; Di Sabatino 
et al., 2018). 
f) Treatments with TG2 inhibitors 
The critical role of TG2 in CD makes inhibition of TG2 activity a potential therapeutic 
target. A number of TG2 inhibitors have been developed, including reversible inhibitors 
such as cinnamoyl compounds, thienopyrimidines, and acylidineoxindoles and 
irreversible inhibitors such as thiadiazoles, epoxides, and dihydroisoxazoles (Plugis and 
Khosla 2015). However, as TG2 is present in all cells, chemical inhibitors of the enzyme 
may have a detrimental effect on processes other than CD. Natural products such as garlic 
and milk present less of a toxicity problem, as they are ingested by many people, without 
adverse side effects.  Milk and garlic have been shown to contain TG2-mediated 
transamidation inhibitors, (Williams et al., 2005; Lee et al., 2007). It is, therefore, 
important to a) develop an assay, which can measure the deamidating activity of TG2, 
and b) to screen natural products with known medicinal attributes in order to assess them 
as potential deamidation inhibitors and moderators of CD. Natural products chosen for 
this study were dietary flavonoids, due to their promising biological activity. 
1.9 Flavonoids 
The flavonoids, one of the most frequent and common groups of natural constituents, are 
important to man because many members are physiologically active. Nearly two thousand 
substances have been described and as a group they are generally distributed among 
vascular plants. (Harborne, J.B., 2013.) Flavonoids consist of a large group of 
polyphenolic compounds having benzo--pyrone structure, which is ubiquitously present 
in plants and in the human diet with numerous potentially health-beneficial biological 
activities. The natural sources of flavonoids are fruits and vegetables (Kumar and Pandey, 
2013). Flavonoids have different biological activities, such as antioxidant, anti-
inflammatory, cholesterol-lowering, antibacterial, hepatoprotective, anticancer, antiviral 
and many other biological functions reported in the literature (Kumar and Pandey, 2013; 
Huang, 2016; Mohana, 2016; Packzoski et al., 2017). Flavonoids are also known to be 
potent inhibitors of numerous enzymes, such as cyclo-oxygenase (COX), 
lipoxygenasexanthine oxidase (XO) and phosphoinositide 3-kinase (Panche et al., 2016) 
(More explanation in chapter 3). 
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1.10 Framework and aims of this study 
As mentioned previously, the TG2 enzyme has an important role in the initiation of 
coeliac disease (CD) due to its ability to convert specific glutamine residues in gluten 
peptides into glutamic acid in a reaction termed as deamidation. However, to date, a 
gluten-free diet is the only accepted form of therapy for CD. Though safe and effective, 
this not an ideal lifestyle due to cost reasons and it has an impact upon the quality of life 
of the sufferer. Therefore, research for developing novel therapeutic strategies appears to 
be a reasonable approach to find alternative treatment options. The hypothesis that 
inhibition of the TG2 activity will be considered as a viable strategy for the treatment of 
CD.  The side effects of using chemical TG2 inhibitors motivated the research towards 
the screening of TG2 inhibitors from natural sources. Natural products chosen for this 
study were dietary flavonoids, due to their promising biological activity. However, to 
recognise inhibitors/activators of TG2, numerous assays to measure and quantify 
transamidating TG2 activity have been established (Pietsch et al., 2013). The classical 
transamidation assay methods are standard end, fluorimetric and colorimetric assays, 
which are still used, although there is a need to develop an easy and more sensitive assay 
relevant to CD (Song, Minsoo, et al., 2016). While mass spectrometry methods have been 
successfully utilised to characterize deamidated peptides in complex mixtures, the results 
so far have largely been qualitative (Ong and Mann, 2005) with associated high costs.  
Therefore, an effort was made to develop and optimise a low-cost TG2 deamidation assay 
that could accurately quantify TG2-mediated deamidation and would be amenable to high 
throughput screening. 
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1.10.1 Aims of the thesis: 
The main aims of the work presented in this thesis were- 
• To screen the effects of different pure flavonoids and dietary flavonoids on the 
hrTG2 and gplTG2 transamidation and deamidation activity.   
• To develop a novel method of collecting flavonoids from plant extracts using 
immobilised metal ion affinity chromatography (IMAC). 
•  To develop a novel colourimetric assay for flavonoids using bicinchoninic acid 
(BCA) 
• To test the in situ activity of TG2 in HT29 cells and the effects of flavonoids on 
this cellular activity using, SDS-PAGE, Western blotting and fluorescence 
microscopy. 
• To develop an assay to quantify the TG2-mediated deamidation activity using 
different substrates, such as plant storage protein gliadin peptide mixtures, the 33-
mer gliadin peptide containing the HLADRQ2 binding sequence.
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 General laboratory reagents 
All laboratory reagents were of the highest grade and purchased from Sigma-Aldrich 
(UK), Lonza (UK) and Zedira (Germany) unless otherwise specified in the text. Pure 
flavonoids (kaempferol, luteolin, epicatechin, apigenin, myricetin, cyanidin, morin, 
naringin, hesperetin, hesperidin, quercetin, catechin, taxifolin) are obtained from sigma-
Aldrich (UK). Casein,N’,N’-dimethylcasein, MTT (3-(4-5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), paraformaldehyde, TritonTM X-100, Phosphatase Inhibitor 
Cocktails 2 (sodium orthovanadate, sodium molybdate, sodium tartrate and imidiazole) 
and 3 (cantharidin, (–)-p-bromolevamisole oxalate, calyculin A), Ammonium persulphate 
(APS), ExtrAvidin-horseradish Peroxidase (HRP) and ExtrAvidin-FITC were obtained 
from Sigma- Aldrich Co. Ltd. (Gillingham, UK). The TG2 inhibitors Z-DON (Z-DON-
Val-Pro-Leu-OMe) and purified human recombinant transglutaminase2 with purified 
guinea-pig liver TG2 were obtained from Zedira GmbH (Darmstadt, Germany). 
VectaShield® containing 4, 6-diamidino- 2-phenylinole (DAPI) was from Vector 
Laboratories Inc (Peterborough, UK). Biotin-TVQQEL was purchased from Pepceuticals 
(Enderby, UK). Biotin cadaverine (N-(5 aminopentyl) biotinamide) and biotin-X-
cadaverine (5-([(N (biotinoyl) amino) hexanoyl] amino) pentylamine) were purchased 
from Invitrogen, UK (Loughborough, UK). N, N, N’, N’- tetramethylethylenediamine 
(TEMED) was from (National Diagnostics, USA), 33-mer gliadin 
peptide((LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF)and pepceutical, UK****). 
2.1.2 Food samples:   
Apples (Malus domestica) Green tea (Camellia sinensis), Strawberry (Fragaria vesca), 
Kale (Brassica oleracea), Capers (Capparis spinose), Garlic (Allium sativum) and Onions 
(Allium cepa), were purchased from a local market. 
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2.1.3 Cell culture reagents 
McCoys 5A medium, foetal bovine serum (FBS), penicillin (10,000 U/ml)/streptomycin 
(10,000 μg/ml) and trypsin (10 X) were purchased from BioWhittaker Lonza Group Ltd., 
UK. Phosphate buffered saline (PBS) was obtained from Life Technologies (Invitrogen, 
UK).  
2.1.4 Cell line 
Human Colonic adenocarcinoma cells (HT-29) from American Type (ATCC, USA). 
2.2 Methods 
2.2.1 Extraction methods 
a) Extraction of proteins from cell lines  
The HT29 cells were cultured (section 2.2.9a) and passaged (section2.2.9b). Once the 
cells were confluent, they were washed twice with ice-cold phosphate buffered saline 
(PBS) to remove the spent medium. Ice cold lysate buffer (50mM Tris/HCl pH 8.5 
containing 0.5% (w/v) sodium deoxycholate, tissue culture 10mg ml-1 protease or 10 mg 
ml-1 phosphatase inhibitor cocktail 2 and 3 (Sigma, UK)) were added to the adherent cells 
while maintaining constant agitation for 30min at 4°C. The cells were scraped off the 
flask using plastic cell scraper. The cell suspension was gently transferred into a pre-
cooled micro centrifuge tube. The cell suspension was homogenized and centrifuged 
(Eppendorf 5702 R) for 5.0min at 22oC at 14,000 x g. The supernatant was used for 
measurement of protein concentration (section 2.2.6a), analysis by electrophoresis 
(section 2.2.7) and Western blotting (section 2.2.8).   
b) Extraction of flavonoids: 
All food samples were cleaned and freeze-dried (Telstar, LyoQuest, UK). Two hundred 
and fifty milligrams of freeze-dried materials were ground to powder in a mortar and 
pestle. The material was mixed with 6.0ml of 62% (v/v) methanol and 6.0ml of 6.0M HCl 
refluxed for 90min at 90OC in the presence of 15.0mg of an anti-oxidant tert-
Butylhydroquinone. Each sample was extracted in triplicate. After the refluxing the 
materials were cooled and centrifuged (5,000 x g for 15min), the volume was made up to 
10.0ml with methanol and the extracts were stored at -20oC in dark bottles until required. 
The extraction conditions (solvent polarity, the addition of acid, extraction time, 
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extraction temperature) were chosen from previously published literature (Vatai, et al., 
2006; Spigno et al/. 2007; Putnik et al., 2016). 
c) Extraction of Vicia faba storage proteins 
Fifty grams of Vicia faba seeds (v Aquadulce Claudia) were soaked in water overnight. 
The cotyledons containing the storage proteins were homogenized in 200.0ml of 50.0mM 
Tris pH 8.0 buffer containing 0.5M NaCl. The homogenate was strained through muslin 
and centrifuged at 20.000 x g for 30.0minutes. The supernatant was collected and dialysed 
against water at 4oC until the precipitated globulin storage proteins appeared in the sample. 
The dialysate was centrifuged at 20.000 x g for 30.0minutes and the precipitate was 
freeze-dried (Telstar, LyoQuest, UK) then stored at -20oC. 
2.2.2 Purification Methods: 
a) Solid Phase Extraction (SPE) 
The C18 Varian Bond Elute SPE cartridge (2.0ml) was washed with 2.0ml of methanol 
followed by 2.0ml of 5.0% (v/v) methanol. One millilitre of flavonoids extracts was 
loaded onto the washed C18 column and 1.0ml fractions collected from this point in glass 
sample vials (2.0ml Chromacol vials). The bound material was eluted with 1.0ml 80.0 % 
(v/v) methanol followed by 1.0ml methanol (100%)( Figure 2-1). The eluted samples 
were dried using a centrifugal concentrator (GeneVac, UK). The extracts were dispersed  
in 0.5 % (w/v) sodium deoxycholate using an ultrasonic bath (Fisherbrand, UK) before 
adding to an assay to measure TGase activity (See Section 0and (2.2.6b)  
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Figure 2-1: Illustration of the main steps of the SPE technique 
1. Column after washing with 2.0 ml of 10% methanol.  2. Loading the column with the mixture made by 
1.0 ml of sample and 9.0 ml of 100% methanol.  3. Analytes elution with 80% methanol. 
b) HiTrap Chelating HP 
All solutions were filtered through a 0.25µm syringe filter (Minisart syringe filter, 
Germany) prior to their application onto the (1.0ml) HiTrap Chelating HP (GE Healthcare, 
UK) column. The column was washed with 5.0ml of distilled and deionised water (DDW) 
before the application of 1.0ml of 15.0mM CuSO4 to provide 75-80% column metal 
loading. After which the columns were washed with 5.0ml DDW followed by 10.0ml of 
methanol containing 0.2% (v/v) 5.0 M NaOH. The food extracts were removed from the 
freezer and allowed to equilibrate to room temperature. One ml of the extract was added 
to 3.0ml of methanol containing 0.2% (v/v) 5.0 M NaOH, the pH was brought to pH 8.0 
by the addition of 1.0ml 20%(v/v) diethanolamine and the extract was applied to the 
copper chelating resin in a syringe at a flow rate of approximately 1.0ml min-1. Unbound 
material was eluted with 10.0ml of methanol containing 0.2% (v/v) 5.0 M NaOH. The 
bound flavonoids were eluted with 5.0ml methanol containing 0.15% (v/v) TFA 
(prepared immediately before use) (See Figure 2-2). Fractions were dried using the 
centrifugal concentrator and dissolved in either sodium deoxycholate or DMSO before 
being included in biotin incorporation, cross-linking and deamidation assay to measure 
TG2 activity (See Section 2.2.6b).  
 Chapter 2 
 
52 
 
 
Figure 2-2: Illustration of the main step of the IMAC technique: 
1, loading the column of With the mixture made by 1.0 ml of sample, 3.0 ml of 100% methanol with 0.2% 
(v/v) of 5M sodium hydroxide and 1.0 of 20% (v/v) diethanolamine. 2, washing the column with 10.0 ml 
100% methanol with 0.2% (v/v) of sodium hydroxide 5M to eliminate analytes that didn’t bind the column. 
3, Elution of flavonoids by addition of 5.0 ml methanol with 0.15% (v/v) of TFA. 
2.2.3 Qualitative analysis using High-Performance Liquid Chromatography 
(HPLC) 
Chromatographic condition: 
The mobile phase used: Distilled and deionised water + 0.02 % (v/v) of trifluoroacetic 
acid (Solvent A). Acetonitrile + 0.02 % (v/v) of trifluoroacetic acid (Solvent B); filtered 
through 0.2m membrane. The column used C12 with TMS end-capping Synergi™ 4 μm 
Max-RP 80 Å, LC Column 250 x 4.6mm.  The detector used LC 200a Series PDA 
Detector, Photo Diode Array Detector model, was provided by PerkinElmer; the UV 
wavelength used was 410nm(See Table 2-1 ). (Ganzera et al,. 2005) 
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Table 2-1: The gradient used in HPLC for flavonoids 
 
Pure flavonoids were prepared (1.0mM in acetonitrile) and filtered through 0.25µm 
syringe filter (Minisart syringe filter, Germany) before the injection to the HPLC. 
Samples obtained by SPE and IMAC were diluted 1:10 in acetonitrile and filtered before 
0.25µm syringe filter (Minisart syringe filter, Germany) the injection on to the HPLC.  
2.2.4 Digestion of gel bands for mass spectrometry  
The biotinylated proteins were separated by 1D PAGE in 5-15% gradient gels (Bio-Rad, 
UK). The biotinylated bands were excised from the gel using a sterile scalpel, cut into 
smaller pieces and transferred slices to a microfuge tube. The gel pieces were covered in 
equal volumes (50.0mM ammonium bicarbonate, water, ACN) and then incubated at 
37oC for 5.0min. The supernatant surrounding the gel pieces was removed and replaced 
with equal volumes of 50.0mM ammonium bicarbonate, water and ACN followed by 
incubation at room temperature for 1.0min. The gel pieces were then mixed and dissolved 
in equal volumes of ACN in order to dehydrate them. The supernatant was removed and 
covered with 50.0mM ammonium bicarbonate for 5.0min until the gel is rehydrated. 
Acetonitrile was then added into the gel and incubated for 15min. The supernatant was 
removed and the gel covered with 100 % (v/v) ACN until the gel shrank. The supernatant 
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was removed, covered with water for 5.0 min until the gel dehydrated and the excess 
supernatant was removed. The gel pieces were then digested by (1.0µl Promega gold 
trypsin as prepared from 0.55µg µl-1, 7.6 µl water and 16.6 µl of 100 mM ammonium 
bicarbonate pH 10.0) and then incubated for overnight at 37oC. The trypsin reaction was 
terminated by adding 1.0µl volume of 1.0 % (v/v) TFA into the samples.  
2.2.5 Mass spectrometry: 
a) Flavonoids 
Food extract samples were analysed by LC-MSMS. Briefly, 1.0uL of each sample was 
injected by Eksigent 425 LC system onto a trap column (Mobile Phase A; 0.1% formic 
acid, B; Acetonitrile with 0.1% formic acid). YMC Triart C18 guard column 0.3 x 5.0 
mm, 300μm  ID) at 10.0μL/min. Mobile phase A for 2.0min before gradient elution onto 
the analytical column (YMC  Triart C18 150 x 0.3mm ID, 3.0 μm) in line to a Sciex 
TripleTOF 5600+ Duospray Source using a 50.0μm electrode, positive mode +5500V.  
The method was run as an MRM-HR (multiple reaction monitoring-high resolution) with 
a TOFMS survey scan 250ms accumulation time, m/z range 5.0 to 620.0, followed by 9.0 
product ion scans for each known flavonoid as follows:  Kaempferol 287.06, Myrecetin 
319.05, Quercetin 303.05, Naringin 273.15, Hespiridin 611.19, morin 303.05, catechin 
291.09, taxifolin 305.06, Hesperitin 303.09 (Figure 3-2).  Declustering potential and 
collision energy were optimised by infusion for each flavonoid.  Food extract samples 
were compared to known standards by LCMS and infusion. 
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Figure 2-3:Flavonoids sturctures 
b) Gliadin 33mer peptides 
Samples (3.0 μL) were injected by Eksigent 425 LC system onto a trap column. (Mobile 
Phase A; 0.1% formic acid, B; Acetonitrile with 0.1% formic acid;). YMC Triart C18 
guard column 0.3 x 5mm, 300 μm  ID) at 10.0 μL/min mobile phase A for 2.0 min before 
gradient elution onto the analytical column (YMC  Triart C18 150 x 0.3mm ID, 3.0μm) 
in line to a Sciex TripleTOF 6600 Duospray Source using a 50.0 μm electrode, positive 
mode +5500V.  The method was set to IDA mode (Information dependent acquisition) 
with the following parameters:  TOFMS survey scan m/z 900-2250 range, 250ms 
accumulation time, Top 15 ions fragmented 100ms accumulation time (m/z range 100-
4000). The following linear gradients were used: mobile phase B increasing from 3% to 
30% over 38.0 min; 40% B at 43.0min followed by column wash at 80% B and re-
equilibration (57.0 min total run time). MS data were searched using PEAKS Studio 8.5 
(Bioinformatics solutions inc. Canada) with the following settings; precursor mass 25.0 
ppm, fragment ion 0.1 Da against custom Wheat database containing the gluten peptide.  
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Maximum missed cleavages 2, digest mode – none.  PTM variable modification oxidation 
[M] and deamidation (NQ). 
c) Gel Bands 
Samples (4.0 μL) were injected by Eksigent 425 LC system onto a trap column (Mobile 
Phase A; 0.1%  formic acid, B; Acetonitrile with 0.1% formic acid; YMC Triart C18 
guard column 0.3 x 5.0mm, 300μm  ID) at 10.0 μL/min mobile phase A for 2.0min before 
gradient elution onto the analytical column (YMC  Triart C18 150 x 0.3mm ID, 3.0 μm) 
in line to a Sciex TripleTOF 6600 Duospray Source using a 50.0μm electrode, positive 
mode +5500V.  The method was set to IDA mode (Information dependent acquisition) 
with the following parameters:  TOFMS survey scan m/z 400-1250 range,  250ms 
accumulation time, Top 30 ions fragmented 50ms accumulation time (m/z range 100-
1500). The following linear gradients were used: mobile phase B increasing from 2% to 
30% over 20.0min; 40% B at 22.0min followed by column wash at 80% B and re-
equilibration (32.0min total run time). MS data were searched using PEAKS Studio X 
(Bioinformatics solutions inc. Canada) with the following settings; precursor mass 25ppm, 
fragment ion 0.1 Da against the SwissProt human database (April 2019).  Maximum 
missed cleavages 2, digest mode – semispecific.  PTM fixed modification 
Carbamidomethylation, variable modification oxidation [M] and deamidation (NQ). 
2.2.6 Assays 
a) Bicinchoninic acid protein assay (BCA) assay  
The principle of the BCA assay based on the formation of Cu2+ protein complex that then 
followed by reduction of Cu2+ to Cu1+ in alkaline conditions. The extent of reduction 
depends on the quantity of protein present, the more the protein higher the amount of 
reduction. The amount of reduction of alkaline Cu2+ was observed by the formation of 
purple-blue complex in alkaline environments. BCA works with all reagents that have a 
reducing centre including the peptide bond (Smith et al., 1985) reducing sugars (Anthon 
et al., 2002) and flavonoids. The BCA can be used for the measurement of protein 
concentrations in the range of 0.2 to 1.0mg ml-1 (Smith et al. 1985). Protein concentration 
was measured using a commercially available kit (Sigma-Aldrich Co Ltd, UK). Bovine 
serum albumin (BSA) was used as the protein standard. However, quercetin was used as 
a standard flavonoid for flavonoid quantification. In brief, protein standards were 
prepared using dilutions of 0-2.0mg ml-1 BSA to produce a linear standard curve, 
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quercetin was prepared using concentration from 40 to 400µM. Standards and samples 
(20.0μl) were added to a 96-well flat-bottomed plate in triplicate. A volume of 200.0μl of 
working BCA reagent (50 parts of reagent A to 1 part of reagent B) was added to each of 
the wells and the plate incubated at 37oC for 30.0min. Absorbance was read at 570 nm 
using a standard 96-well plate reader. The protein content of samples was obtained by 
measuring them against the BSA standard curve. 
b) Transglutaminase deamidation activity assay 
Optimization of ammonium chloride as standard for the deamidation assay was based on 
the Poulin et al., method (2007), with some modifications. Ammonium chloride in 
ultrapure water used to prepare different concentrations from stock of ammonium 
chloride (10.0mM, 1.0mM, and 0.1mM). A volume of 25.0µl of each dilutions of 
ammonium chloride were added to a black fluorescence 96 well microplates (Greiner), 
and supplemented with 200.0l of working reagent containing; 500.0ml of sodium borate 
buffer solution, 2.5ml of sodium sulphite solution and 25.0ml of ultra-pure ethanol 
containing of 1.0g orthophthadialdehyde (OPA). Each microplate corresponding to 
different dilution of ammonium chloride was left for incubation at 20min incubation time 
at 600C. An intense fluorescent product is formed because of the OPA-amine reaction in 
the presence of 2-mercaptoethanol (See Figure 2-4). Release of ammonia readings in 
CLARIOstar Microplate Reader (BMG-LABTECH), relative fluorescence unit (RFU) 
was obtained at λex = 360nm and λem = 430nm.  
 
  
Figure 2-4: The orthophthadialdehyde (OPA) derivatization reaction  
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i. Transglutaminase 2 deamidation activity assay using Vicia faba storage 
protein as substrates 
To a set of glass sample vials (2.0ml Chromacol vials, Phenomenex, UK), 100.0μl of 
storage proteins (10.0 mg ml-1),10.0 mM EDTA was added to three of the tubes while 
10.0mM CaCl2 was added to another three tubes, 100.0µl ultrapure water was added to 
three of glass tubes that serve as blank. Five µg ml-t hrTG2 or 10.0µg ml-1 of gplTG2 
(Zedira) was added to all of these tubes (blank no EDTA or CaCl2, EDTA and CaCl2). 
Hundredμl tris/HCl buffer (pH 8.0) was added to all tubes (blank no EDTA or CaCl2, 
EDTA and CaCl2), 100.0μl of storage proteins (See section 2.2.1c) and 400.0μl of 
ultrapure water was added to three of tubes as a control. The glass tubes were gas sealed 
and incubated overnight at 37oC then 25.0μl was added from each sample to the wells of 
a black fluorescence microplate (Greiner) containing 1.0μl 2-mercaptoethanol. Then 
200.0µl of working reagents containing; 500.0ml of sodium borate buffer solution, 2.5 
ml of sodium sulphite solution and 25.0ml of ultra-pure ethanol containing 1.0g 
orthophthadialdehyde (OPA). Release of ammonia readings inCLARIOstar Microplate 
Reader (BMG-LABTECH), relative fluorescence unit (RFU) was obtained at λex = 360 
nm and λem = 430 nm.  The unit of the TG2 activity in different samples was defined as 
follow; 1 unit of activity is 1nanomole product formed per one hour (1nmol hr-1). 
ii. Transglutaminase 2 deamidation activity assay using the gliadin protein 
as substrate. 
Crude gliadin digest (G3375Sigma) 2.0mg was dissolved in isopropanol, evaporated by 
nitrogen gas and re-suspended in 1.0ml of 0.5% (w/v) sodium deoxycholate by sonication 
in an ultrasonic bath for 10min at room temperature. Gliadin protein samples were 
resuspended in deoxycholate (100.0µl). And used as substrate instead of storage proteins 
and applied to the assay for ammonia release that was described in section 2.2.6. The unit 
of the TG2 activity in different samples was defined as follow; 1 unit of activity is 
1nanomole product formed per one min (1nmol min-1). 
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iii. Transglutaminase 2 deamidation activity assay using the 33-mer gliadin 
peptide as substrates. 
The 33-mer gliadin peptide((LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF)and 
pepceutical, UK****) was prepared in DMSO  (10.0mM)as stock then 1mM solution  
was incubated with 5.0 µg ml-t hrTG2 in presence of CaCl2 (10.0mM), EDTA(10.0mM) 
for 10 min at RT. Then applied to the assay for ammonia release that described in section 
2.2.6.b. Release of ammonia readings in CLARIO star Microplate Reader (BMG-
LABTECH), relative fluorescence unit (RFU) was obtained at λex = 360nm and λem = 
430nm. The unit of the TG2 activity in different samples was defined as follow; 1 unit of 
activity is 1nanomole product formed per one min (1nmol min-1). 
c) Transglutaminase transamidation activity assays 
All the enzymatic assays for TGases have been carried out under optimal conditions of 
pH, Ca2+ and with N, N-dimethylcasein (acyl donor) or casein (acyl acceptor) as acyl 
donor substrates and biotin cadaverine (acyl acceptor) or TVQQEL as (acyl donor) 
substrates. Transglutaminase activity was measured by two different microplate assays. 
i. Biotin-labeled cadaverine incorporation assay 
The amine incorporating activity of TG2 was measured by biotin-cadaverine 
incorporation into N, N’-dimethylcasein. The assay was performed as described by 
Slaughter et al., (1992) with the modifications of Lilley et al.,(1998). Briefly, 96-well 
microtitre plates were coated overnight at 4°C with 250μl of N′, N′-dimethylcasein (10 
mg ml-1 in 100mM Tris-HCl, pH 8.0). The plate was washed twice with distilled water 
and blocked with 250.0 μl of 3% (w/v) BSA in 100.0 mM Tris-HCl, pH 8.0 and incubated 
for 1h at room temperature with gentle agitation. The plate was washed twice with 
distilled water before the application of 150.0μl of either 6.67mM calcium chloride 
(required for enzyme activity) or 13.3 mM EDTA (used to detect background TG activity) 
assay buffer containing 225μM biotin cadaverine (a widely used substrate to monitor TG 
amine incorporating activity) and 2 mM 2 mercaptoethanol. The reaction was started by 
the addition of 50.0μl of samples or positive control (50 ng/well of human recombinant 
TG2) and negative control (100.0 mM Tris-HCl, pH 8.0). After incubation for 1 h at 37°C, 
plates were washed as before. Then, 200.0μl of 100.0mM Tris-HCl pH 8.0 containing 1% 
(w/v) BSA and ExtrAvidin®-HRP (1:5000 dilution) were added to each well and the plate 
incubated at 37°C for 45min then washed as before. The plate was developed with 200.0μl 
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of freshly made developing buffer (7.5 μg ml-1 3, 3’, 5, 5’-tetramethylbenzidine (TMB) 
and 0.0005% (v/v) H2O2 in 100mM sodium acetate buffer, pH 6.0) and incubated at room 
temperature for 15min. The reaction was terminated by adding 50.0μl of 5.0M sulphuric 
acid and the absorbance read at 450 nm. One unit of TG2 activity was defined as a change 
in absorbance at 450nm min-1 
ii. Biotin-labeled peptide cross-linking assay 
The cross-linking activity of TG2 was measured via biotin-TVQQEL peptide 
incorporation into casein as described by Trigwell et al., (2004) with minor modifications. 
The 96-well microtitre plates were coated and incubated overnight at 4°C with casein at 
1.0 mg ml-1 in 100.0 mM Tris-HCl pH 8.0 (250.0μl per well). The wells were washed 
twice with distilled water, before being blocked with 250.0μl of 3% (w/v) BSA in 100.0 
mM Tris-HCl, pH 8.0 and incubated for 1 h at room temperature with gentle agitation. 
The plate was washed twice with distilled water before the application of 150.0μl of either 
6.67 mM calcium chloride and or 13.3 mM EDTA assay buffer containing 5.0μM biotin-
TVQQEL and 2.0 mM 2-mercaptoethanol. The reaction was started by the addition of 
50.0 μl of samples or positive control (50.0 ng/well of human recombinant or guinea-pig 
liver TG2) and negative control (100.0 mM Tris-HCl, pH 8.0) and allowed to proceed for 
1 h at 37°C. Reaction development and termination were performed as described for 
biotin-cadaverine assays. One unit of TG2 activity was defined as a change in absorbance 
450nm of 0.01 at min-1. 
iii. Visualisation of in situ TG2 transamidase activity 
The effect of the significant flavonoids on the TG2 activity was observed using 
immunofluorescence microscopy.HT29 (15,000 cells/well) cells were cultured for 24h on 
8-well chamber slides (ibidi). The medium was then removed and slides incubated for 4 
h with 1.0mM biotin-X-cadaverine (a cell-permeable TG2 substrate; Perry et al., 1995) 
in the culture medium before experimentation. Cells were then treated for 1h with the 
samples (kaempferol, morin, quercetin and Z-DON), washed three times (five min per 
wash) with PBS, fixed with 3.7 % (w/v) paraformaldehyde and permeabilised with 0.1% 
(v/v) Triton-X100, both in PBS for 15 min at room temperature. After washing, cells were 
blocked with 3% (w/v) BSA in PBS for 1 h at room temperature. The transglutaminase 
mediated biotin-X-cadaverine labelled protein substrates were detected by FITC-
conjugated ExtrAvidin® (Sigma-Aldrich) (1:200 v/v) in blocking buffer. The slides were 
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incubated overnight at 4°C. The next day cells were washed as before and nuclei counter-
stained using DAPI in Vectashield mounting medium. The slides were sealed with 
coverslips and stored at 4°C until required. Images were viewed using EVOS FL imaging 
system (ThermoFisher).  
2.2.7 Electrophoresis: 
To observe the activation or the expression of the proteins of interest, SDS- PAGE and 
Western blotting were employed. 
a) Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
The principle of the SDS-PAGE is built on denaturing of proteins and treatment with 
sodium dodecyl sulphate, which is anionic detergent. This process leads to the destruction 
of the secondary and tertiary structure of the protein. Moreover, the charge of the proteins 
when covered with SDS results in an equal mass to charge ratio on all the negative 
charged polypeptides. Therefore, the separation in SDS occurs solely by the size of the 
polypeptide chains. SDS-PAGE was carried out by the method described by (Laemmli et 
al.,1970)(See Table 2-2). Once the protein concentration of the samples was determined, 
(see section2.2.6a). The desired amount of protein was diluted in a 3:1 ratio with 4x 
reducing Laemmli buffer (8% w/v SDS, 40% (v/v) glycerol, 10% (v/v) 2-
mercaptoethanol, 0.01 % (w/v) bromophenol blue, 250.0 mM Tris/HCl pH 6.8; and boiled 
for 10min at 95°C to denature the proteins. Based on the molecular weight of the 
investigated proteins, acrylamide resolving gels were prepared (at different % 
acrylamide) for all experiments.  Two glass plates with combs and spacers of 1.5 or 0.75 
mm thickness were used. The 10% (w/v) acrylamide resolving gel mixture was prepared 
according to the required number of gels, as indicated in Table 2.2. Acrylamide 
polymerisation was initiated by the addition of volumes indicated of 10 % (w/v) 
ammonium persulfate and TEMED (N,N,N’,N’- tetramethylethylenediamine), after 
which the mixture was swirled gently. 
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Table 2-2: Preparation of SDS-PAGE gel 
 
For each gel, about 8ml of resolving gel mixture was transferred into the glass cast to 
allow space for a stacking gel to be added later. Distilled water was carefully overlaid on 
the top layer of the freshly poured gel mixture to create a smooth interface and prevent 
any gel shrinkage. The gel mix was allowed to polymerise at room temperature for 
approximately 30 to 40min. Once the resolving gel had polymerised, water was removed, 
the required amount of 4% (w/v) polyacrylamide stacking gel was prepared and 
polymerised by the adding of 10% (w/v) APS and TEMED as indicated in Table 2-2. 
Immediately after the stacking gel was poured, a plastic comb was placed to form the 
sample wells. Following polymerisation, the gels were placed into a Biorad protean 3 
electrophoretic tank to which electrophoresis buffer (0.01 % (w/v) SDS, 2.5mM Tris, 19.2 
mM glycine, pH 8.3) was added. The protein samples (15-20 μg/well) were loaded along 
with 2.0 μg of protein ladder (BioRad, Hemel Hempstead, UK, 1610374). Electrophoresis 
was conducted at 120 V through the stacking gel and then at 160 V through the resolving 
gel. 
 
 Chapter 2 
 
63 
 
b) Non denaturing PAGE (native gel) 
The non-denaturing PAGE used for the separation of the native, unfolded and non-
denatured proteins. Unlike SDS-PAGE which can separate only individual and denatured 
protein, non-denaturing PAGE was used to confirm the relevant native conformations of 
the proteins. The separation of the proteins by native PAGE relies on certain factors such 
as charge, size and 3D structure of the protein. To maintain the 3D structure of the protein, 
a suitable buffer was used depending on the charge and isoelectric point of the protein.  
The non-denaturing PAGE gel contained 5% resolving gel with a pH 8.8 with larger pores, 
was prepared using the reagents (See Table 2-3Table 2-3). Storage protein samples were 
mixed with 5 x sample loading buffer containing; 2.5ml of 100 mM Tris/HCl pH (6.7), 
1.0ml of glycerol, 6.4ml of ultrapure water and 1.0 % (v/v) bromophenol blue and 
centrifuged at 10,000 x g for 10.0 min. Then 10.0µl of the supernatant protein samples in 
presence of EDTA or CaCl2 were loaded into 5.0 % polyacrylamide gel in a Bio-Rad mini 
gel system using a running buffer containing; 3.0 g of Tris/HCl pH 8.3, 14.4 g of glycine 
in water a final volume of 1.0ml. The gel was run at 170 V until the dye reached the 
bottom of the gel. 
Table 2-3: Preparation and reagents for native gel 
 
Reagent
5% (w/v) 
acrylamide
resolving gel
4% (w/v) 
acrylamide
stacking gel
40% (w/v) 29:1
Acrylamide Bis Acrylamide solution (Molecular
Biology Grade, AppliChem, USA)
3.5 ml 1.0 ml
Protogel® Resolving buffer
(1.5 M Tris-HCl buffer pH 8.8, 0.4% (w/v) SDS)
5.0 ml -
Protogel® stacking buffer
(0.5 M Tris-HCl buffer pH 6.8,)
- 2.0 ml
Distilled water 11.4 ml 6.1 ml
10 %(w/v) ammonium persulphate (APS)
60.0 μl
50.0 µl
TEMED (Melford, UK) 40.0 μl 10.0 µl
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2.2.8 Western blotting  
After the mixture of proteins is separated by SDS-PAGE, the separated polypeptides are 
then transferred to a membrane carrier. The membrane (normally nitrocellulose or 
polyvinylidene fluoride) is attached to the gel-forming a sandwich-like structure, which 
is then transferred to the electrophoresis chamber. Once the electric charge is applied, the 
protein bands travel in the vertical direction from the gel to the membrane and therefore 
are attached to the membrane. The membrane-bound proteins are termed as blotted 
proteins, which can then be further analysed according to the experimental need.  Western 
blotting was based on a method by Towbin et al., (1979) with the modifications. Proteins 
were transferred to nitrocellulose membranes in a Bio-Rad Trans-Blot system. A set up 
of a wet transfer was performed, with the blotting cassettes set up as follows; pre-wet 
sponge - filter paper - gel- nitrocellulose membrane filter - filter paper – pre-wet sponge. 
The layers were then placed into a Western blotting cassette (Biorad) and closed gently 
to avoid air bubbles and placed in the transfer tank that contained chilled transfer buffer 
(25.0mM Tris, 192.0mM glycine pH 8.3 and 20% (v/v) methanol). Proteins were 
transferred at 90 V for 1h. After electrotransfer of the proteins, the membranes were 
washed with Tris-buffered saline (TBS), then blocked for 1 h at room temperature with 
3% (w/v) BSA in TBS containing 0.1% (v/v) Tween-20 with mild agitation. Blocking is 
crucial to prevent non-specific binding of the antibodies to the membrane in subsequent 
steps. Blots were then probed with the one of the following primary antibodies β- actin or 
extravidin horse (HRP) peroxidase primary that is diluted in blocking buffer (1:1000) 
overnight with gentle agitation at 4°C. After incubation, the primary antibodies were 
removed, and blots washed three times for 5 min in TBS/Tween 20. After washing, blots 
were probed with the appropriate (1:1000) horseradish peroxidase (HRP)-conjugated 
secondary antibodies (New England Biolabs Ltd; Hitchin, UK) for 2h at room 
temperature in blocking buffer. Following removal of the secondary antibody, blots were 
extensively washed as above and developed using the Enhanced Chemiluminescence 
Detection System (Uptima, Interchim, France). Images of the blots captured and the bands 
were quantified by the iBright FL1000 imaging system. All band densities were measured 
and normalised to band densities for internal control. To confirm uniform protein loading 
in the gel primary antibodies specific to β actin were used. 
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2.2.9 Cell culture 
a) Maintenance of cells 
Human colonic adenocarcinoma cells (HT-29) was grown and maintained as a monolayer 
in the culture medium. Cells were incubated at 37°C in a humidified atmosphere of 95% 
air/5% CO2. 
b) Sub-culture of cells 
Cells were passaged or sub-cultured when growth reached 70-80% confluence (i.e. every 
3-4 days). On reaching 80% confluence, the cell cultures were either used to seed 
monolayers on cell culture plates for assays, (for example; T75 flasks for Western blot 
analysis, and chamber slides for immunofluorescence staining) or passaged to maintain 
the cell line.  Cells were passaged by removing the growth medium and washing cells 
with sterile phosphate buffered saline (PBS), then detached using trypsin (0.05 % 
w/v)/EDTA (0.02 % w/v) in PBS. Following trypsinisation, 10ml of fully supplemented 
McCoys 5A medium were added to the trypsinised cells. Then, the Ht29 suspended cells 
were harvested by centrifugation at 300-x g at room temperature for 5min. The 
supernatant was discarded, and the cell pellet resuspended in 1.0ml of growth medium 
and further sub-cultured (1:5 split ratio). 
c) Counting and plating cells for experimental analysis 
Cells were subjected to experimental analysis when they reached 70-80% confluence in 
the maintenance flasks. Initially, cells were passaged as described in the previous section 
and, after resuspending in 1.0 ml of the growth medium, automated cell counting carried 
on using a TC20 automated cell counter (BioRad, Hemel Hempstead, UK). The device 
utilised prepared TC20 Trypan blue dye (0.4% (w/v) Trypan blue in 0.81% (w/v) sodium 
chloride and 0.06% (w/v) potassium phosphate dibasic solution). Trypan blue is a vital 
stain that distinguishes between live and dead cells (Takahashi et al., 2006). The role of 
this dye is based on the blue acid dye chromophores which react and are taken up by the 
internal region of dead (non-viable) cells through a damaged membrane, whereas live 
(viable) cells do not take up this dye. A volume of 10.0μl of cell suspension was added to 
10.0μl of Trypan blue solution and left for 4 min to allow cells to be exposed to the stain. 
A volume of 10.0μl of this mixture was then loaded into a chamber of the counting slide. 
The slide was inserted into the slide slot of the TC20 cell counter and cell counting was 
automatically initiated as soon as the cell counter detected the presence of the slide and 
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Trypan blue dye. Viable cell counts per ml were used to determine the volume necessary 
to seed the cells at a required cell density in the growth medium. The cell density of 
50,000 cells/ml was used to plate out the cells. Flasks were then incubated at 37oC. 
d) In situ biotinylation of proteins in HT29 cell lines  
Biotinylation refers to the binding of biotin amine conjugate with the biological proteins 
by cellular TG2. Identification of acyl-donor substrates of TG2 in human intestinal 
epithelial cells, based on the method by Orru et al., (2003). A cell-penetrating substrate 
of TG2; 5-(((N(Biotinoyl)amino)hexanoyl)amino) pentylamine, trifluoroacetic acid  
(biotin-X cadaverine, Invitrogen, UK) was diluted in dimethyl sulphoxide (DMSO)  to 
achieve 180 mM stock solution. This substrate then diluted to 1.4 mM in growth medium 
and used to treat the cell lines, followed by incubation at 37oC in presence of 5% CO2 for 
4.0 h. The cells were treated with flavonoids TG2 inhibitors for 1.0h at 37oC. The cells 
were lysed with buffer (50 mM Tris/HCl pH 8.5 + 0.5%w/v sodium deoxycholate) and 
the lysates stored at -20oC. 
e) Cell viability assessment 
i. MTT reduction assay 
Cell viability was determined by measuring the activity of cellular dehydrogenases by 
MTT (3- (4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) reduction assay 
(Mosmann, 1983). The MTT tetrazolium dye was converted to water-insoluble purple 
formazan in the reductive cleavage of its tetrazolium ring by the respiratory enzyme 
succinate dehydrogenase in active mitochondria and by other cellular dehydrogenases. 
The assay was used to assess cell viability after treatment of the cells with different 
flavonoids treatments. The cell lines (25,000 cells/well) were plated in 24-well flat-
bottomed plates and cells were exposed to required treatment and cell viability 
subsequently determined by incubating with 0.5mg/ml MTT at 37 °C for 1h. After that, 
the medium in each well was carefully aspirated and replaced with 500.0μl of DMSO. 
The plate was then gently agitated to ensure sufficient dissolution of the water-insoluble 
purple formazan crystals. After that, 200.0μl of the resultant solution was transferred into 
a 96-well plate and read at 570nm in CLARIOstar Microplate Reader (BMG-LABTECH), 
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ii. Live cell imaging: 
The effect of kaempferol, morin, and quercetin on the proliferation of HT29 cells was 
observed using real-time live cell analysis. Cells were seeded in 96-well plates at a 
seeding density of 10.000 cells per well in completed growth media for24hr. After that, 
the medium in each well was carefully aspirated and replaced with the growth media with 
flavonoids (kaempferol, morin, and quercetin) 125µM. Three fields of view were imaged 
in each well, with a 10× objective every three hours over Three days using the Incucyte 
S3 Live Cell Analysis System (Essen BioScience) fitted inside an incubator. Confluence 
percentages were calculated using the integrated Incucyte S3 software. 
 
2.3 Statistical analysis 
All graphs and statistics (one-way ANOVA followed by Dunnet's multiple comparison 
test and two-way ANOVA for group comparison) were performed using GraphPad 
Prism® software (GraphPad Software, Inc., USA). All sets of data were based on a 
minimum of three separate experiments and expressed as mean ± standard error of the 
mean (SEM) and p-values <0.05 were considered statistically significant.
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Chapter 3 : Study the effects of flavonoids on the 
transamidation and deamidation activity of TG2 
3.1 Introduction 
Flavonoids have been reported in the literature to have a different biological activity such 
as antioxidant, anti-inflammatory and protective against diseases such as cancers, 
diabetes, cardiovascular diseases and atherosclerosis (Rzepecka-Stojko et al., 2015; 
Huang, 2016; Mohana, 2016 and Packzoski et al., 2017).  Certain flavonoids have been 
shown to moderate the esterase activity of trypsin and acetylcholinestears (Xue, G et al., 
2017). Screening these natural compounds to moderate TG2 activity is appropriate 
because TG2 also posses esterase activity (Folket al, 1966). Looking for as potential 
treatment for coeliac disease (CD) is a sensible option because the only available 
treatment for CD is a gluten-free diet, which is not a favourable lifestyle because gluten-
free options are expensive and are not always easily available (Kelly et al., 2015).  
 Various therapeutic choices have been considered for CD, such as decreasing intestinal 
permeability through inhibitors, pro-biotics, genetically modified grains, therapeutic 
vaccines, acceleration of gastrointestinal degradation of proline-rich gluten by oral 
enzyme supplementation and TG2 inhibitors (Sollid and Khosla, 2011; Bakshi et al., 
2012). Since the activity of TG2 is crucial to the initiation of CD, therefore decreasing 
the activity of TG2 in CD patients will supply a potential treatment choice. TG2 inhibitors 
targeted to reduce the TG2 activity have been considered potential therapeutic tools in 
the treatment of CD (Sollid & Khosla, 2011). However, TG2 is present in every cell and 
chemical inhibition may stop vital cellular processes such as interference with 
inflammatory reactions and the ECM (Sollid & Khosla, 2005). Consideration of these 
factors provides motivation to search for an alternative strategy to treat this condition.  
Biological active components derived from natural sources are in general considered to 
be less or non-toxic. Therefore, naturally occurring TG2 inhibitors in food normally 
ingested may provide an acceptable reagent to be taken orally to moderate the symptoms 
of CD (General introduction chapter 1.8.7f).  
The existence of TG2 inhibitors have been found in several natural products such as garlic 
(D’Argenio et al., 2010 ) and milk (De Jong et al., 2003; Aldubyan 2014), but their 
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structures have not been revealed yet.  In this context, another group of naturally 
occurring compounds the flavonoids which are widely distributed in plants and present 
in the diet with numerous health-beneficial biological activities (Panche et al., 2016). 
These natural products (flavonoids) were used in this study to evaluate their effect on 
TG2 activity as a potential intervention in treating coeliac disease. 
3.1.1 History of Flavonoids 
Flavonoids have been known as pigments in plants, their chemical structure was not 
identified until the end of 19th century (Perez-Vizcain et al., 2018). The research was 
mainly centred on the role of anthocyanin family of flavonoid as pigments. Albert Szent-
Györgyi and his workers (1930s) studied the effects of number of flavonoids on human 
health, they found citrus flavonoids stabilised the biological activity of ascorbic acid. 
Over the years, research on flavonoids has developed from laboratories to reach clinical 
studies in humans. The renewed interest in their health properties has been reflected by 
the number of publications on flavonoids which has increased from 740 per year in 1991 
to more than 9000 in 2015, reaching nearly 90,000 in  2018 ( Perez-Vizcain et al., 2018). 
3.1.2 Chemistry of Flavonoids 
The chemical structure of flavonoids is based upon a fifteen-carbon skeleton containing 
two benzene rings A and B,(Figure 3.1) connected by a heterocyclic pyrone ring (C). The 
benzene ring is either α-pyrone; (flavonols and flavanones) or its dihydro-derivatives; 
(flavonols and flavanones) (Kumar and Pandey, 2013). The position of the benzenoid 
substituent divides the flavonoid class into isoflavonoids (3-position) and flavonoids (2-
position). Generally, flavonoids are divided into a different of classes such as flavonols 
(e.g., quercetin, kaempferol, and myricetin,) flavones (e.g., apigenin, and luteolin), 
flavanones (e.g., hesperetin, and naringenin), and others. The several classes of 
flavonoids differ in the level of oxidation and pattern of substitution of the C ring, while 
individual compounds within a class differ in the pattern of substitution of the A and B 
rings (Kumaur, and Pandey, 2013 Popova and Novza, 2016; and Kashlik.2016). 
Flavonoids exist as aglycones, glycosides, and methylated derivatives. Flavonols differ 
from flavanones by hydroxyl group at the 3-position and a C2–C3 double bond (Aherne 
et al., 2002). In glycosides, the glycosidic linkage is normally positioned in positions 3 or 
7 and the carbohydrate could be L-rhamnose, D-glucose, glucorhamnose, arabinose or 
galactose (Xiao et al., 2016). 
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Figure 3-1: Basic flavonoid structure 
 
3.1.3 Classification of flavonoids 
Flavonoids are derivatives of 2-phenyl-benzo-γ-pyrone. The carbon atoms in flavonoid 
molecules are assembled in two benzene rings, commonly known as A and B, that are 
connected by an oxygen-containing pyrene ring (C). A common part of the chemical 
structure of all flavonoids is carbon skeleton based on the flavan system (C6-C3-C6) 
(Brodowska, 2017). Flavonoids in which the B ring is linked in position 4 are called 
neoflavonoids, whereas when the B ring is linked in position 3 of the C ring they are 
called isoflavones. When the B ring is linked in position 2 the groups can be further 
subdivided into many subgroups based upon the structural characteristics of the C ring. 
These subgroups are flavones, flavonols, flavanones, flavanonols, flavanols or catechins, 
anthocyanins and chalcones (Panche, 2016) (Figure 3-1). 
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a) Flavanols 
 
Figure 3-2 Catechin structure (Example for flavanol) 
 Flavanols are a complex group of polyphenols in the range from the monomeric flavan-
3-ols such as catechin (Figure 3-2) epicatechin, and gallocatechin to polymeric 
procyanidins that known as condensed tannins (Pascual-Teresa et al., 2010). Flavanols 
mainly occur in fruits, tea, apples, kiwi and cereals (Määttä-Riihinen et al., 2015). It is 
reported, that they can enhance the levels of nitric oxide in the blood of people who smoke 
cigarettes and reverse smoking-related disturbances in blood vessels (Brodowska, 2017). 
The most common representative of the flavanol group is catechines, which are found in 
black and green tea, chocolate, apricot, apples, and peach (Gramza et al., 2005). Catechin 
has biological activity such as antioxidation effects (Vinson et al., 2001) anti-
atherosclerotic actions (inhibition of the oxidation of low-density lipoprotein) (Rein et al., 
2000; Murphy et al., 2003) and anti-carcinogenic activity (Gramza et al., 2005)., green 
tea catechins have been reported to have antibiotic properties due to their disruptive effect 
on the bacterial DNA replication process (Brodowska, 2017).- 
b) Flavanones 
 
Figure 3-3: Hesperetin structure (Example for Flavanone) 
The most important flavanones are naringenin and hesperetin (SeeFigure 3-3) aglycones, 
which are widespread in foods (Khan et al., 2014).  Hesperetin is the distinctive flavanone 
of orange, lemon, and lime (Goulas et al., 2012). Naringenin can be found in grapefruit 
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and tomatoes. The main biological activity of flavanones is free radical scavenging, anti-
inflammatory, anticancer, cardiovascular, and antiviral effects (Khan et al., 2014). 
c) Flavonol 
 
Figure 3-4: Quercetin structure (Example for Flavonol) 
Flavonols are an important subgroup of flavonoids and are the most studied subgroup 
because of their antioxidants activities and other biological effects. Flavonols occur in 
consumed vegetables and fruits. Major sources of this subgroup are an apple, tomato, 
onion, grape berries, beverages such as green, black tea and red wine (Makris et al., 2006). 
The most important members of this subgroup are quercetin (See Figure 3-4), kaempferol, 
morin, and myricetin (Hollman et al., 1998; Sivaramakrishnan et al., 2008). Quercetin is 
the most abundant of the flavonol group, which acts as potent antioxidant. It has various 
biological activity, such as antioxidant, anti-inflammatory activity; it increases blood 
vessel strength and acts as an antihistamine (Lesjak, et al., 2018). In addition, quercetin 
can protect against the formation of cataracts, a condition that is also related to the 
deamidating and cross-linking activities of TG2 (Erlund, 2004). Kaempferol is an 
antioxidant flavonol occurring in many edible plants (e.g. tea, kale, beans, tomato, 
strawberries, and grapes) ( Calderon-Montano et al., 2011). Several studies have reported 
the beneficial effects of dietary kaempferol in reducing the risk of stroke, chronic heart 
disease, and cancer (Brodowska, 2017). Moreover, kaempferol has anti-inflammatory and 
neuroprotective properties (Hollman et al., 1998). Morin is found in almonds (Wijeratne 
et al., 2006)], figs and other vegetables (Aggarwal et al., 2006). It has been known to act 
as a potent antioxidant (Wu et al., 1993; Wu et al., 1994), a protein kinase C inhibitor 
(Cao, 2005), xanthine oxidase inhibitor (Cao, et al., 2005), cell proliferation inhibitor 
(Kuo et al., 2007) and an inducer of apoptosis (Manna et al., 2007). Furthermore, morin 
used in the treatment of oral carcinogenesis had a chemopreventive action (Kawabata et 
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al., 1999). Myricetin is commonly found in fruits tea, vegetables, red wine, and berries. 
Myricetin might enhance insulin resistance, in addition to other activities such as anti-
hyperlipidemic, anti-inflammation and anti-oxidative stress (Li et al., 2012). 
d) Flavones 
 
Figure 3-5: Apigenin structure (Example for Flavones) 
 Flavones are very similar to the structure of flavonol subclass compounds, flavonol  
possessing an additional hydroxyl substitution at the C 3-position. The most important 
flavones are luteolin and apigenin (See Figure 3-5). Apigenin is found in onions, parsley, 
tea and oranges (Patel et al., 2007), while luteolin originates from vegetables and fruits 
such as broccoli, celery, carrots, parsley, onion leaves and apple skins (Lin et al., 2008). 
It has been stated that luteolin has several biological properties such as anticancer, anti-
allergy, and anti-inflammation (Galati and O'Brien, 2004), whereas apigenin has anti-
inflammatory, anti- carcinogenic and antioxidant properties (Nabavi et al., 2018). 
e) Isoflavones  
 
Figure 3-6: Genistein structures (Example for Isoflavones) 
Isoflavones are found in soybeans, soy foods, and legumes. They act as phytoestrogens 
through binding to estrogen receptors in mammals (Barros et al., 2011; Vitale et al., 2013) 
and they also have anticancer, anti-microbial, antioxidant, and anti-inflammatory 
activities (Conklin et al., 2007; Chacko et al., 2007) Daidzein and genistein(SeeFigure 
3-6) are the most common isoflavones (Yu et al., 2016). 
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f) Anthocyanidins 
 
Figure 3-7: Cyanidin structure (Example for Anthocyanidins) 
 Anthocyanidins are natural pigments in plants and are responsible for the purple, blue, 
red, and orange colours in many fruits and vegetables. More than 500 diverse 
anthocyanidins are known and have been defined in the literature (Pascual-Teresa et al., 
2010). Anthocyanidins are found in fruits, vegetables, teas, honey nuts, olive oil, black 
currants, blueberries and strawberries (Roy et al., 2009). The most abundant 
anthocyanidins occurring in fruits and vegetables are cyanidins (See Figure 3-7), 
pelargonidin, delphinidin, and peonidin (De Pascual-Teresa et al., 2000). Anthocyanidins 
have been demonstrated to play an important role in cholesterol decomposition, 
cardiovascular disease visual acuity, as well as having antioxidant efficacy (Bagchi et al., 
2004). 
g) Flavonoid analogues 
The most important flavonoid analogues are the glycosides, which consist of aglycone 
part that involves mono- or oligosaccharide moieties bound to the aglycone moiety. The 
main groups of glycosides are cardiac glycosides, cyanogenic glycosides, anthraquinone, 
saponins, glucosinolates, and flavonoids glycosides. In addition, flavonoids commonly 
occur as glycosides. Such as rutinose glycone part with aglycone part either naringin or 
rutin or hesperidin naringin (Bernhoft et al., 2010; Forbes et al., 2014).  
3.1.4 Biological Activities of Flavonoids 
Flavonoids are commonly distributed in human’s daily diet, such as fruits, vegetables, tea, 
and others and are considered as bioactive compounds with various biological activities. 
(Panche et al., 2016). Flavonoids are primarily ingested as a glycone that can be absorbed 
in the small intestine. However, most of the phenolic compounds in food exist as esters, 
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glycosides or polymers that can either be absorbed in these forms or hydrolyzed by 
intestinal enzymes or the colonic microflora; the aglycone or hydrolyzed products can be 
absorbed. 
a) Antioxidant Activity 
Flavonoids with antioxidant actions have been proposed to prevent the development of 
oxidative stress-associated diseases, for example, certain cancers, cardiovascular diseases 
(CVD) and diabetes (Badmus, 2016 and Martin, 2016). Reactive oxygen species (ROS) 
have been involved in the etiology of numerous human diseases such as cellular aging, 
carcinogenesis, mutagenesis, and coronary heart diseases. The ROS are formed during 
normal metabolism or induced by exogenous factors (Badmus et al., 2016 and Chaudry 
et al., 2016). The stimulation of antioxidant enzymes scavenging of ROS or metal 
chelating capability through the flavonoids preventing damage to cellular components 
such as DNA, proteins, and lipids (Lobo et al., 2010). For example, the oxidation of lipids 
leads to lipid peroxidation, which is a free-radical mediated propagation of oxidative 
stress to the polyunsaturated fatty acid component of cell membranes (Heim et al., 2002). 
The possible health value of flavonoids for the prevention and therapeutic uses has led to 
the study and identification of a wide range of bioactive principles, to the flavonoids and 
phenolic compounds in the plants (vegetables, fruits, leaves, seeds, cereal, roots, spices 
and herbs) (Badmus et al., 2016)  
b) Anti-Inflammatory Activity. 
In tissue injury, microbial pathogen infection, and chemical irritation, there is a biological 
process known to occur which is inflammation. Movement of immune cells from blood 
vessels and the release of mediators at the site of damage initiate inflammation. This 
process followed by a release of ROS (reactive oxygen species), RNS (reactive nitrogen 
species) and proinflammatory cytokines helps to eliminate foreign pathogens and repair 
the injured tissue (Kumar et al., 2013). Various flavonoids have a significant effect on the 
function of the immune system and inflammatory cells. Flavonoids such as hesperidin, 
apigenin, luteolin, and quercetin have been reported to have anti-inflammatory and 
analgesic effects. Flavonoids may affect the function of enzyme systems that involved in 
the generation of inflammatory processes, especially tyrosine and serine-threonine 
protein kinases (Kumar et al, 2013; Vezza, et al., 2016 and Zhang, 2016,). 
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c) Anticancer Activity 
Dietary flavonoids have been reported as cancer chemo preventive agents. Consumption 
of onions and/or apples, two major sources of the flavonol quercetin, is inversely 
associated with the incidence of cancer of the prostate, lung, stomach, and breast (Kumar 
et al., 2013 and Hua et al., 2016). Numerous mechanisms have been suggested for the 
effect of flavonoids on the initiation stages of cancer relating to impacts on development 
and hormonal activities (Duthie et al., 2000). Quercetin has been shown to arrest the cell 
cycle in proliferating lymphoid cells. In addition, quercetin exerted growth-inhibitory 
effects on several malignant tumour cell lines in vitro including; P-388 leukemia, colon 
cancer, gastric cancer, human squamous, human breast cancer, and ovarian cancer cells 
(Kumar et al., 2013 and Parvaresh et al., 2016). 
d) Biochemical effects of Flavonoids on enzymes: 
Flavonoids are known to inhibit a number of enzymes such as xanthine oxidase 
(implicated in oxidative injury to tissue by ischemia-reperfusion), phosphodiesterase 
(degradation of cyclic nucleotides into inactive metabolites), aldose reductase 
(responsible for the first steps in the polyol cycle), Ca2+ ATPase (involved in 
excitation/contraction of cardiac muscle), and lipo-oxygenase (catalysing the 
oxygenation) (Agrawal et al., 2011). Flavonols (e.g. quercetin and kaempferol) inhibit 
adenosine deaminase of endothelial cells, whereas, flavones are inactive against this 
enzyme (Hayashi et al., 1993). In addition, a study by Kyo et al (1998) who reported that 
the baicalin and baicalein, flavonoids isolated from a medicinal plant (roots of Scutellaria 
baicalensis Georgi (Lamiaceae)) inhibit intracellular Ca2+ levels rising by reducing 
phospholipase C activity and ability of these flavonoids to inhibit several cellular 
enzymes linked to cell signalling e.g.  protein kinase C, phospholipase A2 and protein 
tyrosine kinase (Musci and Pragathi, 1985). 
e) Flavonoids effects on transglutaminase 2 activity: 
It can be seen from the literature that, there are few studies about the effects of flavonoids 
on transglutaminase 2 activity. Some studies have shown that flavonoids could have an 
effect on the role of TG2 in some diseases, such as, the TG2 cross-linking activity has 
enhancing role in the formation of proteins complex that helps in stabilising the ECM.  
Malla et al., (2016) discussed the effect of flavonoids extracts on the role of TG2 in the 
wound healing process. Beazley and Nurminskaya (2015) showed in their study that, 
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dietary quercetin could be the reason for the reduction of reproductive capacity in female 
mice, and suggest that TG2 may regulate ovarian aging (Beazley and Nurminskaya, 2015). 
Studies show that some flavonoids could influence the role of TG2 in certain diseases. 
For example, as mentioned previously, by enhancing the formation of stable protein 
complexes, which helps in stabilizing the ECM (Malla, 2016). Additionally, Al-basher 
and Al-otibi, 2018 reported in their study, that the olive extract containing flavonoids 
accelerates wound healing process, through encouraging antioxidant capacity and 
expression of TG2, which is required for collagen deposition and re-epithelialization 
process. From the literature, there are no studies describing the effects of flavonoids on 
TG2 activity using transamidating or deamidating assay. Therefore, one of the aims of 
this research was to study the effect of dietary flavonoids on the peptide/protein cross-
linking, amine incorporating, and the deamidating activity of TG2 as a potential method 
to moderate the initiation of coeliac disease (CD) and to fully evaluate any influence the 
dietary flavonoids can have on the enzyme. 
3.2 Aims: 
As discussed previously, Screening the natural compounds to moderate TG2 activity as 
potential intervention in treatment of  coeliac disease (CD) is a functional option because 
the only available treatment for CD is a gluten free diet, which is not favourable for 
number of suffrers because gluten free options are expensive and are not always easily 
available. These natural products (flavonoids) were used in this study to evaluate their 
effect on TG2 activity as a potential intervention in treating coeliac disease. 
This chapter had the following experimental aims: 
•  Study the effect of flavonoids on the amine incorporation activity of TG2 using 
the biotin cadaverine assay (Slaughter et al., 1992). 
• Study the effect of flavonoids on the TG2 peptide cross-linking assay (Trigwell et 
al. 2004). 
•  Investigate the effect of flavonoids on TG2 deamidation activity using an 
optimised OPA assay (See Chapter 6).  
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• Methods and Materials:                                                                                                                                                                   
 See Methods and materials chapter: 
➢ Transglutaminase transamidation activity assays (2.2.6c). 
➢ Transglutaminase deamidation activity assay (2.2.6b). 
3.3 Results  
3.3.1 Effect of flavonoids on the amine incorporation activity of TG2 
a) Flavonoids in DMSO  
To observe the effect of the flavonoids on the amine incorporation activity of TG2, the 
flavonoids standards were dissolved in DMSO, the reason for using DMSO is that it was 
also used to study in situ TG2 activity in cell lines (See cell culture chapter 5). Thirteen 
flavonoids at different concentrations (1.25, 12.5 and125µM) were subjected to an initial 
screen using the biotin cadaverine assay (Slaughter et al, 1992) using hrTG2 as it is 
relevant to CD. In addition, gpl TG2 which is routinely used in TG2 assays in the literature 
because it is seen as being equivalent to human TG2 and is used to moderate the assay 
costs ( Figure 3-8 and Figure3-9). 
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Figure 3-8: The effect of flavonoids /DMSO on the amine incorporation activity of hrTG2:  
Flavonoids standards (1.25, 12.5 and 125 µM) dissolved in DMSO then incubated with   5µgml-1 hrTG2 
after which the TG2 activity was measured according to the method of Slaughter et al (1992)(see the 
Materials and method chapters, section 2.2.6c). The data points represent the mean± S.E.M from three 
independent experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** < 0.0001). All the values are 
as compared to the control(HRTG2 column). 
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Figure 3-9: The effect of flavonoids /DMSO on the amine incorporation activity of gplTG2:  
Flavonoids standards (1.25, 12.5 and 125 µM) dissolved in DMSO then incubated 10µgml-1 gpl TG2 after 
which the TG2 activity was measured according to the method of Slaughter et al (1992). )(see the Materials 
and method chapters, section 2.2.6c).The data points represent the mean± S.E.M from three independent 
experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** < 0.0001). All the values are as compared 
to the control (gplTG2 column). 
The three flavonoids (kaempferol, morin, and quercetin), which have a significant 
inhibitory effect on hrTG2, were selected for further investigation (Figure 3-8). These 
three flavonoids were used to study the effect of mixing flavonoids on the TG2 activity 
and for kinetic analysis of the inhibition of TG2. 
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i.  Effect of mixing flavonoids/DMSO on amine incorporation activity of 
TG2: 
Flavonoids are present in foods not as a single component but as a mixture of many 
flavonoids at different concentrations. Therefore, it was crucial to study the effect of 
combining flavonoids to look for synergism or antagonism in their effects on gplTG2 and 
hrTG2. The combination effect between flavonoids on their inhibitory action was done 
by mixing kaempferol, morin, and quercetin in two different concentration 12.5 and 125 
µM in DMSO. Then, subject to the TG2 amine incorporation assay (Figure 3-10). 
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Figure 3-10: Effect of mixing of flavonoids/DMSO on hrTG2 amine incorporation activity 
Flavonoids are mixed in different mixtures (12.5 and 125 µM) dissolved in DMSO then incubated with 
5µgml-1 hrTG2. After which the TG2 activity of each mixture was measured according to the method of 
Slaughter et al (1992). (see the Materials and method chapters, section 2.2.6c). The data points represent 
the mean (± S.E.M) from three independent experiments. (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, 
**** < 0.0001). All the values of the mixtures were compared to the flavonoids as an individual. 
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Figure 3-11: Effect of mixing of flavonoids/DMSO on gpl TG2 amine incorporation activity 
 Flavonoids are mixed in different mixtures (12.5 and 125 µM) dissolved in DMSO then incubated with 
10µgml-1 gplTG2, after which the TG2 activity of each mixture was measured according to the method of 
Slaughter et al (1992). (see the Materials and method chapters, section 2.2.6c).The data points represent the 
mean (± S.E.M) from three independent experiments. (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** 
< 0.0001). All the values of the mixtures were compared to the flavonoids as individual. 
The combination of flavonoids exert inhibition behavior against hrTG2 activity higher 
than individually, the exception was the effect of morin on gplTG2, which the data 
suggest that statistically no significant effect between their individual and combination 
effect. There is a necessity to examine this inhibition mechanism, so the kinetics of the 
inhibition of TG2 by flavonoids were studied (See next section).  
ii. Kinetics study on the significant flavonoids: 
In order, to understand the mechanism of the inhibition of TG2 by the three flavonoids 
dissolved in DMSO, the Michaelis-Menten constant (Km) was derived using Graph pad 
prism 7.  
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Table 3-1: The kinetics study of flavonoids in DMSO on amine the amine incorporation activity of 
hr TG2 
.  
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Figure 3-12: The study of kinetics for significant flavonoids /DMSO on amine incorporation activity 
of hrTG2 
Kaempferol, morin, and quercetin (125 µM) dissolved in DMSO then incubated with   5µgml-1hrTG2, in 
different concentrations of substrate (biotin cadaverine), after which the TG2 activity was measured 
according to the method of Slaughter et al (1992) (see the Materials and method chapters, section 2.2.6c). 
Then the rate of reaction was calculated. The data points represent the mean± S.E.M from three independent 
experiments. 
In order, to understand the mechanism of the inhibition of TG2 by the three flavonoids 
dissolved in DMSO, the Michaelis-Menten constant (Km) was derived using Graph pad 
prism 7.  
Table 3-1Table3-1 and Figure3-12 show that the Km value of the substrate with hrTG2 
in presence of morin decreased. The other flavonoids (kaempferol and quercetin) 
increased the Km value with the substrate and hrTG2. 
b) Flavonoids in Sodium deoxycholate  
As the aim of this part of the research was to study the effect of flavonoids on the activity 
of TG2 as a potential treatment for coeliac disease (CD). Sodium deoxycholate 
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0.5 %( w/v) was used as a means to disperse thirteen flavonoids, and they were subjected 
to an initial screen using the biotin cadaverine assay to measure the transamidating 
activity of TG2 (Slaughter et al, 1992). Previous work at NTU has shown that TG2 is 
unaffected by sodium deoxycholate and this detergent is similar in structure to the 
detergents released by the bile duct in the digestion of food (Negretti et al., 2017), which 
makes this more relevant to CD. 
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Figure3-13: The effect of flavonoids dissolved in sodium deoxycholate on the amine incorporation 
activity of hrTG2. 
Pure flavonoids (1.25, 12.5 and 125 µM) dissolved in sodium deoxycholate 0.5 %( w/v) then incubated 
with 5µg ml1hrTG2, The TG2 activity was measured according to the method of Slaughter et al (1992) 
described in methods and materials chapter. (see the Materials and method chapters, section 2.2.6c)The 
data points represent the mean± S.E.M from three independent experiments (n=3, P-value * < 0.05, **< 
0.01, *** < 0.001, **** < 0.0001). All the values are as compared to the control untreated TG2. 
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Figure 3-14: The effect of flavonoids /sodium deoxycholate on gpl TG2 amine incorporation 
activity. 
Pure flavonoids (1.25, 12.5 and 125 µM) dissolved in sodium deoxycholate 0.5 %( w/v) then incubated 
with 10µg ml-1 gpl TG2. The TG2 activity was measured according to the method of Slaughter et al (1992) 
described in methods and materials chapter. (see the Materials and method chapters, section 2.2.6c). The 
data points represent the mean± S.E.M from three independent experiments (n=3, P-value * < 0.05, **< 
0.01, *** < 0.001, **** < 0.0001). All the values are as compared to the control untreated TG2. 
Three flavonoids (kaempferol, morin, and quercetin) at 125 µM showed significant 
inhibition for the hr TG2 amine incorporation activity (P>0.0001), while, only quercetin 
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and kaempferol show significant inhibitory (kaempferol p>0.001; quercetin >0.0001) 
effect against gpl TG2. 
i. Effect of mixing flavonoids/deoxycholate on the amine incorporation 
activity of TG2: 
In order to study the combination effects, kaempferol, morin, and quercetin were mixed 
at two different concentration 12.5 and 125 µM in 0.5 %( w/v) sodium deoxycholate then 
subjected to the biotin amine incorporation TG2 assay (See Figure 3-15 and 3-16).  
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Figure 3-15: The effect of flavonoids mixture/deoxycholate sodium on amine incorporation activity 
of hrTG2. 
Flavonoids mixtures (12.5 and 125 µM) dissolved in 0.5% (w/v) sodium deoxycholate then incubated with   
5µgml-1 hrTG2 10µgml-1, after which the TG2 activity measured according to the method of Slaughter et 
al (1992). (see the Materials and method chapters, section 2.2.6c)The data points represent the mean± S.E.M 
from three independent experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** < 0.0001). All the 
values of the mixtures were compared to the flavonoids as an individual. 
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Figure 3-16: The effect of flavonoids mixture/deoxycholate sodium on amine incorporation activity 
of gplTG2. 
Flavonoids mixtures (12.5 and 125 µM) dissolved in 0.5% (w/v) sodium deoxycholate then incubated with   
10µgml-1  gplTG2, after which the TG2 activity measured according to the method of Slaughter et al (1992).  
(see the Materials and method chapters, section 2.2.6c). The data points represent the mean± S.E.M from 
three independent experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** < 0.0001). All the 
values of the mixtures were compared to the flavonoids as an individual. 
The data in Figure 3-15 and 3-16 display the effect of mixing morin; quercetin and 
kaempferol on the inhibition of TG2.The finding suggests that the individual inhibitory 
effect of the flavonoids was overcome after mixing.  
ii. Kinetic analysis for the three significant flavonoids: 
The kaempferol, morin, and quercetin, which have a significant inhibitory effect on the 
amine incorporation activity of TG2 (See Figure 3-14), were used to study the mechanism 
of their inhibitory action. Kinetic plots for the three flavonoids were determined using the 
biotin amine incorporation assay with analysis by Graphpad Prism 7 software (See Table 
3-2 and Figure 3-17).  
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Table 3-2: The study of kinetics for significant flavonoids /Deoxycholate sodium on amine 
incorporation activity of TG2. 
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Figure 3-17: The study of kinetics for significant flavonoids /Deoxycholate sodium on amine 
incorporation activity of hrTG2. 
kaempferol, morin, and quercetin (125 µM) dissolved in sodium deoxycholate 0.5%(w/v)  then incubated 
with    5µgml-1 hrTG2, in different concentrations of substrate (biotin cadaverine), after which the TG2 
activity was measured according to the method of Slaughter et al (1992). (see the Materials and method 
chapters, section 2.2.6c). Then the rate of reaction was calculated using graph pad prism 7. The data points 
represent the mean± S.E.M from three independent experiment 
The findings display that the action of kaempferol and quercetin against hrTG2 increased 
the Km of substrate with hrTG2. Morin displayed a reduction in the Km of the substrate 
with the hrTG2. Whereas, kaempferol and quercetin reduced the Km value of the 
substrate with gplTG2 enzyme. 
3.3.2 Effect of flavonoids to the TG2 peptide cross-linking assay  
In order to observe the effect of the flavonoids on the protein/peptide cross-linking the 
activity of TG2, the flavonoids standards were dissolved in sodium deoxycholate 0.5% 
(w/v) and DMSO then applied to the TG2 activity assay using gpl and hrTG2. 
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a) Flavonoids in DMSO  
Thirteen flavonoids were subjected to an initial screen using the cross –linking activity 
assay (Trigwell et al., 2004) (Figure 3-18and Figure 3-18). All flavonoids show potent 
inhibition action against the cross-linking activity of hrTG2 and gplTG2. 
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Figure 3-18: The effect of flavonoids /DMSO on the cross-linking activity of hrTG2. 
 Flavonoids standards (1.25, 12.5 and 125 µM) dissolved in DMSO then incubated with   5µgml-1 hrTG2. 
and subject to the screen their effect on cross-linking activity according to the method of Trigwell et al 
(2004). (see the Materials and method chapters, section 2.2.6c)The data points represent the mean± S.E.M 
from three independent experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** < 0.0001). All the 
values are as compared to the control. 
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Figure 3-19: The effect of flavonoids /DMSO on the cross-linking activity of gplTG2. 
Flavonoids standards (1.25, 12.5 and 125 µM) dissolved in DMSO then incubated with   10µgml-1 gpl TG2 
and subjected to the screen their effect on cross-linking activity according to the method of Trigwell et al 
(2004). (see the Materials and method chapters, section 2.2.6c)The data points represent the mean± S.E.M 
from three independent experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** < 0.0001). All the 
values are as compared to the control.  
The data in Figures 3.18 and 3.19 display the significant inhibition from most flavonoids 
used, this effect was more potent when using hrTG2 than gplTG2, and related to the 
concentration used. 
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i. Effect of mixing flavonoids on the cross-linking activity of TG2: 
To be in line with the amine incorporation study, the combination effect between 
flavonoids on their inhibitory action was done by mixing kaempferol, morin, and 
quercetin in two different concentration 12.5 and 125 µM in DMSO. Then, subject to the 
TG2 cross-linking assay. 
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Figure 3-20: Effect of mixing of flavonoids/DMSO on hrTG2 cross-linking activity. 
Flavonoids mixtures (12.5 and 125 µM) dissolved in DMSO then incubated with   5µgml-1hrTG2,  after 
which the TG2 activity was measured according to the method of Trigwell et al (2004). (see the Materials 
and method chapters, section 2.2.6c)The data points represent the mean± S.E.M from three independent 
experiments (n=3, P-value**** < 0.0001, ***< 0.001, **< 0.01, *< 0.05). All the values of the mixtures 
were compared to the flavonoids as an individual. 
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Figure 3-21: Effect of mixing of flavonoids/DMSO on gpTG2 cross-linking activity. 
Flavonoids mixtures (12.5 and 125 µM) dissolved in DMSO then incubated with  10µgml-1gplTG2 after 
which the TG2 activity was measured according to the method of Trigwell et al (2004). The data suggest 
that there is no effect of combination the flavonoids on their individual effect. The data points represent the 
mean± S.E.M from three independent experiments (n=3, P-value**** < 0.0001, ***< 0.001, **< 0.01, *< 
0.05). All the values of the mixtures were compared to the flavonoids as an individual 
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The finding shows no change in their cross-linking inhibition action when the flavonoids 
are mixed and compared to the flavonoids as an individual (Figure 3-20 and 3-21). 
ii. Kinetics study for the selected flavonoids in DMSO: 
In order to study the mechanism of action of significant flavonoids in DMSO the 
Michaelis-Menten constant (Km) was analysed using graph pad prism 7.  
Table 3-3: The study of kinetics for selected flavonoids in DMSO on the cross-linking activity of 
TG2. 
 
Table 3.3: Kaempferol, morin, and quercetin (125 µM) dissolved in DMSO, then incubated 5µgml-1 hrTG2 
and 10µgml-1 gpl TG2, in different concentrations of substrate (TVQQEL) after which the TG2 activity 
was measured according to the method of Trigwell et al (2004).Then the rate of reaction was calculated 
using graph pad prism 7. All the values are as compared to the control. 
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Figure 3-22: Kinetics study for the selected flavonoids in DMSO 
Kaempferol, morin, and quercetin (125 µM) dissolved in DMSO then incubated with 5µgml-1hrTG2, in 
different concentrations of substrate (TVQQEL), after which the TG2 activity measured according to the 
method of Trigwell et al (2004). (see the Materials and method chapters, section 2.2.6c). Then the rate of 
reaction was calculated using graph pad prism 7. 
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The findings display that the inhibition effect of all flavonoid reduces the Km value of 
the substrate with the gplTG2 enzyme, except quercetin, which increased the Km value 
of substrate with the gplTG2 (Table 3 3 and Figure 3-22). 
b) Flavonoids in sodium deoxycholate  
Thirteen flavonoids were subjected to an initial screen using the TG2 peptide/protein 
cross-linking assay (Trigwell et al., 2004). 
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Figure 3-23: The effect of flavonoids/ sodium deoxycholate on the cross -linking activity of hrTG2. 
Flavonoids standards (1.25, 12.5 and 125 µM) dissolved in sodium deoxycholate then incubated with   
5µgml-1 hrTG2 and subjected to the screen their effect on cross-linking activity according to the method of 
Trigwell et al (2004). (see the Materials and method chapters, section 2.2.6c). The data points represent the 
mean± S.E.M from three independent experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** < 
0.0001).  
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Figure 3-24: The effect of flavonoids/ sodium deoxycholate on the cross -linking activity of gpl TG2. 
Flavonoids standards (1.25, 12.5 and 125 µM) dissolved in sodium deoxycholate then incubated with   
10µgml-1 gpl TG2 and subjected to the screen their effect on cross-linking activity according to the method 
of Trigwell et al (2004) (see the Materials and method chapters, section 2.2.6c). The data points represent 
the mean± S.E.M from three independent experiments (n=3, P-value * < 0.05, **< 0.01, *** < 0.001, **** 
< 0.0001). 
Most of the flavonoids have an inhibitory action on both of the forms of TG2 and their 
activities were more potent on hrTG2 than gplTG2 (Figure3-23 and Figure 3-24). 
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i.  Effect of mixing flavonoids on the cross-linking activity of TG2: 
In order to study the effect of mixing flavonoids on the protein/peptide cross-linking TG2 
activity, three flavonoids (kaempferol, morin, and quercetin) were mixed in two different 
concentration 12.5 and 125 µM in sodium deoxycholate 0.5%(w/v), then subjected to 
cross-linking assay.  
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Figure 3-25: Effect of mixing of flavonoids/Deoxycholate on hrTG2 cross-linking activity. 
Flavonoids mixtures (12.5 and 125 µM) dissolved in Sodium deoxycholate 0.5 %( w/v) then incubated with    
5µgml-1hrTG2, after which the TG2 activity was measured according to the method of Trigwell et al (2004) 
(see the Materials and method chapters, section 2.2.6c). The data points represent the mean± S.E.M from 
three independent experiments (n=3, P-value**** < 0.0001, ***< 0.001, **< 0.01, *< 0.05). All the values 
of the mixtures were compared to the flavonoids as an individual. 
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Figure 3-26: Effect of mixing of flavonoids/Deoxycholate on gpl TG2 cross-linking activity. 
Flavonoids mixtures (12.5 and 125 µM) dissolved in Sodium deoxycholate 0.5 %( w/v) then incubated with    
10µgml-1gplTG2 after which the TG2 activity was measured according to the method of Trigwell et al 
(2004). (see the Materials and method chapters, section 2.2.6c).The data points represent the mean± S.E.M 
from three independent experiments (n=3, P-value**** < 0.0001, ***< 0.001, **< 0.01, *< 0.05). All the 
values of the mixtures were compared to the flavonoids as an individual. 
The finding shows no synergistic inhibition effects between three flavonoids on TG2 
protein/peptide cross-linking activity ( Figure 3-25 and 3-26). Worth mention that most 
of the combinations are significant compared to the control (hr TG2 or gplTG2)  but they 
may not be significant compared to the single flavonoid. 
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ii. Kinetics study for the selected flavonoids: 
To study the mechanism of action of significant flavonoids in deoxycholate, the 
Michaelis-Menten constant (Km) measured by using graph pad prism 7. The finding 
display that all the flavonoids reduce the Km of the substrate with the TG2 enzyme ( 
Table 3-4 and Figure 3-27). 
Table 3-4: The study of kinetics for selected flavonoids /deoxycholate on the cross-linking activity of 
TG2. 
 
Table 3.4: Kaempferol, morin, and quercetin (125 µM) dissolved in Sodium deoxycholate 0.5%(w/v) then 
incubated with    5µgml-1hrTG2, in different concentrations of substrate (TVQQEL), after which the TG2 
activity measured according to the method of Trigwell et al (2004) (see the Materials and method chapters, 
section 2.2.6c).Then the rate of reaction was calculated using graph pad prism 7. 
0 .0 0 .5 1 .0 1 .5 2 .0
0 .0 0
0 .0 1
0 .0 2
0 .0 3
0 .0 4
0 .0 5
S u b s tra te  (m M )
R
a
te
 o
f 
r
e
a
c
ti
o
n
 (
A
b
 m
in
-
1
)
k a e m p fe ro l
1 2 5  M
m o r in 1 2 5  M
q u e rc it in
1 2 5  M
h rT G 2 (C o n tro l)
 
Figure 3-27: Kinetics study for the selected flavonoids in sodium deoxycholate 
 Kaempferol, morin, and quercetin (125 µM) dissolved in Sodium deoxycholate then incubated with 5µgml-
1hrTG2, in different concentrations of substrate (TVQQEL), after which the TG2 activity measured 
according to the method of Trigwell et al (2004) (see the Materials and method chapters, section 2.2.6c). 
Then the rate of reaction was calculated using graph pad prism 7. 
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3.3.3 Application of flavonoids to deamidation assay: 
As the main aim of this project was related to the identification of natural products which 
can act as an inhibitor for TG2 in coeliac disease. Pure flavonoids were applied to the 
optimised deamidation assay (See chapter 6), using a gliadin protein as a substrate for 
hrTG2.  
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Figure 3-28: Effect of flavonoids on deamidation activity of TG2.  
Pure Flavonoids, at 125µM dissolved in Sodium deoxycholate 0.5 %(w/v) then incubated with 5µgml-
1hrTG2, then applied to OPA assay for measurement ammonia released as described in materials and 
methods chapter, section 2.2.6b)ii. The data points represent the mean± S.E.M from three independent 
experiments (n=3, P value * < 0.05, **< 0.01, *** < 0.001, **** < 0.0001). All the values are as compared 
to the control (hrTG2+ gliadin+Ca+2).  
The data display that at 125µM no flavonoids show a significant reduction in TG2 
deamidation when comparing to the control ( Figure 3-28). 
3.4 Discussion: 
The assessment of potential therapeutics to treat the coeliac disease are typically achieved 
on simplified biological systems e.g. enzyme assays. Although, Stuven et al (2013) have 
reported that some in vitro and in vivo models such as intestinal cell lines and human 
mucosal biopsy cultured have helped in understanding of the pathophysiology of the CD, 
but not all that models have been applied in testing new therapeutics for the disease. 
Currently, adherence to a gluten‐free diet represents the only therapy for coeliac disease 
that has been confirmed to alleviate the symptoms and prevent potential complications 
(Peräaho, M et al., 2003and Bascunan et al., 2017). However, the gluten‐free diet, despite 
being safe and most effective, is not always ideal due to the cost implications, which has 
an impact on the quality of life of the sufferer. A study from England documented 
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dissatisfaction with a gluten‐free diet by the majority of patients with coeliac disease 
(Rashtak et al., 2012). Therefore, research for developing novel therapeutic strategies 
appears to be a reasonable alternative treatment option. The crucial role of the activity of 
TG2 in initiation of CD has introduced a new approach in treatment of this disease by 
exploring substances have an inhibition effect on the activity of TG2. The side effects of 
using chemical TG2 inhibitors as mentioned previously, (See introduction chapter, 
section 3-1) has directed this research towards the screening of TG2 inhibitors from 
natural sources. The natural products chosen for this study are dietary flavonoids due to 
their potent biological activity. Therefore, the aim of this study was to test the effect of 
flavonoids on the activity of gplTG2 and hrTG2. 
Thirteen pure flavonoids were selected to cover most of flavonoids subclasses, they 
divided into a different of classes such as flavonols (e.g., quercetin, kaempferol, morin, 
epicatechin, and myricetin,) flavones (e.g., apigenin, and luteolin), flavanones (e.g., 
hesperetin, and naringin), anthocyanin (cyanidin chloride), catechins (catechin and 
epicatechin), flavonolignans (taxifolin). All 13 flavonoids were dispersed either in 
sodium deoxycholate 0.5 %( w/v) or in DMSO and applied to the TG2 assays in the final 
concentrations of 1.25, 12.5 and 125µM. The reason for using sodium deoxycholate bile 
detergent was to try and mirror the environment of the human lower intestine where TG2 
is located and initiates CD. As the bile salts occur in the duodenum of the small intestine 
which is the main part of intestine where lipid digestion happens, bile salts help in 
emulsifying the fatty foods adsorbing on oil-water interfaces (Malik, 2016).This would 
also help to solubilise the flavonoids in food released by maceration in the mouth and 
digestion in the stomach. 
 
Figure 3-29: Sodium deoxycholate and DMSO chemical structures. 
The screening of the TG2 modulatory effects was done using biotin cadaverine 
incorporation assay (Slaughter et al. 1992) and protein/peptide cross-linking assay 
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(Trigwell et al. 2004). These assays are the most commonly used assays to study the 
transamidation activity of transglutaminases. These assays use the incorporation of a 
biotinylated amine or peptide into such protein substrates as N′, N dimethyl casein or 
casein (Slaughter et al., 1992 and Trigwell et al., 1990), (For a more detailed explanation 
see materials and methods chapter 22.2.6c)i).  
Three flavonoids (kaempferol, morin, and quercetin) in both solvents sodium 
deoxycholate and DMSO, demonstrated inhibitory behavior against hrTG2 and to a lesser 
extent on gplTG2 amine incorporation activity. At 125µM, the reduction in activity was 
around 50% for the 3 flavonoids against hrTG2 activity, whereas, kaempferol and 
quercetin in sodium deoxycholate displayed an inhibition effect for gplTG2 activity. 
Those three flavonoids have a similar chemical structure and they are in the same subclass 
which is the flavonol(Figure 2-3). The detailed structures of the flavonoids differ 
structurally in the position of their hydroxyl group. The unexpected finding is that 
myricetin which is flavonol has moderate inhibitory effect which is statistically  
insignificant compared to other flavonols as the rings A and C are same for the 4 flavonols 
used, but the main difference in myricetin structure is that it contains an  OH group at 
position 5- (Figure 2-3). As mentioned in the literature, the B-ring hydroxyl configuration 
is the most significant determinant of the biological effects of the flavonoids in general 
(Pannala et al., 2001and Burda and Oleszek, 2001). Therefore, it was hypothesized that 
the affinity binding between flavonoids and transglutaminase was related to the position 
of the hydroxyl group within the flavonoids. In the presence of calcium ions, TG2 exposes 
hydrophobic areas within its structure (Pinkas, 2007). This suggests that the interaction 
between the flavonol may rely on the presence of calcium ions. If the flavonols disturb 
the binding of calcium to TG2, preventing the enzyme from completely opening up this, 
in turn, could alter the substrate from binding to the active site cys377. 
These findings show that similar results were obtained from flavonoids with using two 
solvents (DMSO and sodium deoxycholate), this suggests that only kaempferol, morin, 
and quercetin which belongs to flavonol subclass of flavonoids at this concentration using 
the amine incorporation assay have inhibition effect on the amine incorporation activity 
of hrTG2. The major exception was there was a less inhibitory effect on gplTG2 
suggesting that although the two enzymes have similar properties and homology that there 
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are subtle differences between the two enzymes in terms of their interaction with these 
natural products. 
In an attempt to understand the mechanism of the inhibition that the flavonoid performed. 
The Michaelis-Menten kinetic constant (Km) and Vmax were graphically determined to 
measure the kinetic properties of the flavonols on TG2 (Alexander and Griffiths, 1993 
and Chambers and Rickwood, 1993). The Km refers to the concentration of the substrate 
when the reaction velocity is equal to one half of the maximal velocity for the (50% 
Vmax) (Palmer and Bonner 2007 and Roskoski, 2015). However, enzyme inhibition 
refers to the interference of the inhibitors with the enzyme, which usually provides 
information about the mechanism of enzyme action. Inhibition often classified as 
competitive, non-competitive, mixed and uncompetitive depending on the way the 
inhibitor interferes with the enzyme activity and alters the kinetic parameters (Boyer, 
2011).    
Competitive inhibitors are substances that be similar to the substrates and they bind to the 
active site causing lateness to the reactions. Consequently, competitive inhibitors increase 
Km value (decrease the affinity, less chance the substrates can go to active site), and 
Vmax stays the same. Where the uncompetitive inhibitors can bind near to the active site 
but not occupy the active site. As a result, uncompetitive inhibitors minimise the Km 
value (increase affinity) and lower Vmax.  
Data in Table 3 1, Table 3 2, , Figure 3 12 and Figure 3 17 demonstrate that the Km value 
of the substrate with hrTG2 was increased in presence of kaempferol and quercetin 
flavonoids. While the same flavonoids (kaempferol and quercetin) in sodium 
deoxycholate exerted a different mechanism, in presence of gplTG2, as they reduce the 
Km value of substrate with gplTG2. For more explanations, in the absence of flavonoids 
the mean Km values for the biotin cadaverine as a substrate to hrTG2 was 0.05 mM  
(±0.004) and for gpl TG2 0.19 mM (± 0.003), the flavonoids causing a raise in Km value 
in presence of the enzyme affected. The exception was morin; in presence of hrTG2 has 
a low Km value for substrate 0.01 mM (±0.003), in sodium deoxycholate; 0.001 (±0.001) 
in DMSO. The results show that the flavonoids (kaempferol and quercetin) inhibit hrTG2 
via competitive inhibition because the Km increases in competitive inhibition (Boyer, 
2011). The competitive mechanism of inhibition refers to binding of inhibitor at the active 
site on the enzyme.   
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These findings assume that this, at least in part, describes the situation of the inhibition 
of the TG2 enzyme by flavonoids using this substrate. Whereas, morin exhibits 
uncompetitive inhibition of hrTG2 with the biotin cadaverine substrate. Uncompetitive 
inhibitors differ from competitive inhibitors in that they have a separate binding site on 
the enzyme and they only bind to the enzyme when substrate is bound to the enzyme. The 
kaempferol finding agreed with study done by Isao and Ikuyo 1999, they reported that 
kaempferol act as competitive inhibitor for the oxidation of L-DOPA catalyzed by 
mushroom tyrosinase. A study by Chun et al (2002) is another study which agreed with 
these finding, it was reported that the flavonoid act as competitive inhibitors to the activity 
of xanthine oxidase enzyme. As mentioned previously, there are no published reports 
about the effect of flavonoids on activity of TG2 or their mechanism. Whereas, this 
finding is contradictory to previous report by Martinez-Gonzalez and coworkers (2017), 
which mentioned that the main inhibition mechanism determined for polyphenolic 
compounds against digestive enzymes is non-competitive.   
In the literature, it has been suggested that the inhibition of digestive enzymes (e.g 
trypsin) by flavonoids could be dependent on the location of their OH-groups (Gonzaliz 
et al., 2017). Moreover, a study by Xie et al (2015) has concluded that the activity of 
flavonoids as antibacterial is depending on the sites of hydroxyl groups on the aromatic 
rings of flavonoids. However, the methylation of the active hydroxyl groups tended to 
decreases the antibacterial activity of flavonoids (Xie et al., 2015). This could suggest 
that these flavonoids exert their inhibitory effect on TG2 by a similar mechanism. The 
structural variations between flavonoids generally are in the number and the location of 
OH group in B and C rings (Figure2-3), which might affect their hydrophilicity and their 
interaction with transglutaminase. In flavonol subclasses, the number of OH group in ring 
B and C varied from two in kaempferol to three in morin and quercetin, and four in 
myricetin (Figure 2-3). In addition, the study by Fan, J et al (2013) has reported that the 
flavonoids (flavonol) act as naturally occurring inhibitors for dipeptidyl peptidase IV 
(DPP-IV), which is a serine aminopeptidase that is a target for type 2 diabetes therapy. 
The comparison between these effects of flavonoids on the peptidase with the finding of 
this study could speculate the importance of flavonoids in treatment of CD as by 
inhibiting of peptidase will lead to generating of larger peptides which will be too big to 
go through the occludin gaps between the epithelial cells. The transglutaminases are 
believed to have been derived from a common ancestral gene for a cysteine peptidase, as 
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the catalytic core of transglutaminases appears to derive from the minimal ancestral 
structural unit of the thiol-protease fold (Fernandes et al., 2015).  Additionally, many 
studies have reported the inhibition effect of flavonoids on the activity of esterase 
enzymes such as acetylcholinesterase (Dzoyem et al., 2017). For example, a series of 
flavonoid were used as potential multifunctional ligands against Alzheimer disease with 
inhibitory influence against cholinesterases (Faraji et al., 2019). These effects of the 
flavonoids on esterase enzymes might be helpful in the speculation of the importance of 
these study findings, additional experiments needed in future to explain the mechanism 
of the inhibition of TG2 activity by flavonoids. 
The question here is whether purified flavonoids have the same health benefit as the 
flavonoids present in whole food. It was decided to study the effect of the combinations 
of flavonoids on hrTG2 and gplTG2 transamidation activity to mimic the mixtures that 
could be present in food. The three flavonoids (kaempferol, morin, and quercetin) were 
dispersed in sodium deoxycholate or in DMSO in different mixtures and then applied to 
biotin cadaverine incorporation assay (Slaughter et al., 1992). The Figure 3-10 for the 
flavonoids in DMSO show the improvement in the effect of flavonoids when mixed, for 
example, the inhibition effect of kaempferol on the hrTG2 activity was improved by the 
addition of quercetin. As kaempferol alone at 125µM reduce 23.03% of the hrTG2 
activity, whereas, when mixed with morin the reduction in the activity of the hrTG2 was 
75.06% and 65.51% with quercetin. The combination of three flavonoids has higher 
inhibition action than individually, 63.46 %. Another curious finding is that the 
combination of flavonoids has significant inhibitory action at a lower concentration 
(12.5µM). For gpl TG2 activity even mixtures of the three flavonoids have not improved 
the action of individual flavonoids effect on amine incorporation activity of gplTG2 ( 
Figure 3-11). The finding in Figure 3-15 and Figure 3-16 display that the flavonoids 
dispersed in sodium deoxycholate have no synergistic effect among all mixtures used. 
Although, this finding agrees with the literature, which reports that the individual 
antioxidants do not appear to have consistent preventive effects with the mixture of food 
contain antioxidant (Liu, 2003).  For example, several studies have shown that the 
consumption of yellow and green fruits and vegetables inversely related to the risk of 
cancer, due to the presence of β-carotene in plenty in these fruits and vegetables. 
However, the incidence of non-melanoma skin cancer was unaltered in patients receiving 
a β-carotene supplement (Hennekens et al., 1996).  
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To measure the effect of flavonoids on the TG2 protein cross-linking activity in vitro 
according to the method of Trigwell et al (2004), the 13 flavonoids in DMSO and sodium 
deoxycholate were applied to the assay using gpl and hrTG2.  Most of flavonoids display 
–(particularly that dissolved in DMSO)- a significant inhibition effect for the TG2 protein 
cross-linking activity at concentration 1.25, 12.5 125µM. The hrTG2 was more sensitive 
to the effect of flavonoids than gpl TG2 (Figure 3-18, Figure 3-19,  Figure 3-23 and Figure 
3-24). The reduction of TG2 activity ranged from50 to 70% for most of flavonoids. This 
finding is inconsistent with the effect of the flavonoids on amine incorporation assay. 
However, in agreement with a study by Wu, C., and Yen, G., (2005) which demonstrated 
the protection of flavonoids against advanced glycation end products formation that is 
involved in hyperglycemia-mediated oxidative stress through extensive anti-cross-linking 
activities. Moreover, another study by Urios, P et al., (2007) has reported the very potent 
inhibition effect of flavonoids at micromolar concentrations on the formation of the cross-
linking AGE (pentosidine) in collagen, which is involved development of vascular 
complications in diabetes. This effect of flavonoids as mentioned by Urios, P et al., (2007) 
was due to the ability of the flavonoid to binding the transition metal ions that play a role 
in glycoxidation. Further experiments are warranted to explain the mechanism of that 
flavonoids inhibition for the cross-linking TG2 activity. In addition, to the role of 
flavonoids in binding of the transition of metal ions (Ca2+), which play a role in the 
activity of TG2 (Urios et al., 2007). To consistent with the amine incorporation study, the 
same three flavonoids (kaempferol, morin, and quercetin) were selected to study the effect 
of the combination of flavonoids on their inhibition of TG2 cross-linking activity.  
 Data in Figure 3-20,Figure 3-21,Figure 3-25 and Figure 3-26 did not show synergism 
effects between three flavonoids,compared to the inhibition action of the flavonoid 
individually. The inhibitory effect of the flavonoid individually was more pronounced 
than in a mixture. Based on these data, the interactions of flavonoids present in a mixture 
can affect the total cross-linking inhibitory action. These findings are consistent with the 
study of Maria et al (2009), where they demonstrated that the antioxidant action of 
individual flavonoid was changed when compared with mixtures of flavonoids. While 
that flavonoid –flavonoid interactions have effects in the inhibition behavior of TG2 
activity of flavonoids mixtures, there are requirements for more detailed study for 
flavonoid combinations to better understand the mechanisms involved in these 
interactions.  
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The data in Table 3-3, Table 3-4, Figure 3-22 and Figure 3-27, indicate that kaempferol, 
morin, and quercetin in both solvents reduced the Km value of the substrate with hrTG2. 
Therefore, the Km values suggest that the kaempferol, morin and quercetin flavonoids 
exert their inhibition action by un-competitive mechanisms, which disagrees with their 
effect against the amine incorporation activity of TG2. (Figure3-12 and Figure 3-17). On 
the other hand, with the gplTG2,the quercetin works as competitive inhibitor for cross 
linking activity of gplTG2, because it increases the Km value of substrate with the 
enzyme. A study by Ribeiro and coworkers (2014) has mentioned that the quercetin 
flavonoids have uncompetitive inhibitory effect on the activity of the lipoxygenase 
enzymes (inflammatory diseases mediators). As aforementioned, the human recombinant 
TG2 was used to mimic the situation of CD, however, guinea pig TG2 was used because 
is routinely used in TG2 assay in the literature to help reduce assay costs. The comparison 
in these study between two forms of TG2 aimed to investigate if there difference in 
response between two forms toward the biomolecules in the assays. The finding suggests 
that there is variation in the response between hrTG2 and gplTG2, which suggests that 
researchers should use hrTG2 in a study to look at proposed modulators of TG2 activity 
in relation to CD. This finding, show the hrTG2 was more sensitive to flavonoids than 
gplTG2. The subtle difference in homology between gpl and hr TG2 could be the reason 
for these differences, as between human and guinea pig TG2 there is an 80% homology 
(Aeschlimann et al., 1994). Generally, the flavonoid inhibition effect is related to their 
structures, the nature of the enzyme and substrates.  These factors could help in explaining 
the difference in the mechanism of inhibition between hrTG2 and gplTG2, many of 
studies have confirmed the structural activity inhibitory relationship of flavonoids on 
different enzymes (Xie et al., 2003; Phan et al., 2013 and  Daniela et al., 2014).  
As the deamidating activity of TG2 is crucial in initiation of CD and because one of the 
main aims of this research optimised a simple assay for the measurement of the 
deamidating activity of TG2 (See Chapter 6). The pure flavonoids were applied to the 
novel OPA assay to measure their effect on the ammonia released after incubation of 
hrTG2 using gliadin mixture peptides as the substrate (Deamidating activity of hrTG2). 
The concentration of flavonoids used in the assay was 125µM in sodium deoxycholate. 
At this concentration, the flavonoids, exert inhibition for transamidation activity of TG2. 
The data in Figure 3-28 show that not all of the tested flavonoid showed significant 
inhibition effect. The luteolin, epicathecine and hesperidine flavonoids show activation 
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effect on the activity of hrTG2, as the release of ammonia were high. Further experiments 
warranted to study the mechanism of those flavonoids on the activity of TG2 to in relation 
to coeliac disease. The curious finding that the lowest ammonia amount was found in the 
samples with same flavonoids that have inhibitory action on the transamidation activity 
of hr TG2 (kaempferol, morin, and quercetin, See Figure 3-28). Further experiments 
needed to study the link between the effect of the flavonoids on the transamidation and 
deamidation activity of TG2.  
3.5 Summary of key findings 
• From 13 pure flavonoids used in the study, only kaempferol, morin and quercetin 
at concentration 125µM in Sodium deoxycholate or DMSO have a significant 
inhibition effect on the amine incorporation activity of TG2. 
• The Kinetics analysis data suggested that flavonoids (quercetin and kaempferol) 
inhibit hrTG2 via competitive inhibition, whereas, morin exhibits uncompetitive 
inhibition of hrTG2 and gplTG2 with the biotin cadaverine substrate. 
• Combination of flavonoids improves the hrTG2 amine incorporation inhibitory 
impact for the flavonoids dissolved in DMSO, however, no effect from the 
combination, which are dispersed in sodium deoxycholate. 
• Most of the flavonoids are displayed inhibition effect on the cross-linking activity 
of hrTG2 and in low extent gplTG2 and in DMSO more than in Sodium 
deoxycholate. 
• Findings of a combination of flavonoids on the cross-linking activity of TG2, 
show no synergism effects between three flavonoids were their action individually 
effect is more than in mixture, the exception was in a mixture of kaempferol and 
quercetin, which show improvement in the inhibitory action of kaempferol in 
deoxycholate against gplTG2.  
• Km values suggest that the kaempferol, quercetin, and morin exert their inhibition 
action on the cross-linking activity of hrTG2 by un-competitive mechanisms. 
Whereas, quercetin act by competitive inhibition for gpl TG2 activity. 
• Flavonoid at 125µM concentration did not show significant reduction effect on 
the amount of ammonia released (the deamidating activity of hrTG2) comparing 
to the control. 
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Chapter 4 : Extraction and purification of flavonoids from 
food and to study the effects of the extracted flavonoids on 
the TG2 activity  
4.1 Introduction: 
This study, as aforementioned(See Chapter3 introduction section), focused on flavonoids 
as a natural source for the potential TG2 inhibitors in relation to coeliac disease. As the 
selection of the appropriate extraction method is crucial to produce a safe and pure 
biological component. Therefore, this chapter displays attempts to select the optimum 
extraction and purification method for the flavonoids from a food source.  
4.1.1 Flavonoid extraction; 
The extraction of bioactive compounds from natural sources is a very important step. This 
step must meet requirements such as ease of use, efficiency, flexibility, and cost-
effectiveness. In addition, it should extract and preserve the major fraction of the natural 
bioactive substances in the natural sources. Recently, numerous research has been 
focused on the extraction of valued compounds using both classical and innovative 
technologies, including the use of green solvents (Chua 2013). The selection standard of 
the best extraction method depends on the highest recovery, to minimise the degradation 
of the compounds that occur as a result of different process steps (Routray and Orsat 
2012). In the literature, there have been different extraction techniques used for bioactive 
molecules from natural sources, such as; 
• Maceration, infusion, percolation, and decoction: These techniques are the easiest 
methods to extract flavonoids. The alteration in temperature and choice of 
solvents improve the extraction process . 
• Soxhlet extraction, which has been widely used for the extraction of bioactive 
compounds, this method has some disadvantages due to the use of high 
temperature, (Uppugundla et al., 2009; Chua, 2013).  
• Microwave-assisted extraction: depends upon the use of microwave energy to 
facilitate the partition of analytes into the solvent (Trusheva et al., 2007).  
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• Ultrasound-assisted extraction or sonication extraction involves using the 
mechanic influence of the ultrasound to increase the surface contact between 
solvents and samples (Handa, et al., 2008). 
• Other methods such as accelerated solvent extraction and supercritical fluid 
extraction have also being used in the extraction of flavonoids from plant and food 
materials (Azwanida, 2015). 
4.1.2 Flavonoid purification 
Flavonoid purification procedures are generally used to clean-up extracts prior to any 
further analysis by analytical methods such as HPLC and TLC. The purification step aims 
to remove potential interfering components (e.g. macromolecules) that may interfere with 
the analysis. These purification methods include liquid-liquid partitioning with non-
miscible solvents and column chromatography on Sephadex LH-20, preparative HPLC, 
and solid-phase extraction (SPE) using commercially available disposable cartridges 
(Markham et al., 1998and Grayer, 2012). Based on the affinity between flavonoids and 
absorbents, a macro-porous adsorbent has been used in the purification of flavonoids. 
Purification by solid-phase extraction (SPE) is a relatively simple method used for 
elimination of polar, non-phenolic impurities in one-step. However, components of 
products or impurities are irreversibly bonded to the chromatographic surfaces, which 
may affect the selectivity of this method. Which also causes a reduction in the binding 
capacity of the stationary phase (Kraemer‐Schafhalter, et al., 1998). 
In this study, the IMAC (Immobilized metal ion affinity chromatography) technique was 
suggested as purification method for flavonoids from their natural sources. The IMAC 
has been used for purification of proteins. The concept of IMAC has first been produced 
by Porathet al (1975). It was based on the known affinity of transition metal ions such as 
Cu2+, Zn2+, Ni2+, and Co2+ to form co-ordinate covalent complexes with histidines and 
cysteines in aqueous solutions (Hearon 1948) and extended to the idea to use metal ions 
to support the fractionation of proteins in solutions. Initially IMAC developed for 
purification of native proteins with an intrinsic affinity to metal ions (Porath, et al. 1975), 
and then the method has been expanded with a broad portfolio of applications including; 
antibodies, phosphorylated proteins, and recombinant His-tagged proteins (Block, et al., 
2009). There are numerous advantages of IMAC for purification of His-tagged proteins 
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compared to other affinity chromatography methods such as the low costs and the 
simplicity of use.(Derewenda, 2004). 
It is known that flavonoids form coordinate covalent bonds with the copper ions held on 
the IMAC resin due to the presence of hydroxyl groups with oxygen atoms rich with 
electrons, the IMAC method was suggested as purification method for the flavonoids 
from different food extracts. The reason for using this technique is attempt to obtaining 
more purified components from the food extract that the utilising of copper chelating 
resins to capture flavonoids prior to analysis allows the removal contaminants including 
TBHQ and sugars which may subsequently interfere with colorimetric assays (see 
discussion section and Materials and method chapter, section 2.2.2b)).  
4.1.3 Identification of flavonoids 
The identification and quantification of flavonoids in natural sources is a key point for 
the study of their biological activity (Marston and Hostettmann, 2006). A colourimetric 
method is commonly used for the quantification of the total flavonoid content, in which 
the total flavonoid content in methanolic or ethanolic extracts of plants was determined 
based on the formation of flavonoid-aluminum chloride (AlCl3) complex (Naczk & 
Shahidi, 2006). Thin-layer chromatography (TLC) is another technique widely used for 
the qualitative analysis of flavonoids, and it may be appropriate for the quick screening 
of these compounds in plant and food extracts (Stalikas, 2007). Methods such as high-
performance liquid chromatography (HPLC), capillary electrophoresis (CE), and 
capillary zone electrophoresis (CZE), are commonly used techniques due to their high 
efficiency in separation and characterisation of flavonoids (Gullon et al., 2017).  
The commonly used colourimetric assays for quantification of flavonoids is the 
colourimetric Folin-Ciocalteu (F-C) assay. The F-C assay is simple and widely used to 
measure the total phenolics in vegetables and fruits (He et al., 2008). However, the F-C 
assay is unspecific for flavonoids and can detect compounds with an active hydroxyl 
group(s) such as flavonoids, phenolic acids, reducing sugars, ascorbic acid, some amino 
acids, aromatic amines, and proteins. Another method commonly used for quantification 
of flavonoids in reversed-phase high-performance liquid chromatography (RP-HPLC), 
this chromatographic method is sensitive and quantitative. The method has limitations 
due to the limited numbers of pure standard compounds commercially available and the 
resolution of an RP-HPLC column (Block, et al., 1992and Willett, 2002). 
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4.2 Aims: 
As the main aim of this research is screening for the natural inhibitors of TG2 activity as 
a potential treatment for coeliac disease (CD). In addition, the extraction of bioactive 
compounds from natural sources is a very important step. Therefore, the hypothesis was 
developing a low cost, simple, more specific purification method for the flavonoids. This 
would aid the extraction of these components to be used with food extracts in the 
screening of their effect on the TG2 activity in relation to coeliac disease. To test this 
hypothesis, it was aimed to; 
• Develop a colourimetric method to quantify flavonoids in a solution using the 
bicinchoninic acid (BCA) assay (Smith et al., 1985)(see chapter 22.2.6a). 
• Employ IMAC as a novel method for purification of flavonoids from different 
food samples (See chapter 2, section 2.2.2b). 
• Compare the flavonoid yield and purity between IMAC and SPE purification 
methods by RP-HLPC.  
• Study the effect of food extracts on transamidating and deamidating activity of 
TG2. 
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• Methods and Materials:  
See Methods and materials chapter: 
➢ Bicinchoninic acid protein assay (BCA) assay( section2.2.6a).                                                                                                                                                                  
➢ Solid Phase Extraction (SPE)(section 2.2.2a) 
➢ HiTrap Chelating HP( section 2.2.2b) 
➢ Qualitative analysis using High-Performance Liquid Chromatography 
(HPLC)(section2.2.3). 
➢ Mass spectrometry for Flavonoids(2.2.5a) 
➢ Transglutaminase transamidation activity assays(2.2.6c) 
4.3 Results 
4.3.1 Optimization of quercetin as standard for flavonoids quantification   
To quantify of flavonoids in different food extracts, a modified BCA assay (Smith et al., 
1985) was optimised to quantify the flavonoids content by using quercetin as standard. 
The assay found to be sensitive to quercetin concentrations ranging from 40 to 400µM. 
(See Figure 4-1). 
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Figure 4-1: Optimization of quercetin as standard for flavonoids quantification. 
 Quercetin used as a standard to quantify the flavonoids in the food extracts. Different concentration of 
quercetin (0 -400µM) with BCA working reagent was applied to BCA assay (Smith et al., 1985)(see 
Materials and methods chapter, section2.2.6a).  
The data in Figure 4-1display the sensitivity of BCA assay to quercetin, which is using in 
concentration arranged from 0 to 400µM. 
 Chapter 4 
 
113 
 
4.3.2 Flavonoids isolation: 
The isolation of flavonoids is carried out by refluxing fruit or vegetable samples in an 
acidified methanol solution in the presence of an antioxidant tetra butyl hydroquinone 
(TBHQ) (see section 2.2.1b). Then purified using a solid-phase extraction (SPE) method, 
and a novel method for purification of flavonoids, using immobilized metal ion affinity 
chromatography (IMAC). To compare two methods in term of purity and quantity 
obtained, samples from both extractions applied to RP-HPLC for qualitative analysis and 
quantitative assay by BCA method using quercetin as standard. 
a) Solid Phase Extraction (SPE) 
The solid-phase extraction (SPE) procedure allows retaining on of analytes that would 
interact with a C18 resin in the column, especially aromatic compounds, such as 
flavonoids, by the formation of hydrophobic interactions between the analytes and 
stationary phase that is styrene divenylbenzene C18. The use of 80% (v/v) methanol as 
eluent and use of the BCA assay allowed for the quantification of analytes in the following 
concentrations expressed in mg/100g dry weight (DW)  
Table 4-1: Quantity of flavonoids fractions from SPE 
 
b) IMAC method: 
Flavonoids at alkali pH values will show increased deprotonation of hydroxyl groups, 
exposing electron-rich oxygen atoms allowing co-ordinate covalent interactions with 
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divalent metal ions bound to the IMAC resin. The isolation of flavonoid in this method 
was achieved using copper bound to the chelating resin to capture flavonoids prior to 
analysis. Quantification of flavonoids in these fractions was done by BCA assay in 
concentrations expressed (mg/100g) (Table 4-2). 
Table 4-2: Quantity of flavonoids fractions from IMAC 
 
The Table4-1 and Table4-2  show the quantity of flavonoids in different food sample by 
using two different methods of isolation, SPE and IMAC, the data suggest that no 
significant difference in quantity between the fractions using two methods. 
4.3.3 Qualitative analysis using reversed-phase High-Performance Liquid 
Chromatography (RP-HPLC) 
The IMAC method (See materials and methods chapter, section 2.2.2b) was used for 
purification of flavonoids fractions. To compare between SPE and the novel IMAC 
method in term of purity, the flavonoids extracted from different food samples were 
injected onto a C12 RP-HPLC (See Materials and methods chapter 2, section 2.2.3).  
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Figure 4-2: Chromatogram of apple flavonoids extracts. 
Three different fractions from apple samples crude, SPE and IMAC were injected to RP-HPLC.      
The data in Figure 4-2 show that apple IMAC extract chromatogram was more purified 
than crude and SPE extracts chromatograms. Other food samples chromatogram 
(presented in appendices chapter).  
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4.3.4 Qualitative analysis using LC/MS/MS 
In order to confirm that IMAC extract food samples contain flavonoids, the food samples 
were injected to LC/MS/MS, the finding confirm that significant flavonoids were 
involved in some food samples. 
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Quercetin infusion, optimum MSMS fragmentation 
Spectrum. 
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Figure 4-3: optimum MSMS fragmentation spectrum for the quercetin and food extracts which 
contain quercetin 
The data in Figure 4-3 show that apple, strawberry and capers extracts spectrum show the 
same fragmentation of quercetin.  Other food samples spectrum (presented in appendix 
chapter).  
☺ ☺ ☺ 
Strawberry Apple Capers 
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4.3.5 Application of flavonoids extracted from food to the TG2 biotin 
cadaverine assay: 
The biological activities of pure flavonoids against hrTG2 (see chapter 3 flavonoids effect 
on TG2) provided the encouragement to screen flavonoid mixtures extracted from 
flavonoid-rich foods against TG2 activity as a potential treatment for coeliac disease. To 
observe the effect of food extracts on amine incorporation activity of TG2, were 
reconstitute with deoxycholate sodium in concentration (1mg ml-1) then applied to the 
TG2 activity assay using hrTG2 and gplTG2.  
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Figure 4-4: Effect of food extract on amine incorporation activity of TG2. 
 IMAC Food extracts dispersed in sodium deoxycholate 0.5 %( w/v) then incubated with A) 5µg ml-1 hrTG2. 
B) 10µg ml-1 gpl TG2 were subjected to the screen their effect on amine incorporation activity of both 
enzymes according to the method of Slaughter et al (1992) described in methods and materials 
chapter,(section 2.2.6c). The data points represent the mean± S.E.M from three independent experiments 
(n=3, P-value **** < 0.0001). All the values are as compared to the control.  
All food extracts display a significant inhibitory effect on hrTG2 and gplTG2, (Figure 4-4 
A and B) 
4.3.6 Application of flavonoids extracted from food to the TG2 peptide/protein 
cross-linking assay: 
To observe the effect of the food extracts on the cross-linking activity of TG2, the food 
extracts were dissolved in sodium deoxycholate 0.5 % (w/v). Then applied to the TG2 
activity assay using hrTG2 and gplTG2. 
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Figure 4-5: Effect of food on the cross-linking activity of TG2. 
 IMAC Food extracts dispersed in sodium deoxycholate 0.5 %( w/v) then incubated with A) 5µg ml-1 
hrTG2. B) 10µg ml-1 gpl TG2 were subjected to the screen their effect on cross-linking activity of both 
enzymes according to the method of Trigwell et al (2004),(described in methods and materials chapter 
section 2.2.6c). The data points represent the mean± S.E.M from three independent experiments (n=3, P-
value * < 0.05, **** < 0.0001). All the values are as compared to the control. 
Most of the food extracts display a significant inhibitory effect on gplTG2, while, just 
kale and strawberry exert an inhibitory effect on hrTG2 (Figure 4-5 A and B). In addition, 
the data shows the variation in the response to the food containing flavonoids between 
gplTG2 and hrTG2.  
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4.3.7 Application of flavonoids extracted from food to the OPA TG2 
deamidation activity assay  
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Figure 4-6: Effect of food on the deamidating activity of TG2. 
IMAC Food extracts were subjected to the screen their effect on the deamidating activity of 
hrTG2(materials and methods chapter, section2.2.6b). The data points represent the mean± S.E.M from 
three independent experiments (n=three, P-value * < 0.05, **< 0.01). All the values are as compared to the 
control (Gliadin+Ca2++hrTG2). 
The data (See Figure 4-6) show that there is no significant inhibition effect for all food 
extracts on the deamidating activity of hrTG2. Nevertheless, the two extracts from 
Alliums show significant activation of the deamidating activity compared to the control 
(Gliadin+Ca2++hrTG2). 
  
4.4 Discussion 
The biological activity of the dietary flavonoids motivated the study to screen flavonoid-
rich foods and examine their effects against TG2 activity as a potential treatment for 
coeliac disease. Consumption of flavonoid-rich foods, such as fruits and vegetables, is 
associated with a lower prevalence of several diseases. Seven of 12 epidemiological 
studies assessing the risk of coronary heart disease reported protective effects of dietary 
flavonoids (Arts et al., 2005). Other studies also found inverse relation between flavonoid 
consumption and the risk of stroke, colorectal and lung cancers (Keli et al., 1996; 
Hirvonen et al., 2001; Knekt et al, 2002and Arts et al., 2002). It has been proposed that 
dietary flavonoids exert health benefits by an antioxidant mechanism, which elevated at 
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pH 7.0 values, the electron-rich oxygen atoms in the hydroxyl groups can donate electron 
pairs (co-ordinate covalent bonding to electron-deficient atoms such as divalent metal 
ions (Huyut et al., 2018). As these chronic diseases are accompanying with high oxidative 
stress and flavonoids are strong antioxidants in vitro, (Aviram and Fuhrman, 2002; 
Serafini, et al., 2002 and Rietveld, and Wiseman, 2003). 
Because of the numbers of conjugated with target analytes, as the clean-up is usually 
necessary to remove coextracted matrix components that may interfere in subsequent 
steps (Obied et al., 2005), so more selective and sensitive analytical methods are required 
(de Rijke, et al. 2006). In this study, a novel method for purification of flavonoids from 
food extracts was used which is immobilized metal ion affinity chromatography (IMAC) 
(Cheung et al., 2012). This was then compared with a more conventional extraction 
method which is solid-phase extraction (SPE) method (Liu, Houme, et al., 2016).  
The IMAC technique is a specialized form of affinity chromatography, proteins or 
peptides are separated according to their affinity for immobilized metal ions. At pH values 
above neutral, the amino acids cysteine, tryptophan, and histidine form co-ordinate 
covalent complexes with divalent metal ions (e.g., Cu2+, Cd2+, Hg2+, Ni2+, and Fe2+). 
Then, can be eluted by either decreasing the pH to protonate an electron-rich atom, adding 
EDTA (0.05 M) to the mobile phase to chelate and strip the IMAC column of the metal 
ion, or increasing the mobile phase ionic strength (Otter 2003). Elution with imidazole is 
especially suitable for purifying recombinant proteins with poly-histidine fusions by 
competing with the polyhistidine on the his-tagged protein (Alves et al., 2017; Bonner 
2018). 
The IMAC technique has been used in this study to purify flavonoids from different food 
extracts. Based on the formation of coordinate covalent bonds between metal ions 
immobilized in the chromatography resin in the column, e.g. Cu2+ that accepts a pair of 
electrons directly from the deprotonated nitrogen in peptides or oxygen atoms on the 
flavonol. Electron rich oxygen atoms from the hydroxyl groups on the flavonoids as result 
of the alkaline pH that created by methanol with 0.2% (v/v) of 5M sodium hydroxide are 
now able to form coordinate covalent bonds with the copper atom held on the IMAC 
resin. The use of copper chelating resins to capture flavonoids prior to analysis allows the 
removal of contaminants including TBHQ and reducing sugars, which may subsequently 
interfere with colourimetric, assays e.g. BCA.  Other material in the extract without the 
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electron-rich oxygen atoms will peculate through the column in the unbound fraction. 
(See method and material chapter).   
Another more standard method used for flavonoid purification is SPE where alkyl-bonded 
silica or copolymer sorbents broadly used for analyte extraction and enrichment from 
sample extracts, in most cases the sorbent is C18-bonded styrene  and the sample solution 
and solvents, are usually slightly acidified to prevent ionization of the flavonoids, which 
would reduce their retention (de Rijke, et al. 2006). The SPE retains analytes on the 
column, especially polar and aromatic compounds, such as flavonoids, by the formation 
of hydrophobic interactions between analytes and stationary phase that is styrene 
divinylbenzene. Polar material will not be retained and will be eluted with polar solvent 
in the unbound fraction.  
For quantification of extracted flavonoids, the bicinchoninic acid (BCA) assay (Smith et 
al., 1985) was used to compare the quantity yielded between two methods (IMAC and 
SPE). This assay was used based on the ability of polyphenols (flavonoids) to bind with 
metal ions (Ivanov et al., 2001and Wei and Guo, 2014). This assay (BCA) is a 
colourimetric assay that is commonly used to estimate the concentration of protein in a 
sample, protein levels are measured through the formation of a purple, Cu+1(BCA) 2 
chromophore (λmax = 562 nm). BCA assay was optimised in a novel quantification 
method using quercetin as the standard. The use of BCA reagent allows the linear 
detection of quercetin in the standard assay in the range of 40 to 400µM ( Figure 4-1). 
Based on a search in the literature no previous work used BCA for estimation of 
flavonoids in food samples. In this study, the BCA method used for quantification of 
flavonoids in different food extracts, data in Table4-1 and Table 4-2 show that the amount 
is varied between 0.20 to 1.02mg100-1g DWin the IMAC fractions. Whereas, the amount 
in SPE fractions were arranged from 0.19 to 1.16 mg/100g. Green tea had the highest dry 
weight concentration of flavonoids followed by strawberry, kale, capper, and apple. The 
garlic and onion had the lowest flavonoids content. These data are inconsistent with 
Bhagwat, et al., (2014) study that found a higher flavonoid content in, for example, apples 
0.51mg/100g dry weight. This may account for differences as well as different varieties 
(quercetin), garlic 1.9mg/100g (quercetin and kaempferol), green tea 0.54/100g 
(kaempferol and quercetin)(Bhagwat et al., 2014), this difference could be from using 
starting material, different extraction, purification, and quantification method. The 
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comparison between the fractions from two purification methods, in term of purity were 
conducted by RP-HPLC on a C12 resin.   
The chromatograms for food fractions before using any purification method (crude 
extract) contains a lot of impurities as judged by the presence or absence of additional 
peaks in the elution profile, whereas, in chromatograms of SPE fractions less 
contaminating peaks are observed. However, the IMAC fractions have produced a clearer 
chromatogram as judged by the absence of contaminating peaks. Although, there is no 
significant differences between the quantities obtained from both methods, however, the 
HPLC chromatograms confirm that the IMAC fractions contain less contamination peaks, 
which are still observed in SPE chromatograms. These findings suggest that SPE 
extracted all the organic components, whereas IMAC extract the only the components 
that have two hydroxyl groups close together particularly those on the flavonoids. This 
might be due to the capturing of flavonoids using of copper chelating resins, allows the 
removal contaminants including TBHQ and sugars which may subsequently interfere 
with the assays. This finding present that IMAC method as a selective and appropriate 
technique to purify flavonoids in those food samples. 
 The application of chromatographic methods hyphenated with different detectors is 
necessary for identification of the flavonoid conjugates. LC-MS/MS is a powerful means 
to screen biologically active compounds from natural source extracts because of its high 
sensitivity and selectivity (Li, et al. 2009). In this study, the samples of IMAC flavonoids 
extracts were prepared and analysed by mass spectrometry lab in John van Geest Cancer 
Research Centre in Nottingham Trent University. In order to identify the flavonoids 
contents of IMAC food extracts, the samples were subjected to LC/MS/MS. The data (See 
Figure 4-3) display that there is a variation in the type of flavonoids among all the 
samples, although, quercetin occurs as an abundant type of flavonoid. The reason for this 
experiment was to confirm and verify that the IMAC technique is appropriate for 
purification of flavonoids from food samples.  
In addition to pure flavonoids, flavonoid extracts were prepared from apples (Malus 
Domestica), Green tea (Camellia sinensis), Strawberry (Fragaria vesca), Kale (Brassica 
oleracea), Capers (Capparis spinose), Garlic (Allium sativum) and Onions (Allium cepa). 
The extracts were enriched for flavonoids using the novel IMAC method (See methods 
and materials) and quantified using the novel BCA method (Table4-1and Table 4-2).  The 
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extracts were applied to the biotin cadaverine incorporation assay (Slaughter et al., 1992) 
and the peptide cross-linking assay (Trigwell et al., 2004) to examine their effect on TG2 
transamidation activity. The data in Figure 4-4 A and B show that most of the food extract 
display a significant inhibition effect towards the amine incorporation activity of TG2. It 
is worth a mention, that all the food samples used contain the flavonols, which exert the 
inhibition action against the amine incorporation activity when used as pure (Figure3-8 
and Figure3-18). For the effect on cross-linking activity of TG2, most of food extracts 
display inhibition effect on the gplTG2 cross-linking activity. Whereas, only the samples 
from kale and strawberry have inhibition effects on the hrTG2 activity ( Figure 4-5 A and 
B).   
There is difference in sensitivity towards the flavonoids extracts between gpl and hrTG2, 
as most of food extract display a significant inhibition effect towards the gplTG2, 
whereas, only strawberry and kale inhibit the cross linking activity of hrTG2. The subtle 
differences in homology between gpl and hr TG2, as mentioned previously (see chapter 
3) could be the reason for these measured differences between human and guinea pig TG2 
(Aeschlimann et al., 1994). These subtle differences could affect the topography of the 
enzyme’s active site. Although the properties and structure of both gplTG2 and hrTG2 
are similar, there is evidence from these plots (See Figure 4-5 A and B) that there is 
sufficient variation in their structure to demonstrate different responses to the flavonoids 
and the food extracts. As far as is known Guinea pigs do not suffer CD, Humans do, these 
data suggest there is a subtle difference between the two enzymes structures? There are 
indications from data that the search for agents to moderate TG2 in CD must be conducted 
with hrTG2, as the comparison the data of hrTG2 with gplTG2 display variations in the 
response between the two enzymes. 
 From the finding strawberry (33.3%) and kale (28.23%) have higher significant 
inhibition activity against hrTG2 comparing to other food samples. There are a naturally 
variations among the fruits and vegetables in; the overall flavonoid content of fruits and 
vegetables and the protection provided by fruits and vegetables against diseases may 
differ significantly from one kind of fruit or vegetable to another (Guo et al., 1997). These 
variations are the possible reason for the variation in the extent of the effect on TG2 
activity. In addition, worth mention that the flavonols kaempferol and quercetin are 
essentially products of flavonoids in kale vegetables (Olsen et al., 2009). This agrees with 
the previous data when using pure kaempferol and quercetin against TG2 transamidating 
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activity (Figure3-8 and Figure3-13). Whereas, a study conducted by Tomohiro Itoh et al 
2009, mentioned that kaempferol flavonoid extracts from strawberry suppressed the 
intracellular Ca2+ influx in rat basophilic leukemia RBL-2H3 cells.  This may suggest a 
possible mechanism by which flavonoids inhibit TG2 (Tomohiro Itoh et al., 2009). As 
the bioavailability of a compound is a crucial factor for the assessment of any health-
modulating functions in humans. The bioavailability of the flavonol aglycone influenced 
by the nature and degree of modification and substitution on the flavonol (Stevenson and 
Hurst 2007 and Itoh et al., 2009). 
In order to screen the effects of food extracts on the deamidating activity of hrTG2, as 
this activity is crucial for the initiation of CD. The finding showed that no food extracts 
have an inhibition effect after using the optimised OPA assay, (see Figure 4-6). On the 
other hand, the two extracts from alliums (onion and garlic) show activation of the 
deamidating activity. It could be that people with CD could be activating TG in the lamina 
propria after digesting a meal containing onion and garlic (which is a very common 
combination for curry and Mediterranea food). The finding of this study presented that 
the dose produces 50% inhibition effect of the active flavonoids (kaempferol, morin, and 
quercetin) was 125µM. The question here is how much should be eaten from the food 
containing these flavonoids to achieve this 125uM concentration. Based on the literature 
that reported the quantity of flavonoids in food samples, to achieve that concentration the 
patient should eat more than one kilogram of fruit or vegetable which may be unpractical? 
Furthermore, to be effective a bioactive compound, not just should the intake be adequate 
high, however also the bioavailability (the absorption into the body) must be at a suitable 
level to gain active levels within the body (Van der Sluis et al., 2001).  
4.5 Summary of key findings 
• Immobilized Metal Ion Affinity Chromatography (IMAC) was used for the first 
time in the purification of flavonoids from food extracts. 
• BCA assay was used in the quantification of flavonoids in food extracts. By using 
quercetin as standard; the use of the BCA reagent allows the linear detection of 
quercetin in the standard assay in the range of 1.25 to 400µM. 
• The comparison between the fractions from SPE and IMAC purification methods 
in term of purity was done by HPLC, IMAC fractions have produced a clearer 
chromatogram. 
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• Most of the food extract used in this study display a significant inhibition effect 
towards the amine incorporation activity of TG2. 
• Majority of food extracts display inhibition effect on the gpl TG2 cross-linking 
activity. On the other hand, only Kale and strawberry have an effect on hrTG2 
activity. 
• No food extracts were showing inhibition for the ammonia released (deamidation 
activity) effect after using the optimised fluorescence (OPA) assay. 
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Chapter 5 : Study the action of effective flavonoids on the in 
situ activity of TG2 and identification of  TG2 substrates  
5.1 INTRODUCTION 
Transglutaminase 2 (TG2) possess many enzymatic functions’; transamidating, 
deamidating, GTP-binding/hydrolysing activity, intrinsic kinase and isopeptidase 
activities (Griffin et al., 2002; Chen, X et al., 2015). Therefore, it is active in many vital 
biological processes including proliferation, differentiation, and apoptosis (Griffin et al., 
2002; Beninati et al., 2017). In addition, TG2 can incorporate polyamines into acyl-donor 
substrates, which leads to a change of the structure and function of specific proteins. For 
example, TG2 catalyses the polyamine incorporation of spermine and spermidine into the 
neurotransmitter peptide substance P, producing enriched resistance to proteases action 
in vitro (Esposito et al., 1999). In addition, TG2 has ability to catalysing the incorporation 
of polyamines into a variety of substrates including proteins, peptides, mono- and 
polyamines and nucleotides. To fully understand the cellular role of TG2 a knowledge of 
TG2 substrates and interacting proteins, which might be acting as novel drug targets is 
required. In this line, the development of selective TG2 inhibitors could regulate TG2 
activity and therefore could act as novel therapeutic solutions (Badarau et al., 2013). 
There are numerous biochemical and cellular assays, which help to characterise the 
potency of TG2 inhibitors. These assays involve assessing the transamidation activity of 
the target TG2 itself, measuring the TG2 selectivity among the TG isoforms and cross-
reactivity to other catalytic cysteine-containing enzymes (e.g. caspase-3) as well as other 
side effects such as cytotoxicity.  
5.1.1 Viability assays 
In vitro viability assays are necessary tools to aid in the assessment of drug efficacy in 
combination with in vivo analyses. The general concept of in vitro viability assays 
requires the incubation of cells with a particular compound(s) and then measuring for cell 
viability to quantify drug-induced cell toxicity (Single et al., 2015). A cell-based method 
is required for the evaluation the drug induced cell cytotoxicity including measuring 
cellular metabolic activity. A widely used method is the MTT assay based on the ability 
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of viable cells to convert a soluble tetrazolium salt [3– (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] (MTT) into an insoluble formazan precipitate (Supino et 
al., 1995). The MTT assay is a rapid colorimetric quantification assay for the growth and 
survival of cells (Mosmann 1983)Freimoser et al., 1999). In contrast to endpoint 
methodologies, a real-time cell-based assay approach permits following cellular growth 
over the whole time course of an experiment. Real-time assays are classically 
accomplished with equipment capable of capturing cell images at regular time intervals 
and quantifying cellular surface area coverage as a measure of proliferation (Single et al., 
2015).  In this study, human large intestine carcinoma cell lines (HT29) was used with 
MTT and real-time IncuCyte assays to assess the effects of three flavonoids (kaempferol, 
morin, and quercetin) were shown to moderate TG2 activity (Chapter 3) using in vitro 
assays on the viability and the growth of colon carcinoma cells.  
5.1.2 Transglutaminase 2 substrates 
The list of TG2 protein substrates is continuing to grow with the increase in TG2 
enzymatic functions. However, the description of substrates for all these functions, how 
they influence the role of TG2 within the cell is proving difficult. Table 5.1 presents some 
of the major substrates for each chemical reaction catalysed by TG2. 
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Table 5-1: TG2 substrates and their possible involvement in human diseases 
 
Adopted from: Odii and Coussons (2014) 
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5.1.3 Involvement of TG2 substrates in cell life and death 
Many reports have shown that TG2 could act as a pro-apoptotic protein (Fesus, et al., 
1991; Falasca, et al., 2005). Some of the identified TG2 substrates, which have a covalent 
modification, may be related to the induction of the cell death, such as, cytoskeletal 
proteins (e.g. actin and beta-tubulin) and nuclear histone proteins (Ballestar, et al, 1996). 
Transglutaminase 2 catalyses covalent modifications to proteins, that play a role in the 
programmed cell death cascade (Huppertz, Frank and Kaufmann 1999, Tabolacci, et al. 
2019). In addition, TG2 has been shown to cross-link key modulators of cell survival and 
death, such as retinoblastoma protein (Oliverio, S et al., 1997). TG2 can also modify a 
member of Ras superfamily (RhoA) in vivo (Singh et al., 2001). Retonic acid-induced 
activation of transglutaminase leads to the transamidation of the RhoA protein.  (Singh et 
al., 2003). 
5.1.4 The involvement of TG2 substrates in coeliac disease  
The upregulation of TG2 expression and/or function has been shown to be involved in a 
several human diseases, such as coeliac disease, diabetes mellitus, some cancers (e.g. 
breast) and a number of neurological diseases e.g. Alzheimer’s and Parkinson disease 
(Lai et al., 2017). The role of TG2 in coeliac disease is related to deamidation of glutamine 
side chains in a 33mer gliadin peptide, the deamidation reaction is preferred to 
transamidation when the pH decreases (Fleckenstein, B et al., 2002; Fleckenstein, B et 
al., 2004). Thus, gluten proteins and their derived peptides represent substrates of 
different TG2-catalysed reactions. 
5.1.5 Enzymes activity in living intestinal cells 
In order to study the activity of enzymes such as TG2 in the digestive tract, human 
intestinal cell lines demonstrate a valuable model. Transglutaminase 2 functions appear 
to depend on its particular location. The occurrence of different available proteins which 
able to act as a substrate for TG2 in specific cell determines the activity of TG2 (Oliverio 
et al., 1997). The main aim of this study has been focussed on TG2 deamidating activity 
in relation to coeliac disease. Therefore, to better understand the function of the TG2 in 
the initiation of CD it is crucial to identify TG2 substrates in the intestinal cell lines such 
as CaCo2 and HT29 cell lines. Although both of these cell lines are derived from a colonic 
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neoplasm, they display features of small intestinal differentiation in the post-confluent 
state (Pinto, 1983). These cells (HT29 and CaCo2) have been used widely for studying 
TG2 enzymatic activity in situ and for identification of TG2 substrates, more than 25 TG2 
substrates were identified in CaCo-2 cell lines using top-down proteomic methods. 
Whereas, fructose-l, 6-bisphosphate aldolase A was identified as a TG2 substrate in HT29 
cells (Lee et al., 1992; Orrù et al., 2003)  
However, the main impediment to this type of investigation is that there are no animal or 
cell models for CD. With this in mind, this study has focussed on the effect of the 
flavonoids on TG2 activity by using intestinal epithelial cell models. Therefore, 
knowledge on the actions of flavonoids at the GI tract is essential to design dietary and 
pharmacological approaches for the prevention and/or treatment of disease. The later 
sections will explain the interactions of flavonoids in the intestinal tracts. 
5.1.6  Host Metabolism of Flavonoids 
After ingestion, flavonoid glycosides in food are deglycosylated and further conjugated 
in the small intestine where some are absorbed, while the rest pass into the colon where 
they metabolized by the gut microbiota (Manach et al., 1997; Hein, et al., 2008). Two 
enzymes in the human small intestine have been identified to deglycosylate flavonoids 
(Day, Andrea J., et al., 2000; K Németh et al., 2003). The brush border enzyme lactase-
phlorizin hydrolase a was reported to hydrolyse O-glucosides of quercetin, genistein, and 
daidzein in vitro (Day et al., 2000). Whereas, cytosolic beta-glucosidase in the enterocytes 
was stated to hydrolyse O-glucosides of quercetin and genistein, in cell-free extracts from 
human intestine (Day, et al., 1998). Generally, the physicochemical properties such as 
molecular size and configuration, lipophilicity, solubility, and pKa are the most important 
factors influence the absorption of the flavonoid (Hollman 2004). 
5.1.7 Flavonoids actions on the gastrointestinal tract: 
Flavonoids can target the lumen content and/or the different cell types that are involved 
in sustaining gastrointestinal tract (GI tract) physiology. The intestinal monolayer is 
composed of: i) intestinal epithelial cells that engage in nutrient absorption, and the 
preservation of barrier integrity ii) goblet cells that responsible for the production of 
mucins that act as a lubricant and a barrier against bacteria and toxin  incursion and iii) 
Paneth cells that secrete bactericidal peptides (Figure 5-1).Immune cells located at the 
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lamina propria work in combination with the above mucosal cells to integrate the GI tract 
immune system (Brown et al., 2013). Additionally, ingested flavonoids have beneficial 
actions on the GI tract such as i) protection of the intestinal wall against pharmacological 
and food toxins; ii) sustaining the intestinal barrier integrity; iii) modulation of the 
secretion of gut hormones; iv) modulation the GI tract immune system; v) have possible 
anti-colorectal cancer activity; and vi) shape microbiota profiles(Oteiza, et al. 2018) 
 
Figure 5-1 Schematic diagram for intestinal monolayer 
Human carcinoma large intestine epithelial cell lines such as HT29 and CaCo2 have been 
used in the study the different biological actions of different flavonoids. Kameoka et al., 
(1999) used the CaCo2 cell line to study the effect of flavonoids (genistein, biochanin A, 
quercetin, and kaempferol) on the expression of antioxidant proteins.  Salucci and co-
worker (2002) used epicatechin, epigallocatechin gallate, gallic acid and quercetin with 
CaCo2 cells to investigate their antioxidant activity, cellular uptake and cytotoxicity 
effects at different concentrations of flavonoids. The CaCo2 cell lines also have been used 
to study the structure and permeability relationship of flavonoids to this type of cells 
(Fang Yajing et al., 2017). Whereas, HT29 cells were used in the study of the different 
effects of flavonoids such as investigate the antitumor activity of taxifolin in colorectal 
cancer cell lines (Razak, et al, 2018). Based on own search of the literature there are no 
published studies which deal with the effect of flavonoids on the in situ activity of TG2. 
The aim of this chapter was to study the cytotoxicity of the flavonoids (kaempferol, morin, 
and quercetin) which have been shown to moderate the activity of TG2 in vitro (chapter 
3). In addition, using HT29 cells to study the effects of  kaempferol, morin, and quercetin 
on the in situ activity of TG2 and determine some of the cellular substrates TG2 targeted 
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5.2 Hypothesis  
The flavonoids that have TG2 inhibitory actions are non-toxic to use with the human cell 
lines (HT29) and are cell-permeable. In addition, the human cell lines (HT29) contain 
TG2 protein substrates. When cellular TG2 activity is moderated by flavonoids that have 
TG2 inhibitory actions. These protein substrates may be identified.  
To test the hypothesis, it was aimed to; 
•  Study the effect of flavonoids on cell proliferation and cell viability using MTT 
reduction assay and a cell proliferation assay (IncuCyte FLR; Essen BioScience, 
DE). 
• Evaluate the effect of flavonoids on cellular TG2 activity using HT29 cell lines 
through Western blotting and fluorescent microscopy. 
• Identify target TG2 substrates using SDS-PAGE and RP-HPLC/MS/MS. 
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• Methods and Materials:  
See Methods and material chapter: 
➢ MTT reduction assay (section2.2.9e). 
➢ Live cell imaging: (section2.2.9e). 
➢ Visualisation of in situ TG2 transamidase activity (section2.2.6c)iii. 
➢ In situ biotinylation of proteins in HT29 cell lines(2.2.9d) 
 
5.3 Results 
5.3.1 The effect of three flavonoids on cell viability  
A widely used method to determine the cytotoxicity behaviour of drugs includes endpoint 
measuring cellular metabolic activity and real-time assay systems that allow for the 
tracking of cellular growth over the entire time course of an experiment. In order to 
observe the cytotoxic effect of three flavonoids (kaempferol, morin, and quercetin) which 
moderated TG2 in vitro activity (see chapter 3), it was deemed important to observe any 
potential toxic effects, which could influence cell viability. This was done by two methods: 
an (MTT) assay (Vyas et al., 2016 )and a cultured cell proliferation assay (incuCyte by 
ESSEN Bioscience DE). 
a) The effect of flavonoids TG2 inhibitors on cell viability using MTT assay 
 TheHT29 cell extracts were treated with different concentrations of kaempferol, morin 
and quercetin flavonoids, any changes in the cell viability were monitored via MTT 
reduction assay (section 2.2.9e)i.    
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Figure 5-2: MTT reduction assay to measure cell viability in HT29 cells following treatment with 
kaempferol, morin, and quercetin. 
HT29 cells were treated with different concentrations (4-125 µM) of kaempferol, morin, and quercetin. and 
incubated for 1.0 h at 37oC. Cell viability was determined by MTT reduction assay (section 2.2.9). The data 
points represent the mean ± S.E.M from 3 independent experiments. All the values are as compared to the 
control (n=3, P-value * < 0.05, **** < 0.0001).   
The large intestine epithelial HT29 cell line showed no loss of cell viability (as measured 
by MTT reduction assay) when treated with different concentrations of kaempferol and 
quercetin, whereas, morin displayed a moderate but statistically relevant effect on the 
viability of the cells as measured by MTT assay.  
b) The effect of flavonoids TG2 inhibitors on cell growth using a real-time 
proliferation assay (incuCyte). 
 HT29 cells were treated with kaempferol, morin and quercetin flavonoids TG2 inhibitors 
to visualise and quantify any effect on the cell proliferation. 
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Figure 5-3: Images show the effect of significant flavonoids TG2 inhibitors on HT29cell growth 
Cells were treated with kaempferol, morin, and quercetin at 125µM.  Then allowed to proliferate for three 
days. Images were taken using Incucyte S3 live-cell imaging system (10× objective). Control: cells without 
flavonoids treatment.  
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Figure 5-4: The effect of flavonoids TG2 inhibitors on HT29cell Confluence. 
 HT29 cells were treated with (125 µM) of kaempferol, morin, and quercetin. Then allowed to proliferate 
for three days. Their effect on the growth of the cell was determined using Incucyte S3 live-cell imaging 
system (10× objective). (Materials and methods chapter, Section 2.2.9e)ii). The data points represent the 
mean ± S.E.M from 3 independent experiments. All the values are as compared to the control (n=3, P-value 
* < 0.05, **** < 0.0001).   
The data in Figures 5-3 and5-4 shows the inhibition effect of kaempferol, morin, and 
quercetin at 125µM on the HT29 cell growth, the effect of kaempferol and quercetin was 
significantly more than the morin effect. 
5.3.2 Fluorescence microscopy of HT29 cells incubated with biotin-X- 
cadaverine 
 HT29 cells were treated with biotin-X-cadaverine followed by incubation with 125µM 
flavonoids (kaempferol, morin, and quercetin) followed by probing with FITC 
ExtrAvidin.The intensity of green colour indicates intracellular TG2 activity (see section 
2.2.9d).  ZDON used as negative control. 
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Figure 5-5: Fluorescence microscopy of HT29 cells. 
Fluorescence image of the HT29 cell lines incubated with biotin-X-cadaverine (B.X.C) (Materials and 
methods chapter, section2.2.6c)iii ). No B.X.C: untreated HT29 cells as a negative control. B.X.C: HT29 
cells treated with 1.4 mM biotin-X-cadaverine as a positive control. kaempferol, morin, quercetin: HT29 
cells treated with 1.4 mM biotin-X-cadaverine and then 125 µM flavonoids for 1.0 h. Z-DON 125 µM (TG2 
inhibitor):  HT29 cells treated with 1.4 mM biotin-X-cadaverine and then with 125 µM 1.0 h. After 
treatments, cells were fixed and permeabilised before the TG2 activity was visualised using ExtrAvidin - 
FITC (green) and DAPI was used for nuclear staining (blue). The images were viewed using an EVOS FL 
imaging system (ThermoFisher).  
The fluorescence assay confirmed the TG2 inhibitory characteristic of the kaempferol 
because the treatment of HT29 cell lines with this flavonoid displayed significant 
inhibition of in vivo TG2 activity (green colour). Whereas, morin and quercetin showed 
no statistically significant inhibition of in vivo TG2 activity(Figure 5-5).   
5.3.3 Identification of biotin cadaverine labeled proteins in HT29 cells that show 
reduced labeling with flavonoids TG2 inhibitors 
To identify potential protein targets of TG2 activity following treatment by flavonoids, 
cells were incubated with biotin-X-cadaverine and flavonoids. The proteins labeled with 
biotin in the lysates from cells were subjected to SDS-PAGE on a 4-15 % polyacrylamide 
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gradient gel, Western blotting and probed with extravidin HRP. Protein labeled with 
biotin-X-cadaverine were visualised using ECL reagents (2.2.9d) 
   
 
Figure 5-6: Western blotting analysis of the inhibition of TG2 substrate labeling in HT29 cells by 
three significant flavonoids. 
HT29 cells were incubated for 4.0 h with 1.4 mM biotin-X cadaverine (a cell-penetrating substrate of TG2) 
(section 2.2.9d). The biotinylated proteins were extracted and 20 µg separated by SDS-PAGE, transferred 
to nitrocellulose membrane filters and probed with Extra Vidin Peroxidase (Materials and methods chapter, 
section 2.2.9d). HT29 cell lines treated with 1.4 mM biotin-X-cadaverine as a positive control (+ve), HT29 
cell lines treated with 1.4 mM biotin-X-cadaverine for 4.0 h and then treated with 125 µM of flavonoids 
(K, kaempferol, M, morin, Q, quercetin )  and 125µM Z-DON (TG2 inhibitor).  Untreated HT29 cell lines 
(-ve) 1.0 h. The staining of β Actin on the same blots confirmed equal protein loading.  
Two bands were visualized in the negative control of non-biotin cadaverine treated HT29 
cells. In contrast, the positive control cells show three biotin cadaverine labelled protein 
bands, corresponding to approximate molecular weight of 135, 75 and 63 kDa. The 
flavonoids at these concentrations displayed different effects on the in situ activity of TG2. 
Kaempferol showed slight inhibition of the band labelling, more than the effect of morin 
and quercetin. (Figure 5.6). 
5.3.4 Biotinylation and fractionation of TG2 substrates 
The biotinylated target proteins in treated cells were subjected to SDS-PAGE on a 4-15 % 
polyacrylamide gradient gel, Western blotting and probed with extravidin HRP. Protein 
labelled with biotin-X-cadaverine were visualised using ECL reagents. The protein bands 
which showed decreased labelling following kaempferol treatment were excised from the 
gels and subjected to tryptic digestion (see materials and methods chapter 2 section ??). 
Peptide fragments were then directly analysed by RP-HPLC -MS/MS. By this method, 
multiple proteins were identified within a single protein band (Table 5-2). 
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Table 5-2: Identification of TG2 proteins substrates in HT29 cells. 
 
5.4 Discussion: 
In order to test the therapeutic efficacy and safety of the flavonoids (kaempferol, morin, 
and quercetin) that displayed in vitro inhibition against hrTG2 transamidation activity as 
explained in chapter 3. It is important to characterise these proposed flavonoids TG2 
inhibitors in more detail. Obstacles impeded the evaluating of the therapeutic potential 
behaviour of TG2 inhibitors in relation to CD, such as the non-availability of animal or 
cell model for the coeliac disease to test the CD correlated histopathological, 
immunological and serological abnormalities (Auricchio, S et al., 1984 and Papista et al., 
2012). Although HT29 cells are not ideal for studying CD, however, the cells provide an 
indication of the effects of different reagents on disease relevant to a human cell type. 
The HT29 cell line was derived from large intestine carcinomas but are used worldwide 
by the researchers as the model of human intestinal epithelial cells. As TG2 is active in 
the lamina propria of human small intestines and believed to be exported from epithelial 
cells, it would be an advantage to use a small intestinal epithelial cell line (Papista et al., 
2012). However, the human small intestine carcinoma cell line FHs 74 Int are slow to 
grow, difficult to culture and maintain. In this study, HT29 was used and the results must 
be viewed with the limitation that they are not the best cell model but they will provide 
some insight into the role of TG2 in intestinal epithelial cells. 
Kaempferol and quercetin (4 to 125 µM) have no inhibition effect on the large intestine 
epithelial HT29 cell viability (as measured by MTT reduction assay) (Figure2-3)). 
Whereas, morin displayed a moderate inhibition effect on the viability of the cells. Morin 
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shows slight differences in structure compared with the other two flavonoids, as it 
contains hydroxyl group in ring B at carbon 2, while, kaempferol and quercetin contain 
OH groups in other locations (Figure2-3). These findings are in line with the notion that 
was reported by Pradhan et al., (2018), that the presence and location of hydroxyl groups 
on the B-ring of flavonoids impacts on its activity. Additionally, these findings agree with 
the study done by Fernández-Blanco and co-worker (2016), which reported that quercetin, 
has no effect on the viability of HT29 and Caco2 cell lines. One of the proposed 
mechanism of cell protective effect of quercetin is the ability to penetrate into the polar 
medium inside the cells and to protect them against the toxins (Rezaei-Sadabady et al., 
2016). As mentioned by Kuntz and co-workers (1999), the cellular protective effects of 
flavonoids in colon cancer development should be accompanied with the inhibition of 
cell proliferation and/or initiation of the apoptotic pathway to delete cells carrying 
mutations and to maintain a normal cell population. This directed the research to study 
the effect of kaempferol, morin, and quercetin on the proliferation of the large intestine 
epithelial HT29 using the IncuCyte® Live-Cell Analysis Essen Bioscience System. The 
data in Figure 5-3 and Figure 5-4 show a statistically significant inhibitory effect of the 
three flavonoids on cell proliferation. These findings are consistent with the study done 
by Kuntz et al (1999), which reported that flavonoids display growth inhibition effect in 
the absence of cytotoxicity. Furthermore, the anti-proliferative effect the flavonoids are 
in agreement with number of studies that present the anti-proliferative behaviour of 
flavonoids against a number of cancers such as gastric, colon cancer cells and leukemia 
T-cells (Yoshida et al., 1990).  
Flavonoids are as known have antioxidant actions, so the reduction of cell growth might, 
therefore, depend on the ability of these compounds to serve as free radical scavengers. 
The accumulation of dietary flavonoids was higher in the intestinal epithelium than cells 
in other tissues (Kuo, 1998). That indicates that the dietary polyphenols could have a 
significant role in the prevention of colon cancer by blocking hyperproliferation of the 
epithelium. There is a high expression of TG2 in stroma of cancer cells (Eckert et al., 
2015), which suggests this TG2 expression in tumour stroma is required for metastatic 
progression of colon cancer. TG2 was found to induce chemo resistance through 
inhibition of apoptosis and autophagy in human breast cancer cells (Antonyak, M.A., 
2004; Kumar et al., 2010 and Calcagno, et al., 2010). It has been mentioned, in different 
studies that TG2 levels are lower in colon cancer cells comparing to normal cells, and this 
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increase leads to apoptosis and cell growth inhibition (Takaku, et al. 1995 and Kosa, et 
al. 1997). Nevertheless, other studies have proposed that TG2 levels raised in colon 
cancer and may be a useful indicator for the prognosis of colorectal cancer (D'argenio, et 
al. 1995 and Miyoshi, et al. 2010). The development of molecular inhibitors selectively 
targeting TG2 may provide promising results in the treatment of inflammatory disorders 
(Badarau et al., 2013). Published knowledge has displayed the importance of the 
inhibition of TG2 activity as a potential therapeutic intervention in various cancer types 
(Carbone, et al. 2017). Based on these reports and by comparing the significant inhibition 
for the transamidation activity of hrTG2 via the flavonoids used in this study and the anti-
proliferative data of the same flavonoids, all these data could be providing an indication 
that there may be a link in the mechanisms of different actions of these flavonoids. 
As there is little information available on TG2 substrates in HT29 cells, hence the 
identification of the TG2 substrates can be considered an achievement. Moreover, 
because of the association of TG2 with CD, the identification of its substrates in human 
intestinal cell lines may help to identify potentially important drug targets (Caputo et al. , 
2004). To detect the effect of the kaempferol, morin, and quercetin, on in situ and to 
identify the TG2 target substrate biotin-Xcadaverine (a cell-penetrating substrate of TG2) 
was used to label intracellular proteins in HT29 cells via intracellular TG2 activity. When 
viewed with a fluorescence microscope using ExtrAvidin®−FITC to spot biotin labelled 
proteins (Figure 5-5). The data showed that the intensity of green colour in fluorescence 
assay, which reflects the intracellular TG2 activity, was reduced by 125µM kaempferol 
treatment confirming the TG2 inhibitory characteristic of the kaempferol. Whereas morin 
and quercetin their inhibition of TG2 activity in HT29 cells was statistically insignificant, 
these findings are inconsistent with in vitro TG2 assays (Figure3-8 and Figure3-13). 
To understand the reasons for this variation, factors must take into account, such as the 
fact that inhibition of TG2 by the flavonoids was assessed using an in vitro assay, where 
the TG2 and substrates are pure, and the environment of the assay was different. In 
addition, the flavonoids in the cells could be exposed to pharmacokinetics reactions such 
as metabolism that lead to change in flavonoids structure (Manach, and Donovan, 2004), 
which may consequently impact on their effect towards the TG2 in the cell lines. 
Moreover, the presence of other members of TG family in cell lines could provide 
overlapping biological functions that will affect the results of the in vivo assays 
(Facchiano et al., 2006). Additionally, these findings are consistent with the results by 
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González-Gallego et al (2018), which state the flavonoid metabolites have different 
antioxidant and biological properties than their parent compounds.Further studies are 
needed to examine the mechanisms of the actions of the flavonoids on the cellular activity 
of the TG2.  
In order, to determine the specific intracellular TG2 protein targets in the HT29 cells. The 
biotin cadaverine labelled proteins were extracted and analysed by SDS-PAGE, and 
Western blotting. The Western blotting image for HT29 cell lines (Figure 5-6) showed 
that certain bands had partially disappeared in cell treated with the Z-DON. However, the 
intensity of bands in the cells lysates subjected to treatment with kaempferol decreased 
significantly in HT29 cell lines. The morin and quercetin treatments show a non-
significant decrease for the bands chemiluminescent intensity. These findings confirm the 
finding of the fluorescence microscope experiments and agreed with study done by Walle 
and colleagues (1999), which mentioned that effective metabolism by the cancer cells 
(Caco2) might limit the oral bioavailability of flavonoid (chrysin) in humans. However 
they do disagree with the in vitro TG2 assay (Figure3-8 and 3-13).which show that the 
kaempferol, morin, and quercetin have inhibition effect on the TG2 activity. This may be 
partially explained by a different environment and different substrate that the TG2 was 
assayed in.  
Because of the fact, that different physiological activity of TG2 is based on the diversity 
of the protein substrates of the transamidation activity (Ichikawa et al., 2008). Hence, it 
is necessary to have a better knowledge of its substrates, target sites and interacting 
proteins that may act as novel drug targets or new diagnostic markers. Therefore, the 
attempt to identify the protein substrates of TG2 was conducted in order to understand 
the physiological roles of TG2 at the molecular level. Various proteins were identified by 
using SDS-PAGE linked to RP-HPLC-MS/MS, this approach was used previously by 
(Orrù et al., 2003and  Robinson et al., 2007) to detect TG2 protein substrates. The 
advantage of the current method was to use the biotin-X-cadaverine, which is the cell-
penetrating synthetic TG substrate as a probe to identify TG2 protein substrates. This 
amine substrate does not need the addition of a calcium activation buffer and does not 
interfere with normal cell processes (Esposito and Caputo, 2005). The proteins were 
extracted from gel by first dehydration in acetonitrile and hydration in 50.0 mM 
ammonium bicarbonate, followed with trypsin digestion as described in Material and 
Methods (see chapter 2 section2.2.4). The tryptic peptide samples were then directly 
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analysed by RP-HPLC-MS/MS in which multiple proteins were identified within a single 
protein band (~70 kDa). Identified proteins following peptide mapping using software 
were listed in Table5-2. 
As this band was extracted from 1D Gel, many proteins have been detected, however, the 
proteins that show high sequence coverage and corresponding to the band size were 
selected from the data. The peptide sequences obtained from MS/MS were searched for 
homologies in the databases; (https://www.uniprot.org/). The identified TG2 substrates 
in this study indicate the diversity of proteins with biological functions might be used as 
substrates of TG2. 
According to the TRANSDAB database 
 http://genomics.dote.hu/wiki/index.php/Category:Tissue_transglutaminase  
Some of the identified proteins have not been previously identified as TG substrates in 
either HT29 cells or in other cell lines. These include the BAG family molecular 
chaperone regulator 3, and RAF proto-oncogene serine/threonine-protein kinase. 
According to their biological functions, the identified target proteins were categorised 
into several groups. These include chaperone proteins, kinases, serine/threonine-protein 
kinase transferase, activator, DNA-binding and actin binding. The BAG family is a 
multifunctional group of proteins which have several functions ranging from apoptosis to 
tumorigenesis. Six BAG family members were identified in humans, which have been 
proposed to play a role in  HIV infection, carcinogenesis, and Parkinson’s disease 
(Kabbage and Dickman 2008). Therefore, these proteins are considered as potential 
therapeutic targets, and their expression in cells may act as a predictive tool for those 
diseases.  
BAG-3 (CAIR-1/Bis) has a unique domain arrangement: it contains a WW domain 
followed by a proline-rich region with PXXP motifs (Figure 5-7) (Kabbage and Dickman 
2008). The CAIR-1 annotation happened when calcium entry blocker-treated cells 
showed increased BAG3/CAIR-1 expression levels (Doong, et al. 2000). Overexpression 
of BAG-3 resulted in the inhibition of the degradation of poly-ubiquitinated Hsp70 client 
proteins (Doong, et al. 2003). BAG-3 has a potential role in both cancer and HIV therapies. 
In cancer cells, BAG-3 was found damaging the response to therapy and sustaining cell 
survival, hence, they are considered as a probable target for anti-neoplastic therapies 
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(Rosati, et al., 2007).  In HIV-1, BAG-3 blocks the function of p65, providing a potential 
tool for suppressing HIV-1 gene expression (Rosati, Leone, et al. 2007). 
 
Figure 5-7: Structure of the human BAG3 
Structure of the human BAG family proteins, showing the conserved BAG domain, TXSEEX and PXXP 
repeats, nuclear localization signal (NLS), and WW domain. The number of amino acids is shown on the 
right of BAG protein. 
Another protein was identified as serine/threonine-protein kinase, which works as a 
regulatory link between the MAPK/ERK cascade and the membrane-associated Ras 
GTPases. This regulatory link has crucial roles in determining cell fate processes 
including proliferation, differentiation, apoptosis, survival and oncogenic transformation 
(Brown, et al. 2013). Upon activation, Raf-1 phosphorylates mitogen-activated protein 
kinase kinase (MEK), which in turn activates mitogen-activated protein 
kinase/extracellular signal-regulated kinases (MAPK/ERKs), leading to the propagation 
of signals (Chen, et al., 2001). Additionally, it plays a function in the oncogenic 
transformation of epithelial cells through repression of the TJ protein, occludin (OCLN) 
by activating the up-regulation of a transcriptional repressor SNAI2/SLUG that stimulates 
down-regulation of OCLN (Brown, et al. 2013). It is noteworthy, that TG2 has kinase 
activity since it was indicated that in breast cancer cells, TG2 phosphorylates insulin-like 
growth factor-binding protein-3 (IGFBP-3), thereby minimising its pro-apoptotic activity 
(Mishra & Murphy, 2004). Therefore, it might be interacting with this protein as substrate 
to perform the protein kinase activity. 
Heat shock factor protein 4, is the other protein identified in this study, which has already 
been reported as substrates for TG2, but not in HT29 cells. Cells from most organisms 
respond to a diversity of stresses through the rapid synthesis of a highly conserved series 
of polypeptides known as heat shock proteins (HSPs). There are considerable indications 
that these stress proteins are critical for survival at both normal and high temperatures. 
HSPs also appear to play a crucial role in the development of thermotolerance and 
protection from cellular damage associated with stresses such as cytokines, ischemia, and 
energy depletion (Kregel et al., 2002). Heat shock factor protein 4 belongs to the Hsp70 
group of the protein and has been linked with different functions in the human body 
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(Tavaria et al., 1996and Morano, 2007). Proteins in the Hsp70 group have common 
protein sequences, however, they synthesized in response to different stimuli. Several 
studies have reported, that the activation of these proteins was accompanying with the 
increase of tolerance to a diversity of stresses. Such as, hypoxia (Guttman, et al. 1980and  
Hahn and Li 1982),  ischemia (Marber, et al. 1995), energy depletion  (Schläfli, et al. 
2011), cytokines such as tumor necrosis factor-α (TNF-α) (Jaattela and Wissing 1993) , 
acidosis (Weitzel, Pilatus and Rensing 1985), and ultraviolet radiation (Barbe, et al. 1988). 
Benjamin and co-workers (1998) reported that the heat shock proteins are crucial for the 
wound healing process through protection of the tissues against injury. These actions were 
performed by repairing any damaged proteins.  As TG2 is also involved in the wound 
healing process, hence it is likely that TG2 might be interacting with Hsp 70 to protect 
the intestinal cells from harmful components as one of its biological function. The 
accurate mechanisms by which TG2 interacts with this substrates are not clear and 
additional studies are reasonable to elucidate the interaction of TG2 with these proteins 
in human intestinal cell lines and its implications in the physiological functions. 
The noticeable finding from this part of the work is the presence of numerous number of 
proteins identified in gel extracts. To deconvolute the results it could be necessary to use 
Captavidin-agarose (García-Aljaro, Muñoz and Baldrich 2009). These avidin proteins 
have the ability to form tight complexes with one or more biotinylated compounds 
(substrates) (Haugland and Bhalgat 2009). It could be utilised to bind and release 
biotinylated bio components thus reducing the background contamination. An additional 
experiment is needed in future using captavidin in order to capture specific TG2 
biotinylated substrates.  
Generally, in relation to coeliac disease as mentioned in literature flavonoids such as 
quercetin exert their cellular protective effect in CD by different mechanisms, such as 
restoration of intestinal barrier tight junction impairment that induced by oxidative stress 
and inflammatory cytokines (Suzuki and Hara 2011). Flavonoids have been assessed in 
normal and cancer cultured cells, and studies have shown that these bio compounds 
exerted their effects in a selective way, which mean by using the same concentrations, 
same compounds, and same assay induced. For example, the major catechin in tea, 
(EGCG) has been reported to activate the apoptosis of different types of cancer, such as 
gastric cancer ( Facchiano 2006, Horie, et al. 2005), colon cancer (Chen, et al. 2003), lung 
cancer (Yang, et al. 1998). However, study by Hsu et al (2003) has reported a differential 
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effect of EGCG on cell proliferation in normal human primary epidermal keratinocytes 
after 24 h of exposure (Hsu, et al. 2003). These differences expose the problems with 
different research groups working with different cell lines.  
5.5 Summary of key findings 
• Quercetin and kaempferol did not influence on Ht29 cell viability, whereas morin 
has slight effect. 
• The fluorescence assay confirmed the TG2 inhibitory characteristic of the 
kaempferol on Ht29 cell lines. 
• BAG family molecular chaperone regulator 3, and RAF proto-oncogene 
serine/threonine-protein kinase are proteins were identified as TG substrates in 
HT29.  
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Chapter 6 : Optimisation of Deamidation Assay  
6.1 INTRODUCTION 
The most abundant in-vivo and in-vitro processes involving proteins are post-translational 
modifications, such as oxidation, phosphorylation, glycosylation, and deamidation 
(Gervais 2016). Deamidation and oxidation could be damaging to all proteins; for 
example, oxidation has been reported to be associated with several pathological diseases, 
such as ischemia perfusion, rheumatoid arthritis, and atherosclerosis (Stadtman 1990). 
Whereas, deamidation is associated with a group of age-related disorders, neurological 
diseases, cataracts and autoimmune diseases such as rheumatoid arthritis and coeliac 
disease (Riggs, Gomez and Julian 2017). On the other hand, glycosylation can play a key 
role in improving proteins stability (Solá and Griebenow 2009). Deamidation affects 
asparagine (Asn or N) and glutamine residues of proteins (Gln or Q) (Robinson and Rudd 
1974; Hasan, et al., 2006; Schroeter and Cleland 2016). Asparagine deamidation proceeds 
by a succinamide intermediate and that of glutamine by a glutanimide intermediate 
producing aspartic and glutamic acid, respectively (See Figure 6-1). In-vitro deamidation 
is undesirable, but perhaps unavoidable because deamidation proceeds none 
enzymatically independent of the pH value (Patel et al., 1990). It may lead to changes in 
the secondary, tertiary or quaternary structure of proteins, thus compromising their 
function or promoting undesired protein-protein aggregation (Gupta and Srivastava 2004; 
Dutta, et al., 2012).  
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Adapted from Cournoyer et al., 2008 
Figure 6-1: Schematic demonstration for non-enzymatic asparginine and glutamine deamidation 
reactions. 
6.1.1 Non-enzymatic deamidation: 
There are two non-enzymatic post-translational modifications of proteins – deamidation 
of glutamine and asparagine, and racemisation of aspartic acid, which are essential 
reactions in the aging of cells and organisms (Truscott and Friedrich 2016). The in vivo 
release of ammonia from protein-bound amides results in alterations to proteins such as, 
conformational changes and the loss of biological activity. For example, the decrease in 
the potency of human growth releasing factor results from the deamidation of asparagine 
residues (Huang, et al., 2005).  Another non-enzymatic, post-translation is racemisation, 
the major amino acids involved in racemisation are Asp and Asn. Racemisation leads to 
the accumulation of abnormal proteins in numerous human tissues. It has an important 
impact in the pathogenesis of diseases in old age such as the formation of cataracts, 
atherosclerosis, and cerebral age-related dysfunctions (Ritz-Timme and Collins 2002).  
Acid or alkali pH values are responsible for the non-enzymatic deamidation (Robinson 
1974) Deamidation catalysed by acid is less important at physiological pH. In an acidic 
environment, the carbonyl side chain of protein-bound glutamine becomes protonated to 
a hydroxyl, which leads to an increase its susceptibility to nucleophilic attack by water 
(Cournoyer and O’Connor 2008). Base-catalysed deamidation starts by deprotonation of 
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the backbone amide of protein-bound glutamine, leading to the formation of a negatively 
charged amide that reacts with the carbonyl side-chain generating a glutinamide 
intermediate. This reaction is enhanced in basic conditions and is principally prohibited 
when the C-terminal amino acid is proline (Cournoyer and O’Connor 2008). Similar 
reaction mechanisms can be drawn for asparagine.  
6.1.2 Enzymatic deamidation: 
Several enzymes that have been reported to deamidate the amide groups of proteins; 
transglutaminases, peptidases, and peptidoglutaminases (Hamada and Swanson 1994; 
Zhao, et al., 2016). Modifications of proteins mediated by enzymes are more effective 
than non-enzymatic deamidation (chemical), due to their ability to work at under milder 
conditions and their high specificity (Yong, Yamaguchi and Matsumura 2006). The 
deamidation rate of protein-bound amide residues is dependent on the properties of 
solution such as temperature, ionic strength, pH, buffer ions, the primary sequence of the 
target proteins and their three-dimensional structure. (Maeda, 1977; Robinson 2002). A 
negative charge forms when a deamidation occurs at neutral pH, which occasionally, also 
leads to β- isomerization. These modifications in structure may influence the biological 
properties of peptides and proteins (Robinson 2002a). It has been recorded that small 
levels of deamidation (e.g. 2-6 %) may significantly enhance protein functions. For 
example, the deamidation of glutamine in wheat proteins improves their solubility in 
mildly acidic conditions by lowering their isoelectric point (Zhang, Lee and Ho 1993). 
6.1.3 Biological impact of deamidation 
It has been proposed that in vivo deamidation of proteins acts as a molecular timer of 
biological actions and as a mechanism for post-synthetic production of proteins of cellular 
significance (Robinson 2002b). The lack of reliable experimental and theoretical 
information about the deamidation of proteins leads to an insufficient understanding of 
deamidation and its biological impacts. There are various implications of the deamidation 
of protein glutamine residues such as in degenerative proteinopathies, including 
Alzheimer’s disease (AD), Parkinson’s disease (PD), cataracts, vascular dementia (VaD) 
and coeliac disease(CD) (Serra 2016). 
In coeliac disease, the immunologic peptides such as 33-mer arrive at the lamina propria 
where they are deamidated by TG2, which is crucial for the peptides to act as HLA-DQ-
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restricted T-cell antigens that are responsible for initiating the disease ( Lauret and 
Rodrigo 2013). Production of negative charges in gluten-derived peptides due to 
deamidation catalysed by TG2 promotes their binding affinity to the autoimmune disease-
associated HLA molecules. (See chapter 1 section 1-8) (Hasan, et al., 2006; Stamnaes and 
Sollid 2015 and Serra, et al., 2016). As the most published methods for measuring the 
deamidating activity of TG2, use mass spectrometry technique. Hence, there is necessity 
to establish a simple low-cost method to confirm deamidation by TG2. These methods 
would enable investigation of naturally occurring inhibitors of TG2 and their potential 
use as moderators of coeliac disease. 
6.1.4 Seed storage proteins as a tool for deamidation studies  
The amount of storage proteins in seeds has been found to be 10% dry weight (DW) (in 
cereals) to 40% DW (in certain legumes and oilseeds) (Shimada, et al., 2003; Liu, et al., 
2017). One of the oldest cultivated legumes is the faba bean (Vicia faba). The major 
proteins in Vicia faba are albumins (20%) and globulins (60%) as convicilin, vicilin and 
legumin (Liu, et al., 2017).  The albumin includes trypsin inhibitors and contains more 
sulfur-containing amino acids than the globulins (Mandal 2000). These dicotyledonous 
seed storage proteins accumulate in high quantities in seed throughout mid-maturation 
period of seed growth and are utilised during germination, and they have been shown to 
become more electronegative after the initiation of germination (Manda, 2000). It has 
been proposed that this is a prerequisite to degradation by de novo synthesised peptidase 
enzymes. It has been reported that transglutaminase enzymes were not involved in 
dicotyledonous seed storage protein deamidation(Shutov et al., 1987). Previous work at 
NTU (Durose et al., 2003) has shown that an enzyme purified from 14-day old 
germinating Vicia faba seeds could incorporate biotin cadaverine into N`, N`, dimethyl 
casein in a calcium-dependent manner. This enriched enzyme preparation was able to 
deamidate day 1 after germination Vicia faba storage globulins. This was demonstrated 
by increased electronegativity of the storage proteins on a non-dissociating 
polyacrylamide gel after treatment with the enriched Vicia faba TG2. The deamidation 
was inhibited by EDTA showing that this protein deamidation was calcium ion-
dependent, inhibited by a cystamine and partially inhibited by ZDON a specific active 
site inhibitor of mammalian TG2 (Badarau, et al., 2013). The use of these legumin storage 
proteins and the increased electronegativity on a non-dissociating PAGE as a measure of 
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deamidation provided an initial attempt to measure the deamidating activity of human 
recombinant TG2. 
Storage proteins could be used as a tool to study the deamidation catalysed by TG2. The 
important group in constituents of cereal grains is the proteins, which is, represent in a 
range of 8-12%. In particular, storage proteins, which in some cereals considered as 
initiating factors for coeliac disease (CD) (Koehler, Wieser and Konitzer 2014). In this 
research, storage proteins used as a substrate for TG2 to optimised a fluorimetric assay to 
measure the deamidation of glutamine in the cereal peptides. Storage proteins represent 
about 70–80% of total grain proteins. Their main role is to afford the grain embryo with 
nitrogen and amino acids during germination (Cournoyer and O’Connor 2008). It consists 
of prolamins (gliadins) and glutenins (glutelins). Glutenins are insoluble in weak acids 
such as acetic acid. Whereas, prolamins are insoluble in water, but soluble in aqueous 
alcohol solutions (e.g. 60–70% (v/v) ethanol). Prolamins characterised by a high content 
of proline and glutamine (35–37% glutamine and 17–23% proline) (Cournoyer and 
O’Connor 2008; Koehler, Wieser and Konitzer 2014). The high content of proline has 
two implications; first, they make gluten proteins resistant to completely proteolytic 
degradation in the gastrointestinal tract by protease enzymes. This leads to the production 
of peptide fragments in the stomach and small intestine. Second, proline affects the 
specificity of the TG2 toward glutamine and, therefore, only specific glutamine residues 
in the gliadin peptides are substrates for deamidation, which are initiators of CD. Peptides 
with high glutamine are good substrates for the TG2 (Cournoyer and O’Connor 2008).  
6.1.5 Measurement of deamidation: 
The deamidation of proteins leads to a charge and mass shift in the overall structures of 
proteins, which produces a mixture of isomers that impede accurate measurement the 
deamidation, due to the difficulty in differentiation those mixtures (Cournoyer and 
O’Connor 2008). Quantification of the deamidation in peptides or proteins generally 
precedes a series of techniques to separate the mixture of isomers by different methods, 
such as chromatography, electrophoresis, chemical derivatives, isoelectric focusing, 
enzymatic digests, or mass spectrometric methods (Lampi 1998). These processes often 
result in differential responses or losses of the amidated and deamidated peptides, which 
complicit the quantitation. (Robinson et al. 2005).  
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Numerous methods have been used for quantification of protein/peptide deamidation. 
Robinson, et al (2005), utilised direct electrospray injection and fragmentation in a 
Fourier transform mass spectrometer, to measure the deamidation of lens crystalline that 
is associated with cataracts and aging. Another published work by Jia and Sun (2017) 
reported that using structure-based descriptors for deamidation prediction provides better 
understanding of the molecular basis of deamidation processes. 
Other published methods for measurement the deamidation are:  
• Proteolytic digestion, Kameoka, and Imoto (2003) used a peptidase that cleaves 
on the N-terminal side of an l-aspartyl residue. Mass spectrometry used to detect 
deamidation of asparagine and isomerisation of aspartyl residues in hen egg 
lysozyme as a model protein (Kameoka, Ueda and Imoto 2003). 
• Reversed-phase HPLC, generally, chromatography is an attractive method for 
separation and can be used in combination with other methods that help in 
identifying the separated species. For example, RP-HPLC used to measure the 
deamidation rates of peptides and the enzyme kinetics correlated with the protein 
isoaspartyl methyltransferase (Murray and Clarke 1984). 
• Ion exchange chromatography, useful for separating species depending on their 
ionic charge.  Could be used to separate the deamidated form the native a 
protein/peptide, as for example, asparagine/glutamine are converted to their 
ionizable acid homologues (Huang, et al. 2005). 
• Electrophoresis, Gel electrophoresis could be used to visualise proteins affected 
by deamidation, as both the shape and isoelectric point are altered. For example, 
non-denaturing PAGE has proved a useful technique for the analysis of the three 
forms of partially deamidated calmodulin (N97 to isoD/D97), where the isoD97 
form migrated the slowest followed by the D97 and then N97 form (Johnson, 
Langmack and Aswad 1987). Staminas et al (2008), measured peptide 
deamidation and transamidation simultaneously through capillary electrophoresis 
(CE) to detect factors that affect the relative tendency for the two possible 
products. 
• Nuclear magnetic resonance (NMR), 2D NMR has been utilised for 
differentiation of the aspartyl from isoaspartyl residues in peptides. This technique 
provides additional structural information, however, the disadvantage is that each 
experiment needs a large amount of sample, which may make this technique is 
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inappropriate to biological experiments deamidation (Chazin, et al. 1989, 
Mamula, et al. 1999, Cournoyer and O’Connor 2008). 
However, this current research concentrates on the deamidation mediated by hrTG2; to 
date, most of published assays are for quantifying the level of deamidation catalyzed by 
TG2 are used either capillary electrophoresis or mass spectrometry techniques. 
Fleckenstein et al (2002) studied the affinity of different peptides to TG2, characterized 
the specificity of the enzyme, and examined the tendency of the enzyme to catalyse 
transamidation and deamidation reactions through using capillary electrophoresis with 
fluorescence-labeled gliadin peptides (Fleckenstein et al., 2002). Dørum et al (2009) used 
mass spectrometry method to measure the differences in the degree of deamidation for 
the different gliadin epitopes (Dørum, et al., 2009b).The mass spectrometry methods have 
been successfully utilised to characterize peptides in complex mixtures, these results so 
far have largely been qualitative (Ong and Mann 2005) with the associated high costs.  
Therefore, an effort was made to optimise a low-cost assay that could accurately measure 
the TG2 catalysed deamidation.  
The measurement of ammonium ions in solution has been conducted by a variety of 
methods, include the Berthelot colour reaction (Weatherburn 1967), titration, electrode-
based, enzymatic and colourimetric/ fluorimetric methods (Barsoliti 2001). The 
fluorimetric method based on the reaction of ammonia with a reagent to form a colour 
complex that is measured by spectrometry or fluorometry. The first colour reaction used 
was the indophenol reaction, described by Berthelot in 1859; the bluish colour was 
formed as a result the reaction of ammonia with phenol and hypochlorite (Proelss and 
Wright 1973). Another colourimetric reaction is the Nessler reaction, in which a brown-
orange colour produced due to reaction of ammonia with potassium or mercury iodide in 
an alkaline solution (Avan 1980).  Furthermore, ammonia assay kits from Sigma was used 
by Berti and his coworkers (2007) to measure the quantity of ammonia released after 
treatment of gliadins (extracted from bread wheat flour) with TGase from Strepto 
Verticillium sp. This assay based on the reaction of ammonia with reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) and α-ketoglutaric acid (KGA) in the presence 
of L-glutamate dehydrogenase (GlDH) leads to formation of L-glutamate and oxidized 
nicotinamide adenine dinucleotide phosphate (NADP+). The reduction of the absorbance 
due to the oxidation of NADPH will proportional to the ammonia concentration.  
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There are two fluorimetric reagents that have been used successfully for amino acid 
analysis: fluorescamine and o-phthaldialdehyde (OPA). The main advantages to these 
methods are rapidity, simplicity, specificity and high sensitivity (Barsoliti 2001). The 
OPA reagent is particularly suited to measuring pico mole to-nano mole amounts of 
ammonia in samples (Schuster 1988; Roth 1971). Roth (1971) showed that OPA in 
aqueous alkaline medium reacts with amino acids in the presence of 2-mercaptoethanol 
(2-ME) leading to the formation of fluorescent compounds. Ortho-phthaldialdehyde and 
2-mercaptoethanol react with primary amines including the number of amino acids (Lee 
and Drescher 1978) (See Figure 6-2). 
 
Figure 6-2: schematic representation for the reaction of OPA and primary amino groups. 
Adapted from Held, 2001 
The reaction can be used to assay ammonium ions (NH4
+) in specialised situations 
(Taylor, et al. 1974 and  Corbin 1984). Because of the high sensitivity and low detection 
limit of the OPA-sulfite-NH3 reaction, the OPA was used in a number of different 
methods (Kulla and Zuman 2008). Therefore, the aim of this research is to develop an 
assay to measure ammonia-based upon a reaction with OPA resulting in a fluorescent 
adduct which measured 340nm ex and 430nm em. The method was developed as a 
microplate assay at NTU (Aldubyan 2014). 
6.2  Hypothesis 
A simple assay for measurement the TG2 deamidation activity would be essential for 
testing the effect of a biologically active compound on the TG2 activity as a potential 
treatment of coeliac disease.      To test the hypothesis, it was aimed to; 
• Optimise the OPA assay for gliadin protein and 33-mer peptides as a substrate to 
TG2 to measure the release of ammonia. 
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• Methods and Materials:  
See Methods and material chapter: 
➢ Transglutaminase deamidation activity assay(section2.2.6b). 
6.3 Result  
Because of the high content of glutamine in Vicia faba storage proteins, these proteins 
were isolated from Vicia faba cotyledons one day after the initiation of imbibition. They 
were then used as the deamidation substrates to follow hrTG2 deamidation assays. 
Previous work is done in NTU (Aldubayan 2014) showed that the rate of natural 
deamidation of the isolated storage proteins from Vicia faba cotyledons increased (as 
judged by increased electronegativity) between 7th to 14th days after seed germination 
(See Figure 6-3). It is not yet been established the nature of the enzyme responsible for 
the deamidation of the storage proteins in the dicotyledonous seeds, but it has been 
hypothesised that the deamidation precedes proteolytic degradation (Müntz 1996). 
Previous work at NTU suggests that a Vicia faba transglutaminase is responsible for the 
deamidation of the storage proteins. 
 
Figure 6-3: The non-denaturing PAGE of Vicia faba storage proteins isolated from the cotyledons 
of seeds at different days following germination.                  
Adopted from (Aldubayan 2014). 
It has been hypothesised that legume storage proteins isolated early after imbibition of 
water can provide a useful tool to measure the calcium-dependent deamidating activity of 
human TG2 the enzyme central to the initiation of CD. 
6.3.1 Non-denaturing PAGE (Qualitative assay for TG2 deamidation activity) 
a) non-denaturing PAGE of seed storage proteins 
Non-denaturing PAGE of seed storage proteins (qualitative assay), used to visualise the 
effect of EDTA and Ca2+ on deamidation activity of hrTG2. Seed storage proteins from 
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Vicia faba were incubated with hrTG2, as described in (materials and methods chapter), 
and then subjected to non-denaturing PAGE. An increase in the electronegativity of 
proteins samples was observed (See Figure 6-4). 
 
Figure 6-4: non-denaturing PAGE of Vicia faba storage proteins. 
50.0μl Storage proteins (10 mg ml-1) isolated from Vicia faba seeds were incubated with 50.0μl hrTG2 
(5µg/ml-1) in the presence of 50.0μl Ca2+or EDTA (2mM). After overnight incubation at 37oC, the proteins 
(10 μl) were loaded onto a 5% (w/v) polyacrylamide gel and subjected to non-denaturing PAGE (materials 
and methods chapters,Section 2.2.7b)). A (water +storage protein + hrTG2).), B (EDTA +storage protein + 
hrTG2), C (Ca2+ +storage protein + hrTG2). The gel bands were revealed using Instant blue stain (Expedeon, 
UK).  
The Vicia faba storage proteins incubated with hrTG2 in the presence of 2.0 mM CaCl2 
showed increased electronegativity compared to samples incubated with EDTA and the 
water. 
b) non-denaturing PAGE of seed storage protein treated with hrTG2 at 
different CaCl2 concentrations 
In order to observe the effect of increasing Ca2+ concentration on deamidation activity, 
seed storage proteins from Vicia faba were subjected to non-denaturing PAGE with 
different CaCl2 concentrations and change in the electronegativity (increased 
electronegativity) was observed (See Figure 6-5). 
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Figure 6-5:  Effect of different concentrations of Ca2+ on the deamidation of Vicia faba, storage 
proteins. 
 50.0μl Vicia faba, storage proteins (10 mg ml-1) incubated with 50.0μl hr TG2 (5µg/ml-1) in the presence 
of 50.0μl EDTA (2mM) or 50.0μl CaCl2 at different concentrations. After overnight incubation at 37oC, the 
proteins (10 μl) were loaded onto a 5% (w/v) polyacrylamide gel and subjected to non-denaturing PAGE 
and instant blue staining (materials and methods chapter, section 2.2.7b).  
 
Figure 6-5 shows that the increasing of electronegativity of the samples with Calcium 
increased by increasing the calcium concentration. 
 
 
 
 
 
 
 
 
 
 
 Chapter 6 
 
160 
 
6.3.2 OPA assay (quantitative assay for TG2 deamidating activity) 
To validate the qualitative data shown in Figure 6-4 and Figure 6-5 there is a necessity to 
develop and optimise quantitative assay to quantify the deamidation by measuring the 
ammonia released during the interaction. 
a) Optimization of ammonium chloride as standard for deamidation 
To develop an assay for measureing TG2 deamidating activity, a fluorescent microplate 
ammonium assay (Poulin and Pelletier 2007) was optimised to quantify the release of 
ammonia catalysed by the deamidating activity of TG2. Previous work at NTU (Aldubyan 
2014) showed that this assay was very sensitive to ammonia in the micromolar 
concentration range.   
                         
0 .0 0 0 0 .0 0 5 0 .0 1 0 0 .0 1 5
0
1 0 0 0
2 0 0 0
3 0 0 0
A m m o n iu m  c h lo r id e  (m M )
R
e
l
a
t
i
v
e
 f
l
o
u
r
e
s
e
n
c
e
(
R
F
U
)
A
0 .0 0 0 .0 5 0 .1 0 0 .1 5
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
A m m o n iu m  c h lo r id e  (m M )
R
e
l
a
t
i
v
e
 f
l
o
u
r
e
s
e
n
c
e
(
R
F
U
)
B
0 .0 0 .5 1 .0 1 .5
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
A m m o n iu m  c h lo r id e  (m M )
R
e
l
a
t
i
v
e
 f
l
o
u
r
e
s
e
n
c
e
(
R
F
U
)
C
 
Figure 6-6: Optimization of ammonium chloride as standard for deamidation. 
 Ammonium chloride (0-1mM) was used as a standard to quantify the ammonia released in the deamidation 
assay. Different concentration of ammonium chloride A; 0-0.01mM, B; 0-0.1mM, C; 0-1mM, with OPA 
were applied to a fluorescence microplate and the interaction between ammonium ions and OPA resulted 
in a fluorescent adduct, which was measured at λex = 360 nm and λem = 430 nm using a Fluostar Optima 
96 well plate reader(Materials and methods chapter, section2.2.6b). 
The sensitivity range of the assay was determined, and the data displayed that the assay 
was sensitive to ammonium in concentrations between 0.0025 to 1mM (See Figure 6-6). 
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b) Deamidation assay for storage proteins (Vicia faba) (Quantitative assay) 
The fluorescence microplate assay was used to measure the release of ammonia from the 
seed storage proteins after treatment with gpl or hrTG2 (± Ca2+). Vicia faba storage 
proteins incubated with either human recombinant or guinea pig liver TG2 in the presence 
of 2mM CaCl2 showed a significant increase in the release of ammonia compared to other 
treatments (see Figure 6-7). 
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Figure 6-7: Deamidation of storage proteins using TG2. 
 Seed storage proteins (SSP) (10.0 mg ml-1) isolated from Vicia faba seeds were incubated with gpl TG2 
and hrTG2 (1 mg ml-1) in (+/-) of Ca2+ for 16 h at 37oC. The supernatant was assayed for ammonia by OPA 
assay. (Materials and methods chapter,section2.2.6b).The data point A = SSP, B = SSP+EDTA, C = SSP+ 
Ca2+, D = WATER+SSP+TG2, E = EDTA+ SSP + TG2, F = Ca2+ + SSP + TG2. The data points represent 
the mean ± S.E.M from 3 independent experiments (n=3, ****P-value < 0.0001). All the values are as 
compared to the control (Column A). The unit of the TG2 activity in different samples was defined as 
follow; 1 unit of activity is 1nanomole product formed per one hour (1nmol hr-1). 
The Figures show that the highest ammonia quantity was from the sample (F) that contain 
TG2 with calcium. 
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c) Deamidation assay for Vicia faba storage proteins by TG2 at different 
calcium concentrations 
 The release of ammonia from the seed storage proteins when treated with gpl or hr TG2 
in the presence of different calcium concentrations was measured by the fluorescence 
microplate assay as shown in Figure 6-8. 
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Figure 6-8: Effect of different concentrations of Ca2+ on Deamidation of storage proteins. 
 Seed storage proteins (SSP) (10.0 mg ml-1) isolated from Vicia faba seeds were incubated with gpl TG2 
(10.0µg/ml-1) and hrTG2 (5.0µg/ ml-1) in presence of increased concentrations of Cacl2for 16 h at 37oC. 
The supernatant was assayed for ammonia (Materials and Methods chapter, section 2.2.6b). The data points 
represent the mean ± S.E.M from 3 independent experiments (n=3, ****P-value < 0.0001). All the values 
are as compared to the control (column A). The unit of the TG2 activity in different samples was defined 
as follow; 1 unit of activity is 1nanomole product formed per one hour (1nmol hr-1). 
The Vicia faba storage proteins incubated with gpl or hr TG2 in the presence of different 
CaCl2 concentrations showed increased ammonia quantity with increasing concentrations 
of calcium (See Figure 6-8). 
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d) Deamidation assay of Vicia faba storage proteins in the presence of TG2, 
CaCl2, and variable cystamine concentrations. 
 Cystamine is known to be an inhibitor of TG2 (Jeitner et al., 2018), in order to observe 
how cystamine affected the deamidating activity of TG2, the seed storage proteins from 
Vicia faba were incubated with hrTG2 and CaCl2 with variable concentrations of 
cystamine. 
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Figure 6-9: Deamidation of storage proteins using hr and gpl TG2 in presence of different 
concentrations of Cystamine. 
 Seed storage proteins (SSP) (10.0 mg ml-1) isolated from Vicia faba seeds were incubated with hrTG2 
(5.0µg/ ml-1) or gplTG2  (10.0µg/ml-1) in presence of Cacl2 and cystamine as inhibitor with increasing 
concentrations, (0.025, 0.5 and 2.5mM) for 16 h at 37oC. The supernatant assayed for ammonia (see 
materials and methods chapter, section b)2.2.6b) . A = Ca2+ + SSP + TG2, B = cystamine 0.025mM, C = 
cystamine 0.5mM, D = cystamine 2.5mM. The data points represent the mean ± S.E.M from three 
independent experiments (n=three**P-value < 0.001, ****P-value < 0.0001). All the values are as 
compared to the control (Column A).  The unit of the TG2 activity in different samples was defined as 
follow; 1 unit of activity is 1nanomole product formed per one hour (1nmol hr-1). 
The Vicia faba storage proteins incubated with CaCl2 and TG2 in the presence of 
increasing cystamine concentrations showed a decrease in measurable ammonia released 
compared to the Ca2+ control. (See Figure 6-9). 
 
 
6.3.3 Gliadins  
Having established a method to quantify the ammonia released by TG2 from Vicia faba 
storage proteins, it was decided to change the substrate to gliadins peptides mixture, as it 
has a crucial role in the initiation of CD. 
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a) Deamidation assay for gliadin protein 
As the main aim of this research is measuring the deamidating activity of hrTG2 against 
gliadin peptides in relation to coeliac disease. The microplate deamidation assay 
developed for Vicia faba storage proteins was transferred to the assay of the deamidation 
of wheat (Triticum) gliadin peptides (Sigma). Because the deamidation of gluten peptides 
in gliadins by TG2 is crucial for the peptides to act as HLA-DQ-restricted T-cell antigens 
that are responsible for initiating the celiac disease (Garber et al., 2017).   
A fluorescence microplate assay was optimised to measure the release of ammonia from 
a crude preparation of wheat (Triticum) gliadin peptides when treated with hrTG2 (± 
Ca2+) (See Figure 6-10) 
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Figure 6-10: Deamidation assay for gliadin. 
 Gliadin (2.0 mg ml-1) incubated with 5.0 µg ml-1 hrTG2 in presence and absence of Cacl2 (2mM) for 10 
min at RT. A = gliadin+water+hrTG2, B + gliadin+EDTA+hrTG2, C = gliadin+Ca2+ +hrTG2.(Materials 
and methods chapter,section 2.2.6b). The data points represent the mean ± S.E.M from 3 independent 
experiments (n=3, ***P-value < 0.001). All the values are as compared to the control (column C). The unit 
of the TG2 activity in different samples was defined as follow; 1 unit of activity is 1nanomole product 
formed per one min (1nmol min-1).  
The treatment of wheat gliadin peptides with hrTG2 in presence of Ca2+ resulted in the 
significant release of ammonia (Figure 6-10). There was also release of ammonia from 
the gliadin peptides treated with water and EDTA. 
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b) Deamidation of crude gliadin protein by hr TG2 with increasing incubation 
times 
To optimise the appropriate time for measuring the ammonia released in the assay, the 
gliadin protein was incubated with an increasing time period (1.0- 60min) with hrTG2 
(See Figure 6-11). 
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Figure 6-11: Deamidation assay for gliadin peptide mixture in increasing time of incubation. 
 Gliadin (2.0 mg ml-1) incubated with 5 µg ml-1 hrTG2 in presence of Cacl2 (2mM) in increasing the time 
of incubation at RT.(Materials and methods chapter,section 2.2.6b).The data points represent the mean ± 
S.E.M from 3 independent experiments. The unit of the TG2 activity in different samples was defined as 
follow; 1 unit of activity is 1nanomole product formed per one min (1nmol min-1).  
The optimum incubation time for the hrTG2 with gliadin protein was found to be between 
2 to 10 min at RT. 
c) Comparison between the deamidation activity of hrTG2 and denatured 
hrTG2 using gliadin protein as substrate. 
In order to confirm the ammonia released in this assay was hrTG2 dependent, active 
hrTG2 and denatured (boiled) hrTG2were incubated with -gliadin in the presence of 
CaCl2 (See Figure 6-12).  
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Figure 6-12: Deamidation assay for gliadin protein in a different form of TG2. 
 Gliadin (2.0 mg ml-1) incubated with active hrTG2 5 µg ml-1 and denatured hrTG2 in +/- Cacl2 (2mM) for 
10 min at RT. (Materials and methods chapter,section 2.2.6b)The data points represent the mean ± S.E.M 
from three independent experiments (n=3, ****P-value < 0.0001). All the values are as compared to the 
control (black columns). The unit of the TG2 activity in different samples was defined as follow; 1 unit of 
activity is 1nanomole product formed per one min (1nmol min-1).  
The treatment of wheat (Triticum) gliadin protein with different forms of hrTG2 in 
presence of Ca2+ resulted in a significant difference in the release of ammonia between 
the active form denatured and no hrTG2 samples (See Figure 6-12). 
d) Deamidation activity with increasing human recombinant TG2 
concentrations using gliadin protein as substrate. 
A fluorescence microplate assay used to measure the release of ammonia from the wheat 
(Triticum) gliadin protein when treated with increasing concentrations of hrTG2 in the 
presence of calcium See Figure 6-13. 
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Figure 6-13: Deamidation assay for gliadin protein in increasing concentration of hrTG2. 
 Gliadin peptides (2.0 mg ml-1) incubated with different concentrations of hrTG2 (0.05 - 5000 ngml-1) in 
presence of Cacl2 (2mM) for 10 min at RT.A = 0, B = 0.05, C = 0.50, D = 5.0, E = 50, F =5000.0 ngml-1. 
The ammonia released was measured (seematerials and methods chapter, section 2.2.6b)ii). the data points 
represent the mean ± S.E.M from 3 independent experiments (n=3, ****P-value < 0.0001). All the values 
are as compared to the control (A). The unit of the TG2 activity in different samples was defined as follow; 
1 unit of activity is 1nanomole product formed per one min (1nmol min-1).   
The wheat (Triticum aestivum) gliadin protein incubated with increasing hrTG2 
concentrations in the presence of CaCl2 showing the increased release of ammonia with 
increasing concentrations of hrTG2. The result indicates that the TG2 dependent 
ammonia released can be measured using the ammonia detection microplate method.  
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e) Deamidation activity of hrTG2 with increasing calcium concentrations 
using gliadin protein (substrate) 
The fluorescence microplate assay used to measure the release of ammonia from gliadin 
protein when treated with hrTG2 in the presence of increasing calcium concentration as 
shown in Figure 6-14. 
 
A B C D E F G H
0
5
1 0
1 5
C a
+ 2
 c o n c [m M ]
U
N
IT
 O
F
E
N
Z
Y
M
E
 A
C
T
IV
IT
Y
**
*** ***
****
A = 0
B = 0 .2 5 m M
C = 0 .5 m M
D = 1 m M
E = 2 m M
F = 4 m M
G = 6m M
H = 8m M
 
Figure 6-14: Deamidation of Gliadin protein using different Concentration of CaCl2. 
 Gliadin (2.0 mg ml-1) incubated with 5µg ml-1 hrTG2 in presence of increased concentrations (0.25 – 6mM) 
of Cacl2 at RT. (Materials and methods chapter,section 2.2.6b).The data points represent the mean ± S.E.M 
from 3 independent experiments (n=3, ****P-value < 0.0001). All the values are as compared to the control 
(A). The unit of the TG2 activity in different samples was defined as follow; 1 unit of activity is 1nanomole 
product formed per one min (1nmol min-1).  
The gliadin protein incubated with hrTG2 in the presence of different CaCl2 
concentrations showed the increased release of ammonia with increasing concentrations 
of calcium. The highest concentrations of calcium that give highest quantity of ammonia 
were from 2-6mM. 
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f) Deamidation activity of hrTG2 with other proteins (Albumin and amylase) 
instead of using gliadin. 
To examine the TG2 specificity of the deamidation assay, albumin and α-amylase were 
used instead of hrTG2 (Figure 6-15),  
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Figure 6-15: Deamidation assay for hrTG2 in prescience of Albumin and α-amylase. 
 Gliadin protein (2.0 mg ml-1) incubated with 5 µg ml-1 hrTG2 compared with other samples containing 
albumin or α-amylase (5 µg ml-1). (materials and methods chapter, section 2.2.6b).The data points represent 
the mean ± S.E.M from 3 independent experiments (n=3, ****P-value < 0.0001). All the values are as 
compared to the control (Column A). The unit of the TG2 activity in different samples was defined as 
follow; 1 unit of activity is 1nanomole product formed per one min (1nmol min-1).   
The finding displays a significant reduction in ammonia released in albumin and α-
amylase containing samples (Figure 6 -15). 
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g) Effect of TG inhibitors on deamidation of gliadin protein by active hr TG2 
In order to compare the effect of known TG2 inhibitors on the deamidating activity of 
TG2, two selected TG2 inhibitors (cystamine and ZDON) were incubated with hrTG2 in 
the presence of CaCl2 (See Figure 6-16). 
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Figure 6-16: Deamidation assay for gliadin protein by active TG2 in the prescience of known TG 
inhibitors. 
 Gliadin protein (2.0 mg ml-1) incubated with 5 µg ml-1 thrTG2 in presence of different concentrations of 
cystamine and ZDON in 10 min at RT. A = gliadin+ water, B = gliadin+ TG2+Ca2+, C= cystamine 10.0mM, 
D= cystamine 1.0mM, E = cystamine 0.20mM, F = cystamine 0.02mM, G = ZDON1mM, G= ZDON 
0.1mM, h = ZDON 0.01mM. (materials and methods chapter,section 2.2.6b)The data points represent the 
mean ± S.E.M from 3 independent experiments (n=3, ****P-value < 0.0001). All the values are as 
compared to the control (Column B).  The unit of the TG2 activity in different samples was defined as 
follow; 1 unit of activity is 1nanomole product formed per one min (1nmol min-1).  
The gliadin protein (2.0mg ml-1) incubated with hrTG2 (5 µg ml-1) in presence of CaCl2 
(2mM) cystamine (0.02 – 10.0mM) and ZDON (0.01 -1.0mM), no significant inhibition 
of deamidation of gliadin protein observed, significant inhibition was at higher 
concentration 10mM. This result indicated that cystamine and ZDON at this level of 
concentrations were unable to inhibit the deamidating activity of hrTG2 using gliadin 
protein as substrates (See Figure 6-16). 
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h) Deamidation of gliadin protein using inactive hrTG2   
To compare the deamidation activity between active TG2 and modified active site 
(Cys277, Cysteine replaced by serine) (inactive TG2; Zedira, De), the modified active 
site TG2 was incubated with gliadin protein in the ±of CaCl2 (See Figure 6-17). 
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Figure 6-17: Deamidation assay for gliadin by inactive TG 2. 
 Gliadin (2.0 mg ml-1) incubated with 5 µg ml-1of inactive hrTG2 or active hrTG2 in presence of (± Ca2+) 
(2mM) for 10 min at RT. (materials and methods chapter,section 2.2.6b)The data points represent the mean 
± S.E.M from three independent experiments (n=three, **P-value < 0.005). All the values are as compared 
with each other. The unit of the TG2 activity in different samples was defined as follow; 1 unit of activity 
is 1nanomole product formed per one min (1nmol min-1).  
The treatment of wheat gliadin protein with the inactive form of hrTG2 in +/- Ca2+ 
resulted in the similar release of ammonia amount comparing to the active form of hrTG2 
(See Figure 6-17).  
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i) Effect of TG inhibitors on deamidation of gliadin protein by inactive hr 
TG2 
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Figure 6-18: Deamidation assay for gliadin by inactive TG2 in the prescience of known TG 
inhibitors. 
 Gliadin protein (2.0 mg ml-1) incubated with 0.5 µg ml-1 inactive hr TG 2 in presence of different 
concentrations of cystamine and ZDON in 10 min at RT. A = gliadin+ water, B = gliadin+ TG2+Ca2+, C= 
ZDON1mM, D= ZDON 0.1mM, E ZDON 0.01mM =, F = cystamine 1mM, G= cystamine 0.2mM, H = 
cystamine 0.01mM. (materials and methods chapter,section 2.2.6b)The data points represent the mean ± 
S.E.M from 3 independent experiments (n=3, ****P-value < 0.0001). All the values are as compared to the 
control (Column B).  The unit of the TG2 activity in different samples was defined as follow; 1 unit of 
activity is 1nanomole product formed per one min (1nmol min-1).  
The gliadin protein incubated with CaCl2 and inactiveTG2 in presence of cystamine (0.02 
– 1.0mM) and ZDON (0.01 – 1mM),both inhibitors were unable to show inhibition of 
deamidation at these concentrations. This result indicated that cystamine and ZDON at 
this level of concentrations were unable to inhibit the deamidating activity of inactive 
hrTG2 using gliadin protein as substrates (See Figure 6-18). 
To validate that ammonia released represents the deamidation of gliadin protein by TG2 
and to mimic the celiac disease condition, 33-mer gliadin peptide fragment identified as 
the gliadin fragment, which initiates CD, was applied to the assay. This peptide fragment 
is produced by normal gastrointestinal proteolysis, which becomes a potent T cell 
stimulator after deamidation by tissue transglutaminase (TG2). (Herrira et al., 2018) 
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6.3.4 Deamidation of 33 mer gliadin peptides by hrTg2: 
The fluorescence microplate assay used to measure the release of ammonia from the 33-
mer gliadin peptide when treated with hrTG2 in the presence of calcium and/or TG2 
inhibitors as shown in Figure 6-19. 
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Figure 6-19: deamidation assay for33-mer gliadin peptide using hr TG2. 
 33-mer gliadin peptide (1mM) incubated with 5 µg ml-t hrTG2 in presence of CaCl2 (2mM), EDTA(2mM), 
ZDON (1mM) and cystamine (2mM) in 10 min at RT.  1= 33-mer gliadin peptide + Ca2+ , 2 = 33-mer 
gliadin peptide + EDTA , 3 =  33-mer gliadin peptide +ZDON , 4 = 33-mer gliadin peptide +cystamine. 
(materials and methods chapter, section 2.2.6b). The data points represent the mean ± S.E.M from three 
independent experiments (n=three, ****P-value < 0.0001, **P-value < 0.01,). All the values are as 
compared to the control (Column 1). The unit of the TG2 activity in different samples was defined as 
follow; 1 unit of activity is 1nanomole product formed per one min (1nmol min-1).  
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a) Comparison between 33mer gliadin peptides and gliadin protein protein 
using active human recombinant TG2. 
The fluorescence microplate assay used to measure the release of ammonia from the 33-
mer gliadin peptide when treated with hrTG2 in the presence of calcium and compared 
with ammonia released from gliadin protein as shown in  
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Figure 6-20: comparison between 33-mer gliadin peptide and gliadin protein using hrTG2. 
Gliadin (2.0 mg ml-1) and 33-mer gliadin peptide (1mM) incubated with 5 µg ml-1 hrTG2 in presence of 
CaCl2 (2mM), EDTA (2mM), ZDON (1mM) and cystamine (2mM) in 10 min at RT. (materials and 
methods chapter,section 2.2.6b)A: gliadin mixture peptides+Ca2+ +hrTG2. B: gliadin mixture 
peptides+EDTA +hrTG2. C: gliadin mixture peptides+Z-don +hrTG2. D: gliadin mixture 
peptides+cystamine +hrTG2. A*: 33-mer gliadin peptides+Ca2+ +hrTG2. B*: 33-mer gliadin 
peptides+EDTA +hrTG2. C*:33-mer gliadin peptides+Z-DON +hrTG2. D*:33-mer gliadin 
peptides+Cystamine+hrTG2. The data points represent the mean ± S.E.M from three independent 
experiments (n=three, ****P-value < 0.0001, **P-value < 0.01,). All the values are as compared to the 
control (Column A and A*).). The unit of the TG2 activity in different samples was defined as follow; 1 
unit of activity is 1nanomole product formed per one min (1nmol min-1).  
The 33-mer gliadin peptide incubated with hrTG2 in +/- Ca2+ and known TG inhibitors 
(cystamine and ZDON) then compared with same treatments using gliadin protein. No 
difference for ammonia released between gliadin protein and 33-mer peptides, the 
difference was in effect of the cystamine on the ammonia quantity. An unexpected finding 
was that cystamine inhibited the ammonia released by hrTG2 when the 33-mer gliadin 
peptide was used in the assay, (Figure 6-20) 
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b) Comparison between 33mer gliadin peptide and gliadin protein using 
inactive hr TG2. 
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Figure 6-21: comparison between 33-mer gliadin peptide and gliadin proteins using inactive human 
recombinant TG2. 
Gliadin (2.0 mg ml-1) and 33-mer gliadin peptide (1mM) incubated with 5 µg ml-1 inactive hrTG2 in 
presence of CaCl2 (2mM), EDTA (2mM), ZDON (1mM) and cystamine (2mM) in 10 min at RT. (Materials 
and methods,section 2.2.6b). The data points represent the mean ± S.E.M from three independent 
experiments (n=three, ****P-value < 0.0001) All the values are as compared to the control using graph 
pad7. 
The 33-mer gliadin peptide incubated with an inactive form of hrTG2 in +/- Ca2+ and 
known TG inhibitors then compared with same treatments using gliadin protein. The data 
shows there is a significant difference between gliadin protein and 33-mer gliadin peptide 
in releasing of ammonia and effect of ZDON and cystamine. 
6.3.5 Deamidated Peptide Sequencing by Mass Spectrometry: 
In order to validate the data of fluorescence assay, samples were prepared to run by a 
mass spectrometry technique to detect the deamidation of gliadin peptides. The samples 
containing 33- mer peptides with either EDTA or Calcium ions were incubated with 
active hr TG2, then applied to mass spectrometry.  
The mass spectrum data did not show a significant difference in deamidation level 
between all the samples comparing with undeamidated peptides (control)(Summary of 
Data are presented in appendices chapter). 
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6.4 Discussion: 
Deamidation of gliadin by TG2 is critical for the initiation of the immune response by 
allowing binding of gliadin peptides to two variants of type II human leukocyte antigen 
(HLA) called HLA-DQ2 and DQ8, which in turn induce the inflammation and villous 
atrophy (coeliac disease). To measure the deamidation activity of TG2, there is a necessity 
to establish a simple assay for the quantification of the TG2 deamidation activity, which 
could be used in studying of proposed TG2 inhibitor as a potential intervention on the 
CD. 
The seed`s storage proteins of leguminous plants (legumin and vicilin) undergo 
deamidation prior to processing by proteolytic enzymes ultimately aiding the 
development of the emerging plant (Müntz 1996). The deamidation of the legume storage 
proteins in the seeds will provide vital nitrogen for the emerging plant's protein synthesis 
before the peptidase enzymes degrade the storage proteins. The deamidation of the 
storage proteins after the onset of germination can be viewed using non-denaturing PAGE 
(See Figure 6-3). They have become more electronegative due to deamidation in the 
protein bodies within the cells of the cotyledons by a deamidating enzyme (plant 
transglutaminase?) as germination proceeds. The storage proteins could be developed into 
a useful tool to measure the calcium-dependent deamidating activity of gpl and hrTG2, 
the enzyme that important to the initiation of CD (Mehta and Eckert 2005, Sollid and 
Jabri 2011).  
Previous work at NTU (Aldubayan 2014) presents a preliminary attempt to optimise the 
Vicia faba storage proteins for a TG2 deamidation assay. That study reported the highest 
natural deamidation rate was between 7th to 14th days of seed germination in Vicia faba 
globulins (See Figure 6-3). Furthermore, by using non-denaturing PAGE reported the 
increased electronegativity as result of incubation of Vicia faba storage proteins with 
gplTG2 in presence of 2mM CaCl2, this increase was calcium-dependent compared to 
samples incubated with EDTA and the blank, those findings were tentatively validated 
using microplate OPA assay to measure ammonia. However, to date, no effective assay 
has been produced to quantify the deamidation activity of hrTG2 or the release of 
ammonia from the target proteins/peptides.  As mentioned previously, the deamidation of 
gluten peptides by TG2 is crucial for the peptides to act as HLA-DQ-restricted T-cell 
antigens in coeliac disease (CD) (Stamnaes and Sollid 2015). Therefore, in this research, 
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the aim was to optimise an assay for quantification of the ammonia released from seed 
storage proteins, a mixture of gliadin peptides and a 33mer peptide (deamidation) by 
modifying a previously published assay (Poulin et al., 2007).   
In order to mimic the environment of coeliac disease, human recombinant TG2 was used 
to visualise TG2 deamidation activity using Vicia faba storage proteins. The increased 
electronegativity of the Vicia faba storage proteins observed in non-denaturing PAGE, by 
incubation with hrTG2 in presence of calcium ions, means an increase in the protein’s 
electronegativity and migration towards the anode comparing with samples incubated 
with EDTA or control (See Figure 6-4). To examine the effect of increasing calcium 
concentration, the Vicia faba storage proteins were incubated with hrTG2 in the presence 
of different CaCl2 concentrations, the finding show increased electronegativity dependent 
on the concentration of calcium (See Figure 6-5) (Tian, et al., 2014; De Re, Magris and 
Cannizzaro 2017). These results confirm deamidation of amide nitrogen from the Vicia 
faba storage proteins by hrTG2 is a calcium-dependent deamidation (See Figure 6-5). 
Moreover, these results support a previous NTU study (Aldubayan 2014) which used 
gplTG2 while the current study hrTG2 was used.  
As mentioned before, the aim was to quantify the deamidation activity of TG2. Therefore, 
there was a necessity to translate the qualitative deamidation assay of Vicia faba proteins 
(non-denaturing PAGE assay) into a quantitative assay. By using an OPA reagent, the 
flouremetric microplate assay was optimized. The assay is based on the reaction of OPA 
with NH4
+ released in the Vicia faba storage protein by the enzyme action of TG2, 
resulting in a florescence signal. The intensity of the signal would be proportional to the 
amount of ammonia in solution and consequently level of deamidation induced by TG2 
in the presence of calcium ions (see introduction section). Through developing this 
microplate deamidation assay, many problems encountered, due to the high background 
of the assay, which could be resulting from the reaction of OPA with amines that occur 
in a number of ambient environments such as air, water, hair and foods (Del castello 
1990). To help in resolve these problems distilled water from different sources were used 
in preparation of the assay reagents, to reduce the source of background signal (data not 
presented), ultrapure water was used throughout in the preparation of all reagents to give 
consistent results. Another source of the variations in the results was using plastic 
microfuge tubes in the assay. These tubes were not gas sealed enough to prevent of the 
released ammonia from leaking at 37oC. To solve this problem, glass sealed vials 
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(chromocol) were used with crimp sealed gas-tight lids, which proved to provide 
consistent results. In this study, different buffers were used such as HEPES, Tricine and 
Tris all of them at two concentration 100 and 50 mM, and pH 8.3. They produced 
inconsistent results (Data not presented). Finally, lowering the Tris/HCl buffer 
concentration to 10mM (pH 8.3) produced consistent results required for a robust assay. 
This buffer concentration was low enough not to interfere in the development of the OPA 
ammonium assay. The data in Figure 6-6 shows that a microplate assay can be used to 
quantify the ammonia in the concentration range from 0.0025 to 1mM. This data supports 
the previous study that mentioned the OPA reagent exhibits greater sensitivity to amines 
rendering it suitable for measurement of picomole to-nano mole range of ammonia and 
amino acids in a sample (Peterson 1983).  
Using Vicia faba storage proteins as substrates for gplTG2 or hrTG2, the release of 
ammonia was measured after overnight incubation at 37oC (See Figure 6-7).  The results 
indicate that there is a high quantity of ammonia released in samples with CaCl2 
(8.28nmol/hr ±0.68), comparing to other samples which suggest that the ammonia 
released is Ca2+ dependent. However, results indicate that there is ammonia released in 
EDTA (3.3nmol/hr ± 0.45) and blank samples by either gpl or hrTG2; it is a small but a 
detectable change. The possible reasons for detected ammonia (deamidation) in EDTA 
and blank samples are the exogenous calcium was not completely removed by EDTA or 
perhaps by nonenzymic deamidation (Raki, et al. 2007).   In order to examine whether 
the ammonia released from the storage proteins was calcium-dependent or not. Different 
concentrations of CaCl2 were used in the assay for both gpl and hr TG2 samples (See 
Figure 6-8 a and b), the finding shows the ammonia releasing (deamidation) was 
enhanced by increasing calcium ions concentration 0.025 to 10 mM Ca2+. The 
deamidation of the seed storage proteins was reduced in the presence of known 
transglutaminase 2 inhibitors e.g. cystamine (See Figure 6-9), cystamine inhibition was 
dose-dependent, showing the highest inhibition at 2.5mM. The deamidation assay 
indicates that deamidation of seed storage proteins of Vicia faba was dependent on the 
presence of TG2 and Ca2+ ions. As the main aim of this research is, develop assay to 
measure the deamidating activity of hrTG2 against gliadin peptides because of its 
relevance to celiac disease. The microplate deamidation assay developed for Vicia faba 
storage proteins was transferred to the measurement of the deamidation of wheat gliadin 
peptides.  
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The ingestion of gluten is the critical factor in the initiation of celiac disease (Siegel and 
Khosla 2007). Gluten found in cereals such as wheat, barley, and rye, it consists largely 
of monomeric and polymeric proteins called gliadins and glutenins. They have a complex 
composition, rich in proline (15%), glutamine (35%) and hydrophobic amino acids (19%) 
collectively known as prolamins (Barro, et al. 2016). The gliadin protein (2.0mgml-1) was 
incubated with 5.0 µgml-1 of hr TG2 for 10 min in presence of 2mM of Ca2+ ammonia 
released was recorded, 10.74 nmol min-1 (±0.45). This finding is in line with the amount 
of ammonia measured in study by Berti et al., (2007) after microbial TGase treatment of 
gliadins. By comparing the amount of ammonia in sample contains calcium ions with 
samples containing EDTA or blank, Figure 6-10 shows there was a significant increase 
in ammonia measured in samples containing hrTG2 and Ca+2 ions. Although, detectable 
ammonia was also measured in absence of Ca2+ suggesting that the deamidation of gliadin 
protein was enhanced but not dependent on presence of calcium ions (see Figure 6-10).  
The amount of ammonia released using gliadin protein was observed at different 
incubation times. The data (See Figure 6-11) shows that ammonia released peaked and 
was constant after 2.0min. This result is in agreement with the previous NTU work by 
Aldubyan 2014, which mentioned that deamidation and release of ammonia from gliadin 
peptides proceeded at a faster rate than the deamidation of Vicia faba storage proteins 
(Aldubyan 2014).  
To confirm, an enzyme-dependent activity, instead of using active hrTG2, boiled hr TG2 
was applied to the assay. The findings show a significant decrease (>50%) in the ammonia 
released in both boiled and non-hrTG2 samples, this finding confirm that the ammonia 
released from incubation of hrTG2 with gliadin protein was catalysed by a biologically 
active hrTG2 (See Figure 6-12). In addition, the data in Figure 6-13 show a significant 
increase in the ammonia released (deamidation) by increasing the concentration of hr 
TG2,however, there is detectable ammonia in absence of TG2, this might be due to 
spontaneous deamidation of protein which could occur at all pH values. This modification 
may be able to arise spontaneously in ‘ageing’ proteins (Anderton 2004).  
The amount of TG2 that give highest ammonia quantity ranged from 0.25-50 ng. 
Additionally, the results in Figure 6-14 indicated that the ammonia released (deamidation) 
after incubation of gliadin mixture peptides with hr TG2 was enhanced by increasing 
calcium ions comparing with no Ca2+. In order to examine the specificity of this 
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deamidation to TG2, albumin and α-amylase proteins were used instead of gliadin 
peptides in the assay. These findings display that the ammonia released was reduced to 
about 50% when other proteins used in the assay (see Figure 6-15), this suggest that 
ammonia released was specific to hrTG2.   
To observe the effect of the TG2 inhibitors on the deamidation activity of TG2, two 
commercially available TG inhibitors, were used cystamine and Z-DON, in this assay. 
Cystamine is a nonspecific reversible non-competitive TG inhibitor which can reversibly 
inhibit TG by binding to the catalytic site, (Keillor et al., 2015; Szondy et al., 2017; Jeitner 
et al., 2018). It exerts the TG2 inhibitory action by the formation of disulphide mixture 
with the active site cys277 that leads to preventing TG2 catalytic activity (Jefiner, 2018). 
It is considered as a nonspecific TG2 inhibitor because it will form disulphide mixtures 
wth surface as well as active site sulphydryl groups on proteins, but is still used by 
biologists (As of early 2018 there have been more than 200 publications citing this 
compound as a TG2 inhibitor) (Palanski and Khosla 2018). Z-DON has been designed to 
irreversibly inhibit glutamine-dependent amidotransferases (Hausch et al., 2003). It 
targets the active site cys277 residue of the TG2 (IC50 of >1M). It has been designed to 
react covalently with the highly nucleophilic sulphur atom from the catalytic site cys 
residue in TG2, leading to completely inactivation of the enzyme (Badarau et al., 2013). 
These inhibitors were unable to prevent the release of ammonia from gliadin mixture 
peptides in the presence of (250 ng) of hrTG2, cystamine (0.02 – 10.0mM) and ZDON 
(0.01 - 1.0mM). Cystamine was found to have an inhibitory effect at high concentrations 
>10mM (See Figure 6-16). Based on this data the active site Cys277 might be not involved 
in all the deamidation of the gliadin mixture peptides. This motivated the study to expand 
this experiment to use inactive human recombinant TG2 (Cys277, cysteine replaced by 
serine) instead of active TG2. This form of TG2 (250ng) was incubated with gliadin 
protein 2.0 mg ml-1.  
A striking observation was that the release of ammonia was similar when using active 
hrTG2. The high value (10.34±0.78nmol min-1 ) compared to the control sample with no 
hrTG2 (4.13±0.19nmol min-1(see Figure 6-17) suggesting that either the cysteine 277 at 
the active site of hrTG2 is not exclusively involved in the deamidation reaction of TG2 
or that the assay is in some way compromised. Although, this finding disagrees with 
Staminas et al., (2010), which hypothesized that TG2 mutants impede the calcium 
triggered conformational change that is required for deamidation activity (Stamnaes, et 
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al. 2010). However, it is consistent with previous finding, (See Figure 6-10) shows that 
the ammonia releasing (deamidation) of gliadin protein by TG2 is calcium enhanced not 
dependent. Cystamine and ZDON as TG2 inhibitors applied to examine their effect on 
ammonia released from inactive TG2. The data in Figure 6-18 shows no significant 
inhibitory action at the concentrations used cystamine (0.02 – 1.0mM) and ZDON (0.01 
– 1mM). To help in clarifying these finding, there was a necessity to use the 33-mer 
gliadin peptide that is deamidated in initiation CD with this form of TG2 (see 
section1.8.4).  
There could be some discussion about these findings, particularly when ammonia also 
released after incubation of gliadin proteins with TG2 may not be from deamidation only, 
but could be produced by transamidation (see section 1.5.3). Because the gliadin peptide 
mixture contains both lysine and glutamine in the peptide mixture it could be argued that 
the ammonia released was derived from transamidation as well as deamidation. The 
general acceptance in the literature is that deamidation has been shown to occur parallel 
to transamidation proceeding via the same catalytic pathway. The ratio of transamidation 
versus deamidation is high in the presence of amine (Fleckenstein, B. et al 2002).  It has 
been assumed that the transamidation assays of biotin cadaverine incorporation 
(Slaughter et al., (1992) and peptide incorporation (Trigwell et al., 2004) fairly reflect the 
deamidation activity of TG2. They both proceed via the same catalytic mechanism but it 
should be remembered that there will be little or no deamidation in the presence of an 
amine. It is difficult to rule the possibility that deamidation is different to transamidation 
without an assay to measure the two activities. Moreover, deamidation by TG2 could be 
a substrate-dependent (Stamnaes 2008).  
To validate that the ammonia released does represent the deamidation of gliadin protein 
by hrTG2 and to mimic the celiac disease condition, 100µM of 33-mer gliadin peptide 
fragment were incubated with two different forms of transglutaminase 2, the active and 
inactive forms. A peptide fragment of (α2-gliadin56–88) 33mer   
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF), produced by normal 
gastrointestinal proteolysis, becomes a potent T cell stimulator after deamidation by tissue 
transglutaminase (TG2) (Schalk et al 2017). This fragment contains high proline content 
(13 of 33 residues are proline), which is responsible for its high resistance to breakdown 
by intestinal brush-border and luminal proteases enzymes (Qiao et al., 2004). Crucially 
this peptide does not contain any lysine and as such, there can be no transamidation.  The 
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only amine residue is on the first amino acid in peptides structure and this represents an 
alpha-amino not an epsilon amino present in the lysine side chain. TG2 uses the epsilon 
amino on the side chain of lysine for the transamidating reaction. The data in Figure 6-19 
and Figure 6-20 show there is no significant difference between the quantity of ammonia 
released between gliadin peptide mixtures and 33-mer peptides after incubation with 
active hrTG2. These findings suggest that the ammonia released in the assay is due to the 
deamidation catalytic action of hrTG2. By applying inhibitors (cystamine and ZDON) to 
the assay, cystamine displays a significant inhibition on the ammonia released from 33-
mer gliadin, whereas there is no clear inhibition with gliadin protein (Only at high 
concentration).  On the other hand, ZDON treatment samples did not show any inhibition 
on both gliadin protein and 33-mer peptides (Figure 6-20).  
By incubation, the inactive form of TG2 with the 33-mer peptide, finding display that 
there is a significant reduction in releasing of ammonia comparing to gliadin peptide 
mixture sample (See Figure 6-8). This result suggests that ammonia released when the 
inactive TG2 incubated with gliadin peptide mixture is due to other peptides other than 
33-mer gliadin peptide. Moreover, neither cystamine nor ZDON gives any inhibition. The 
data presented in this study agrees with the previous research saying that this sequence 
specificity of TG2 clarified the variation between peptides as TG2 substrates 
(Fleckenstein et al., 2002). In order to confirm the data of fluorescence assay, samples 
were prepared to run by mass spectrometry technique to detect the deamidation of gliadin 
peptides. The samples containing 33- mer peptides with either EDTA or calcium were 
incubated with active hr TG2, and undeamidated peptides as control were applied to mass 
spectrometry. The non and deamidated peptides eluted at the same point on the reversed-
phase gradient and the mass difference of 1Da between deamidated and undeamidated 
peptides, making it difficult for MS to recognise the deamidated peptide. Further 
experiments are needed for purification and identification of deamidated through specific 
chromatographic method before applying to high sensitive mass spectrometer.  
6.5 Summary of key findings 
• Modified ammonia assay developed to quantify the ammonia released in 
deamidation activity for hrTG2 
• Deamidation of storage proteins by hrTG2 was calcium-dependent and was 
verified by the OPA assay. 
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• Deamidation of gliadin protein by hr TG2 was enhanced by calcium, but there is 
detectable ammonia released in the EDTA and control samples. 
• Cystamine and ZDON did not inhibit the ammonia released from incubation of 
gliadin protein with hrTG2. 
• Inactive TG2 (Cys277, cysteine replaced by serin shows deamidating activity using 
the crude gliadins peptides mixture. The release of ammonia was, similar to that 
produced by active hrTG2, this finding suggests that deamidation might occur in 
another part of the hrTG2 molecule other than the active site. 
• To confirm that ammonia released was because of deamidation not transamidation 
the33-mer gliadin peptide that initiates CD was used. This peptide does not 
contain lysine excluding the possibility of a transamidation reaction. This peptide 
fragment produced quantifiable ammonia when incubated with active hrTG2. This 
activity was inhibited by cystamine. This finding shows that hrTG2 has a 
quantifiable deamidating activity toward the 33mer gliadin peptide sequence and 
other gliadin peptide sequences 
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Chapter 7 : General discussion and future work: 
7.1 Discussion and Future work 
Tissue transglutaminase (TG2) is a universally expressed enzyme of the mammalian 
transglutaminase (TG) family that catalyses the formation of an intra- or inter-molecular 
isopeptide bond between glutamine and a lysine side chains, leading to the post-
translational modification of proteins.  The isodipeptide bonds formed between cross-
linked proteins are peptidase resistant (Kanshan et al., 2015). In addition to protein-
protein cross-linking, TG2 mediates the incorporation of primary amines into proteins 
and, in the absence of amine nucleophiles, water acts as the nucleophile resulting in the 
deamidation of protein/peptide glutamine residues to glutamate (Figure 1-1; Kárpáti et 
al., 2018). The biological functions of TG2 include tissue repair, inflammation, and the 
development of some cancer, fibrosis and coeliac disease (Kobayashi et al., 1998; 
Bergamini et al., 1999 and Verederio et al., 2005). Transglutaminase 2 upregulation has 
been involved in many different diseases processes. For example, neurodegenerative 
disorders such as Huntington’s and Parkinson’s diseases (Hoffner and Djian, 2005), 
different cancers such as breast, ovarian and pancreatic (Mangala and Mehta, 2005). The 
deamidating action of TG2 is involved in the development of age-related cataract and in 
the initiation of the coeliac disease (see chapter 1). In coeliac disease, dietary gluten in 
wheat, rye, and barley leads to an abnormal immune response in genetically liable 
individuals carrying the human leukocyte antigen (HLA)-DQ2 or -DQ8 
haplotypes(Hietikko, et al. 2018). Coeliac disease, characterized by small-bowel mucosal 
damage, which develops gradually from normal villous morphology to inflammation, and 
finally to villous atrophy (Lebwohl, Sanders and Green 2018).  
The adaptive immune reaction occurs in coeliac disease individuals is dependent on 
deamidation of undigested gliadin (33mer) peptide found in the intestinal lamina propra 
by the TG2 (Dahlbom, et al., 2005; Lionetti and Catassi, 2011; Cebolla et al., 2018). 
Deamidation magnifies the immunogenicity of the 33mer  gliadin peptide, facilitating 
binding to the HLA-DQ2 or HLA-DQ8 molecules on antigen-presenting cells, the only 
currently available treatment, is removal of gluten from the diet. Although, in recent years 
the high quality of gluten-free products has improved; however, the adherence to these 
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products depends on different individuals and environmental factors (Hall et al., 2013), 
such as, not easily available in for all suffers or it is expensive (Kelly et al., 2015).  
The critical role of TG2 in CD makes inhibition of TG2 activity a potential therapeutic 
target. A number of TG2 inhibitors have been developed, including reversible inhibitors 
such as cinnamoyl compounds, thienopyrimidines, and acylidineoxindoles and 
irreversible inhibitors such as thiadiazoles, epoxides, and dihydroisoxazoles (Plugis and 
Khosla 2015). However, as TG2 is present in all cells, chemical inhibitors of the enzyme 
may have an unfavorable effect on cellular processes other than CD. Natural substances 
such as garlic and milk present less of a toxicity problem, as many people without adverse 
side effects ingest them.  Milk and garlic have been shown to contain TG2-mediated 
transamidation inhibitors, (Williams et al., 2005; Lee et al., 2007;Aldobyan,2014).  
Flavonoids, a group of natural substances with changeable phenolic structures, are found 
in vegetables, fruits, roots, stems, grains, flowers, and tea. These natural products possess 
beneficial effects on health such as anti-oxidative, anti-mutagenic, anti-inflammatory and 
anti-carcinogenic effects. In addition, their ability to modulate key cellular enzyme 
function (Heller and Forkmann 2017)(See Chapter 3). Some studies have shown that 
flavonoids could have an impact on the role of TG2 in some diseases. These effects 
include the influence of flavonoids extracts on the role of TG2 in the wound healing 
process, the role of dietary quercetin in the reduction of reproductive capacity in female 
mice, and the proposed role of TG2 in the regulation of the ovarian aging process. 
(Beazley and Nurminskaya 2016, Malla, et al. 2016). From the literature, there are no 
studies describing the effects of flavonoids on transamidating or deamidating TG2 
activities. As mentioned in publication, more than 80% of drug substances were directly 
from natural products or were the molecules derived from natural sources. Therefore, the 
main aim of this study was to screen the effect of dietary flavonoids on the amine 
incorporating and protein cross-linking activity of TG2 as well as the deamidating activity 
(see chapter 3) as a potential method to moderate the initiation of coeliac disease (CD). 
In addition, trying to optimise a simple assay for measurement the TG2 deamidation 
activity that would be essential for testing the effect of biological active compound on the 
TG2 activity as potential treatment of coeliac disease.  
Thirteen pure flavonoids were used in this study, including; quercetin, kaempferol, morin, 
myricetin, apigenin, luteolin, hesperetin, hesperidin, naringin, cyanidin, catechin, 
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epicatechin and taxifolin. Three flavonoids (kaempferol, morin and quercetin) in either 
sodium deoxycholate or DMSO, demonstrated inhibitory behaviour against hrTG2 and to 
a lesser extent on gplTG2 transamidating amine incorporation activity, at 125µM, 
(Figure3-13 and Figure 3-14). Those three flavonoids have a similar chemical structure 
(Figure2-3). The major structural difference between flavonoids was in the position of 
hydroxyl groups.  In general the B-ring hydroxyl configuration is the most significant 
determinant of the biological effects of the flavonoids (Burda and Oleszek, 2001 and 
Pannala et al., 2001). Therefore, it was hypothesised that the position of the hydroxyl 
group within the flavonoids was related to the affinity of binding between flavonoids and 
transglutaminase. In the presence of calcium, TG2 exposes hydrophobic pockets (Pinkas, 
et al. 2007). This suggests that the interaction between the flavonol and Tg2 may rely on 
the presence of calcium ions. If the presence of the flavonol disturbs the binding of 
calcium to TG2 it may prevent the enzyme from completely opening up, this, in turn, 
could alter the substrate from binding to the active site cys377. The major exception to 
TG2 enzyme inhibition was that there was less inhibitory effect on amine incorporation 
activity of gplTG2 suggesting that although the two enzymes have similar properties and 
homology that there must be subtle differences between the two enzymes in terms of their 
interaction with these natural products, perhaps around the calcium-binding sites or 
hydrophobic pocket.  
The effect of flavonoids on the TG2 protein cross-linking activity in vitro was assessed 
according to the method of Trigwell et al (2004), the 13 flavonoids (see above) dissolved 
in DMSO and sodium deoxycholate were applied to the assay using gpl and hrTG2.  Most 
of flavonoids display – (particularly that dissolved in DMSO) - a significant level 
inhibition (p<0.05) for the hrTG2 protein cross-linking activity at concentration 1.25, 
12.5 125µM. The hrTG2 was more sensitive to the effect of flavonoids than gpl TG2. The 
finding of the cross-linking assay was in agreement with studies that reported intensive 
inhibition effect of flavonoids on cross-linking of proteins (Wu and Yen 2005, Urios, 
Grigorova-Borsos and Sternberg 2007). In addition, to the flavonoids binding to the 
enzyme or substrate it is also known that they bind divalent metal ions including Ca2+, 
which play a role in the activity of TG2 (Urios et al., 2007).   
 In an attempt to understand the mechanism of the inhibition of TG2 by the flavonoids 
kinetic analysis was performed. The Michaelis-Menten kinetic constant (Km) and Vmax 
were graphically determined to measure the kinetic properties of the flavonol on TG2. 
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The data showed  variation in the mechanism of inhibition among the flavonoids used. In 
the inhibition of amine incorporation activity of hrTG2 (Table3-1,Table 3-2 and Figure3-
12, Figure 3-22), the data displayed the competitive inhibition mechanism with the biotin 
amine substrate by kaempferol and quercetin. (The Km value of the biotin substrate with 
hrTG2 was increased the presence of the flavonoids) (Boyer, 2011). Whereas, morin 
exhibited uncompetitive inhibition of hrTG2 transamidating activity with the biotin 
cadaverine substrate. In contrast the inhibition of the cross-linking activity (See Table 
3-3,Table 3-4 and,Figure 3-27 and Figure 3-17) of kaempferol, morin, and quercetin was 
uncompetitive inhibiton.The differences between that mechanism is in the competitive 
mechanism, the inhibitor may link to the free enzyme (Amine et al., 2016), the inhibition 
here refers to binding of inhibitor at or near to the active site on the enzyme, While, the 
uncompetitive inhibitors specifically targets the enzyme-substrate (ES) complex without 
competing with the substrate for binding (Palmer and Bonner,2007; Dougall and Unitt 
2015). These findings describe the situation of the inhibition of the TG2 enzyme by 
flavonoids using this substrate. Although, there are no published reports about the effect 
of flavonoids on activity of TG2 or their mechanism, whoever, Many studies have 
confirmed that the flavonoid inhibition effect is related to their structures, and the nature 
of the enzyme and substrates, as from the data, the difference in the mechanism of 
inhibition is might be related to that factors. (Xie et al., 2003; Phan et al., 2013, Ribeiro, 
Daniela et al., 2014).  
 It was decided to study the effect of the combinations of flavonoids on hrTG2 and 
gplTG2 transamidation and cross–linking activity to possibly mimic the mixtures that 
could be present in food. The data in Figure 3-10,Figure 3-11,Figure 3-15and Figure 3-16 
display that the combination of three flavonoids have a higher inhibitory action on the 
amine incorporation activity ofTG2 than when they are presented individually. Another 
curious finding is that the combination of flavonoids has significant inhibitory action at a 
lower concentration (12.5µM). For gpl activity, even mixtures of the three flavonoids 
improve the action of individual flavonoids effect on amine incorporation activity of 
gplTG2. In contrast, Kaempferol, morin, and quercetin were mixed, and applied in cross-
linking activity assay, according to the method of Trigwell et al (2004). Data in Figure 3 
20, Figure 3 21, Figure 3 25 and Figure 3 26 show no synergism effects between three 
flavonoids, individually the inhibitory effect was more pronounced than in a mixture.This 
finding agrees with the literature, which reports that the individual antioxidants do not 
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appear to have consistent preventive effects with the mixture of food contain antioxidant 
(Liu, 2003). 
As the deamidating activity of TG2 is crucial in initiation of CD and because one of the 
main aims of this research was optimising a simple assay for measurement the 
deamidating activity of TG2 (See Chapter 6). The pure flavonoids were applied in the 
OPA assay to measure their effect on the deamidating activity of hrTG2). The data in 
Figure 3-28shows that none of the tested flavonoids have a significant reduction in 
amount of ammonia released when a mixture of gliadin peptides was used as the substrate. 
The ammonia released with kaempferol, morin and quercetin at 125µM were 
consequently (9.7nmol min-1 ± 0.47; 9.2nmol min-1 ± 0.46; 9.8nomol min-1 ± 0.44) this 
means that these flavonoids inhibit ̴ 20% of ammonia released compared to the control. 
It is worth mentioning, that kaempferol, morin, and quercetin are also active against 
amine incorporation activity of TG2 (Figure3-13) 
This finding suggests that those flavonoids are active against TG2 activity in general, so 
the food containing morin and quercetin such as kale and strawberry could help the CD 
patient and offer new trend in helping the CD sufferer.  
The biological activity of the dietary flavonoids motivated this research to screen 
flavonoid-rich foods and examine their effects against TG2 activity as a potential 
treatment for coeliac disease. As it's known, the analyses of flavonoids in plants, medicine, 
and food products are more complicated. Therefore, the novel method for purification of 
flavonoids from food extracts was suggested, which is Immobilized Metal Ion Affinity 
Chromatography (IMAC) (Cheung et al., 2012). The yield and purity of this method then 
compared with a more conventional Solid Phase Extraction (SPE) method (Liu, Houme 
et al., 2016). For the quantification of extracted flavonoids, the bicinchoninic acid (BCA) 
assay (Smith et al., 1985) was used to compare the quantity yielded between two methods 
(IMAC and SPE). The BCA assay relies on the Biuret reaction of the peptide bond 
reducing Cu2+ to Cu+, which then chelated by BCA to produce a purple colour. Other 
compounds with a reducing centre can be quantified using BCA e.g. reducing sugars 
(Anthon and Barrett 2002).With this reason that flavonoids were quantified using BCA 
reagent because they also possess the ability to reduce divalent metal (Ivanov et al., 
2001and Wei and Guo, 2014). 
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 Data in Table4-1 and Table 4-2 show that the amount of flavonoids varied between 0.20 
to 1.12mg 100-1g DW. Whereas, the amount in SPE fractions were arranged from 0.16 to 
0.26 mg/100-1gDW. The comparison between the fractions from two purification methods 
in term of purity was determined by RP-HPLC. The chromatograms for food IMAC 
fractions have produced a clearer chromatogram as judged by a reduction in background 
peaks (Figure 4-2). Although there are no significant differences between quantities 
obtained from both methods, the HPLC chromatograms confirm that the IMAC fractions 
contain fewer contamination peaks, which are observed in SPE chromatograms (Figure 
4-2). These findings confirm that SPE extracted all the organic components with the 
ability to bind to a C18 , whereas IMAC extracts the components that have at least two 
hydroxyl groups close together on an organic structure particularly those on the 
flavonoids. This finding confirms that IMAC method provides a more selective and 
appropriate technique to purify flavonoids in those food samples. Additionally, IMAC 
fractions were subjected to LC/MS/MS in to confirm that fractions contain flavonoids; 
the data (Figure 4-3) were reported that all food fraction contains flavonoids, although, 
they differ in type of flavonoid available in each fraction.  
In addition to pure flavonoids, flavonoid extracts were prepared from apples (Malus 
Domestica), green tea (Camellia sinensis), strawberry (Fragaria vesca), kale (Brassica 
oleracea), capers (Capparis spinose), garlic (Allium sativum) and onions (Allium cepa). 
The extracts were applied to the biotin cadaverine incorporation assay (Slaughter et al., 
1992) and the peptide cross-linking assay (Trigwell et al., 2004) to examine their effect 
on TG2 transamidation activity. The data in Figure 4-4 A and B display the inhibition 
behaviour of most of the food extracts used towards the amine incorporation activity of 
TG2. Whereas, their effect on cross-linking activity of TG2, was not the same on two 
forms of TG2, as most of food extracts display inhibition effect on the gplTG2 cross-
linking activity. Whereas, only the samples with kale and strawberry have inhibition 
effects on the hrTG2 activity (See Figure 4-5 A and B).  The finding display the difference 
in the sensitivity towards the flavonoids extracts between gpl and hrTG2 activity. The 
subtle differences between hrTG2 and gplTG2 could affect the topography of the 
enzymes active site. In order to screen the effects of food extracts on deamidating activity 
of hrTG2, as mentioned previously, this activity is crucial for initiation of CD. No food 
extract showed inhibition of hrTG2 deamidating activity using the optimised fluorescence 
assay, (See Figure 4-6). However, the two extracts from alliums (onion and garlic) show 
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stimulation of the deamidating activity (high ammonia released). In light of the finding 
of this study, the people with coeliac disease should perhaps try to avoid containing food 
containing too much onion and garlic. The study of the relationship between consumption 
of the dietary flavonoids containing food and the CD prevalence might give another 
indication about the effects of dietary flavonoids on the CD suffers. 
The main impediment in the evaluating of the therapeutic potential behavior of TG2 
inhibitors in relation to CD, is the unavailability of animal or cell model for the coeliac 
disease that could be used to test the CD histopathological, immunological and serological 
abnormalities (Auricchio, S et al., 1984 and Papista et al., 2012). As the TG2 is active in 
the lamina propria of human small intestines and believed to be exported from epithelial 
cells. It would be an advantage to use a small intestinal epithelial cell line to test the 
therapeutic efficacy and cellular safety of flavonoids that have TG2 inhibition action 
(kaempferol, morin, and quercetin), (Papista et al., 2012). Although HT29 cells are not 
ideal for studying CD, however, this cell line may provide a marker about the effects of 
different reagents on disease-relevant to a human cell type. The HT29 cell line is derived 
from large intestine carcinomas was used in this study to examine the effect of flavonoids 
on the cell viability, cell proliferation, in situ TG2 activity and identification of proposed 
TG2 substrates. The data (See Figure 5-2) displayed that the kaempferol and quercetin (4 
to 125 µM) did not show a statistically significant inhibition effect on the HT29 cell 
viability; morin displayed inhibition effect on the viability of the cells (as measured by 
MTT reduction assay). On the other hand, the three flavonoids did show a statistically 
significant inhibitory effect on the proliferation of HT29 cell lines (Figure 5-3).  
These findings are in agreement with the study that stated the cellular protective effects 
of flavonoids in colon cancer development should be accompanied with the inhibition of 
cell proliferation to delete cells carrying mutations and to maintain a normal cell 
population (Kuntz et al., 1999). It is worth mentioning, that by connecting the inhibitions 
action of the studied flavonoids for the transamidation of hrTG2 (Figure 3-8  and figure 
3-13) with the anti-proliferative data of the same flavonoids ( Figure 5-4), could speculate 
that there is a link in the mechanisms of both actions of these flavonoids. To discover the 
in situ action of the active flavonoids against the TG2 activity (kaempferol, morin, and 
quercetin) and to identify the TG2 target substrate. Biotin-X cadaverine (a cell-
penetrating substrate of TG2) was used to label intracellular proteins in HT29 cells via 
intracellular TG2 activity (Almami, et al,. 2014). The data (Figure 5-5) showed that the 
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intracellularTG2 activity was reduced by using kaempferol, which is in agreement with 
in vitro TG2 inhibitory effect (Figure 3-8). While the morin and quercetin inhibition effect 
on intracellular TG2 activity was statistically insignificant. These findings are 
inconsistent with in Vitro TG2 assays.  
The reasons for this dissimilarity might be the fact that the environment of in vitro assay 
was different. As the flavonoids, TG2 and substrates were pure, in contrast, in the cell 
model were the flavonoids are exposed to metabolism and presence of other TG2 isoforms. 
In addition, to the presence of various proteins which could act as an alternative substrate 
to the TG2.  Hence, it is necessary to have a knowledge of intracellular TG2 substrates 
targets, and interacting proteins that may act as novel drug targets or new diagnostic 
markers. Various proteins with biotin-x-cadaverine were identified by using SDS-PAGE/ 
western blotting and ExtrAvidin HRP detection. the appropriate proteins were extracted 
from gel and because of the band was extracted from 1-D gel, many proteins have been 
detected., The mass spec identified proteins that show high sequence coverage and 
corresponding to the band size were selected from the data. The peptide sequences 
obtained from MS/MS were searched for homologies in the databases. Some of the 
identified proteins have not been previously identified as TG substrates either in HT29 or 
in other cell lines. These include the BAG family of molecular chaperone regulator 3 
proteins, and RAF proto-oncogene serine/threonine-protein kinase (Table5-2). 
    As mentioned previously, the deamidation activity of TG2 is crucial in the initiation of 
coeliac disease. However, to date, no effective assay has been produced to quantify the 
deamidation activity of hrTG2 or the release of ammonia from the target proteins. 
Therefore, was attempt to develop and optimise an assay to measure the deamidation 
activity catalysed by TG2.  Previous work at NTU (Aldubayan 2014) presents a 
preliminary attempt to optimise Vicia faba storage proteins for a TG2 deamidation assay, 
by using non-denaturing PAGE. It was reported that was increased electronegativity as 
result of incubation of Vicia faba storage proteins with gplTG2 in presence of 2mM CaCl2. 
This increase in electronegativity was calcium-dependent compared to samples incubated 
with EDTA and the blank. These findings were tentatively validated using microplate 
OPA assay to measure ammonia. It is important to remember that there can be little or no 
deamidation in the presence of an amine (Fleckenstein, B. et al 2002). Therefore, it is 
important to have an assay to measure and quantify the deamidating activity of 
transglutaminases. To mimic the environment of coeliac disease, human recombinant 
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TG2 was used to visualise TG2 deamidation activity using Vicia faba storage proteins 
(see Figure 6-4). The results confirm deamidation of amide nitrogen from the Vicia faba 
storage proteins by hrTG2 is a calcium-dependent deamidation (See Figure 6-5). These 
findings support a previous NTU study (Aldubayan 2014) which used gplTG2 while the 
current study hrTG2 was used. As the aim was to quantify the deamidation activity of 
TG2. it was necessity to translate the qualitative deamidation assay of Vicia faba proteins 
(non-denaturing PAGE assay) into a quantitative assay. By using an OPA reagent, the 
flouremetric microplate assay was optimised. The assay is based on the reaction of OPA 
with NH4+ released in the Vicia faba storage protein by the enzyme action of hrTG2, 
resulting in a fluorescence signal. The intensity of the signal would be proportional to the 
amount of ammonia in solution and consequently level of deamidation induced by hrTG2 
in the presence of calcium ions (see introduction section). The results (See Figure 6-7)  
indicate that there is a high quantity of ammonia released in samples with Cacl2, 
comparing to other samples, which suggest that the ammonia released from the storage 
proteins is Ca2+ dependent. The conclusion from previous data is the deamidation of seed 
storage proteins of Vicia faba was dependent on the presence of hrTG2 and Ca2+ ions.That 
is in agreement with the published role of transglutaminase, as their activity dependant 
on the presence of calcium (Chrobok, et al. 2018). 
 Because of the ingestion of gluten is the critical factor in the initiation of coeliac disease 
(Siegel and Khosla 2007). The microplate deamidation assay was transferred to the 
measurement of the deamidation of wheat gliadin peptides by hrTG2. Different time of 
incubation (Figure 6-11) and series of TG2 concentration (See Figure 6-13) were 
examined, the finding demonstrates that the deamidation of the gliadin was fast compared 
with the using storage protein as substrate.As the optimum time give a high quantity of 
ammonia was varied from 2 to 10 mins this. It must, however, be recommended that care 
should be taken to measure the ammonia release as quickly as possible while performing 
the assay.  Moreover, these findings confirm the dependence of releasing ammonia on 
increasing the concentration of TG2 (See Figure 6-13). The finding in Figure 6-10 refers 
to that the deamidation of gliadin protein was enhanced but not dependent on the presence 
of calcium ions. As it was unexpected to note that the detectable amount of ammonia in 
samples with EDTA. The application of commercially available TGase inhibitor 
(cystamine and Z-DON). Cystamine only at high concentration (10mM) inhibit the 
ammonia release (deamidation). However, Z-DON were unable to prevent the release of 
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ammonia from gliadin mixture peptides in the presence of hrTG2 (See Figure 6-16), even 
though, Z-DON is a good inhibitor of amine incorporation. One possibility expanding 
this finding could be that deamidation does not require the active site to be in the different 
conformation as far polyamine incorporation or protein cross-linking.  Based on this data 
the active site Cys277 might be not involved in all the deamidation of the gliadin mixture 
peptides. This driven the experiments to use inactive human recombinant TG2 (Cys277, 
cysteine replaced by serine) instead of active TG2. An unexpected observation was that 
the release of ammonia was similar when using active hrTG2 compared to the control 
sample with no hrTG2 (see Figure 6-17) suggesting that either  the cysteine 277 at the 
active site of hrTG2 is not exclusively involved in the deamidation reaction of TG2 or 
that the assay is in some way compromised.Overall, the data of this study suggested the 
following: the ammonia releasing (deamidation) was fast, increasing by increasing the 
concentration of TG2, enhanced but not dependent on presence of calcium ions, and 
suggesting that the cysteine 277 at the active site of hrTG2 is not exclusively involved.  
There could be some discussion about these findings, particularly when ammonia also 
released after incubation of gliadin peptide mixtures with TG2 may not be from 
deamidation only, but could also be produced by transamidation (see chapter 1). The 
general notion in the literature is that deamidation has been shown to occur parallel to 
transamidation proceeding via the same catalytic pathway. The ratio of transamidation 
versus deamidation is high in the presence of amine (Fleckenstein, B. et al 2002). In order, 
to confirm that the ammonia released was due to the deamidation activity of hrTG2. The 
fragment of 33-mer gliadin peptide (100µM) was used as a substrate with active and 
inactive hrTG2 (this fragment which crucially does not contain any lysine and as such, 
there can be no transamidation). The data in Figure 6-19 and Figure6-20 did not show 
significant difference between the quantity of ammonia released between gliadin peptide 
mixtures and 33-mer peptides after incubation with active hrTG2. These finding, suggest 
that the ammonia released in the assay was due to the deamidation catalytic action of 
hrTG2. Furthermore, based on the finding of 33-mer peptides, this assay suggests the 
specificity of these peptides to deamidated by active TG2. The comparison of active TG2 
with inactive TG2 data (See Figure 6-21), the data show that 33mer peptides have not 
been deamidated by the inactive form whereas gliadin mixture deamidated by inactive 
TG2.  
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A set of experiments were performed and analysed by a mass spectrometer to validate 
this assay, the data from MS displayed insignificant deamidation of peptides and not able 
to distinguish the deamidated peptide from the undeamidated peptide (data not shown). 
This was because both peptides eluted at the same position on a C18 mass spec column 
and with the same % of ACN, the difference between deamidated and un deamidated 
peptides just one Dalton which made the analysis difficult.  An analysis which could be 
resolved in the time allowed. Further work is currently being undertaken to resolve the 
problem using HILIC and ion-exchange chromatography. Numerous methods have been 
used for quantification of protein/peptide deamidation. However, this current research 
concentrates on the deamidation mediated by TG2 as mentioned previously; to date, the 
most of published assays are for quantifying the level of deamidation catalysed by TG2 
are used either Capillary electrophoresis or mass spectrometry techniques. The mass 
spectrometry methods have been successfully utilised to characterize peptides in complex 
mixtures, these results so far have largely been qualitative (Ong and Mann 2005) with the 
associated high costs.  Therefore, this study suggests the OPA assay, which is a low-cost 
and simple assay that could measure the TG2 deamidation activity and would be essential 
for testing the effect of the biologically active compound on the TG2 activity as potential 
treatment of coeliac disease.   
Based on the findings of this study, a recommendation can be made for future work. This 
study focused on the effect of flavonoids on the TG2 transamidation and deamidation 
activity. Other transglutaminase isoforms might be included in the study of the specificity 
of kaempferol, morin, and quercetin, which display inhibition effect toward the TG2. In 
addition, using other dietary flavonoids will give more knowledge about the effect of 
those flavonoids on the TG2 activity. Moreover, including other food extracts, which 
contains flavonoids, will be highly recommended as the consumption of food differ from 
person to another.  Future studies are strongly recommended to test those flavonoids on 
coeliac disease human biopsies to elucidate their effect on the activity of TG2. The 
successful achievement of the clinical trial for these flavonoids could prove innovative 
towards the treatment of coeliac disease. This would mean that flavonoids based treatment 
in the form of an oral tablet could regularly be prescribed for the coeliac disease sufferers.  
Future studies are necessary to test the efficacy of the flavonoids TG2 inhibitors on other 
cell lines. For example, the inhibitors could be tested on neuronal cell lines such as N2a 
or on the white blood leukemia cell line K562; both of these cell lines have active TG2. 
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In the deamidation section, a further experiment could clarify whether the active site 
cysteine is required for deamidation. The exact nature of the deamidation conformation 
of TG2 would have to be determined using X-ray crystallography.  Additionally, more 
experiments using high sensitive mass spectrum with gliadin peptides could confirm and 
validate the data of this assay.   
7.2     Conclusion 
This study was aimed at the identification of TG2 inhibitors from natural sources, as the 
products derived from natural sources are believed less or non-toxic. In this study, the 
flavonoid was studied as active biological natural products. Three of 13 pure flavonoids 
were displayed inhibition behaviour on the hr TG2 and in less extent gplTG2 amine 
incorporation activity, kaempferol, morin, and quercetin. However, the majority of 
flavonoids have inhibition effects on the cross-linking activity of TG2. Flavonoid did not 
show significant inhibitory effect on the amount of ammonia released (deamidating 
activity of hrTG2) comparing to the control. A new method for purification of flavonoids 
from food extracts was suggested in this study, which is Immobilized Metal Ion Affinity 
Chromatography (IMAC). In addition, BCA assay was optimised in a new quantification 
method using quercetin as standard. For amine incorporation activity, most of food 
extracts display a significant inhibition effect towards the hrTG2 and gplTG2. Whereas 
in cross-linking activity, the majority of food extracts display inhibition effect on the gpl 
TG2 cross-linking activity, only Kale have effect on hrTG2 activity. In the deamidation 
activity, no food extracts were showing inhibition for the ammonia released (deamidation 
activity) effect after using the optimised fluorescence assay (OPA) assay. The kaempferol 
and quercetin display an inhibition effect on growth of the HT29 cell line. The 
fluorescence assay confirmed the TG2 inhibitory characteristic of the kaempferol on 
HT29 cell lines. Numerous proteins were identified within a single protein band, which 
could act as TG2 substrates. Moreover, in this study, modified ammonia assay developed 
to quantify the ammonia released in deamidation activity for hrTG2. In conclusion, this 
was first study examined the effect of the flavonoids on the activity of TG2, the finding 
of this study displayed significant inhibition effect of three flavonols (Kaempferol, morin, 
and quercetin) on the transamidation activity of TG2. In addition, the novel method for 
the purification (IMAC) of flavonoids extracts from food samples was used in this study. 
According to the search in publication, this is first study used BCA method as a 
colorimetric method for quantification of flavonoids in the food extracts. Moreover, new 
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fluorescence microplate assay for deamidation activity of TG2 was optimised. Further 
experiments needed to validate this assay in future. Based on the finding of this study, the 
new biological effect of flavonoids was detected, which could offer new direction in 
therapeutic of CD, although, not all food containing flavonoid could be recommended to 
that CD sufferers.
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